Glucocortioid mimetics, methods of making them, pharmaceutical compositions, and uses thereof

ABSTRACT

Compounds of Formula (IA) and (IB) 
                         
wherein R 1 , R 2 , R 3 , A, B, C, D, and E are as defined herein, or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.

RELATED APPLICATIONS

This application claims benefit of U.S. Ser. No. 60/689,412, filed Jun.10, 2005, which is hereby incorporated by reference in its entirety.

FIELD OF THE INVENTION

The present invention relates to glucocorticoid mimetics or ligands,methods of making such compounds, their use in pharmaceuticalcompositions, and their use in modulating the glucocorticoid receptorfunction, treating disease-states or conditions mediated by theglucocorticoid receptor function in a patient in need of such treatment,and other uses.

BACKGROUND OF THE INVENTION

Glucocorticoids, a class of corticosteroids, are endogenous hormoneswith profound effects on the immune system and multiple organ systems.They suppress a variety of immune and inflammatory functions byinhibition of inflammatory cytokines such as IL-1, IL-2, IL-6, and TNF,inhibition of arachidonic acid metabolites including prostaglandins andleukotrienes, depletion of T-lymphocytes, and reduction of theexpression of adhesion molecules on endothelial cells (P. J. Barnes,Clin. Sci., 1998, 94, pp. 557-572; P. J. Barnes et al., TrendsPharmacol. Sci., 1993, 14, pp. 436-441). In addition to these effects,glucocorticoids stimulate glucose production in the liver and catabolismof proteins, play a role in electrolyte and water balance, reducecalcium absorption, and inhibit osteoblast function.

The anti-inflammatory and immune suppressive activities of endogenousglucocorticoids have stimulated the development of syntheticglucocorticoid derivatives including dexamethasone, prednisone, andprednisolone (L. Parente, Glucocorticoids, N. J. Goulding and R. J.Flowers (eds.), Boston: Birkhauser, 2001, pp. 35-54). These have foundwide use in the treatment of inflammatory, immune, and allergicdisorders including rheumatic diseases such as rheumatoid arthritis,juvenile arthritis, and ankylosing spondylitis, dermatological diseasesincluding psoriasis and pemphigus, allergic disorders including allergicrhinitis, atopic dermatitis, and contact dermatitis, pulmonaryconditions including asthma and chronic obstructive pulmonary disease(COPD), and other immune and inflammatory diseases including Crohndisease, ulcerative colitis, systemic lupus erythematosus, autoimmunechronic active hepatitis, osteoarthritis, tendonitis, and bursitis (J.Toogood, Glucocorticoids, N. J. Goulding and R. J. Flowers (eds.),Boston: Birkhauser, 2001, pp. 161-174). They have also been used to helpprevent rejection in organ transplantation.

Unfortunately, in addition to the desired therapeutic effects ofglucocorticoids, their use is associated with a number of adverse sideeffects, some of which can be severe and life-threatening. These includealterations in fluid and electrolyte balance, edema, weight gain,hypertension, muscle weakness, development or aggravation of diabetesmellitus, and osteoporosis. Therefore, a compound that exhibited areduced side effect profile while maintaining the potentanti-inflammatory effects would be particularly desirable, especiallywhen treating a chronic disease.

The effects of glucocorticoids are mediated at the cellular level by theglucocorticoid receptor (R. H. Oakley and J. Cidlowski, Glucocorticoids,N. J. Goulding and R. J. Flowers (eds.), Boston: Birkhauser, 2001, pp.55-80). The glucocorticoid receptor is a member of a class ofstructurally related intracellular receptors that when coupled with aligand can function as a transcription factor that affects geneexpression (R. M. Evans, Science, 1988, 240, pp. 889-895). Other membersof the family of steroid receptors include the mineralocorticoid,progesterone, estrogen, and androgen receptors. In addition to theeffects mentioned above for glucocorticoids, hormones that act on thisreceptor family have a profound influence on body homeostasis, mineralmetabolism, the stress response, and development of sexualcharacteristics. Glucocorticoids, N. J. Goulding and R. J. Flowers(eds.), Boston: Birkhauser, 2001, is hereby incorporated by reference inits entirety to better describe the state of the art.

A molecular mechanism which accounts for the beneficialanti-inflammatory effects and the undesired side effects has beenproposed (e.g., S. Heck et al., EMBO J, 1994, 17, pp. 4087-4095; H. M.Reichardt et al., Cell, 1998, 93, pp. 531-541; F. Tronche et al., Curr.Opin. in Genetics and Dev., 1998, 8, pp. 532-538). Many of the metabolicand cardiovascular side effects are thought to be the result of aprocess called transactivation. In transactivation, the translocation ofthe ligand-bound glucocorticoid receptor to the nucleus is followed bybinding to glucocorticoid response elements (GREs) in the promoterregion of side effect-associated genes, for example, phosphoenolpyruvatecarboxy kinase (PEPCK) in the case of increased glucose production. Theresult is an increased transcription rate of these genes which isbelieved to result, ultimately, in the observed side effects. Theanti-inflammatory effects are thought to be due to a process calledtransrepression. In general, transrepression is a process independent ofDNA binding that results from inhibition of NF-kB and AP-1-mediatedpathways, leading to down regulation of many inflammatory and immunemediators. Additionally, it is believed that a number of the observedside effects may be due to the cross-reactivity of the currentlyavailable glucocorticoids with other steroid receptors, particularly themineralocorticoid and progesterone receptors.

Thus, it may be possible to discover ligands for the glucocorticoidreceptor that are highly selective and, upon binding, can dissociate thetransactivation and transrepression pathways, providing therapeuticagents with a reduced side effect profile. Assay systems to determineeffects on transactivation and transrepression have been described(e.g., C. M. Bamberger and H. M. Schulte, Eur. J. Clin. Invest., 2000,30 (suppl. 3), pp. 6-9). Selectivity for the glucocorticoid receptor maybe determined by comparing the binding affinity for this receptor withthat of other steroid family receptors including those mentioned above.

Glucocorticoids also stimulate the production of glucose in the liver bya process called gluconeogenesis and it is believed that this process ismediated by transactivation events. Increased glucose production canexacerbate type II diabetes, therefore a compound that selectivityinhibited glucocorticoid mediated glucose production may havetherapeutic utility in this indication (J. E. Freidman et al., J. Biol.Chem., 1997, 272, pp. 31475-31481).

Novel ligands for the glucocorticoid receptor have been described in thescientific and patent literature. For example, PCT InternationalPublication No. WO 04/093805 discloses selective spirocyclicglucocorticoid receptor modulators potentially useful in treating manyinflammatory diseases, including rheumatoid arthritis and Crohn'sdisease. PCT International Publication No. WO 04/026248 disclosesoctahydro-2H-naphtho[1,2-f]indole-4-carboxamide derivatives as selectiveglucocorticoid receptor modulators potentially useful in treating forthe treatment of many inflammatory diseases, including rheumatoidarthritis and Crohn's disease. PCT International Publication No. WO04/075840 discloses selective non-steroidal glucocorticoid receptormodulator with potential use as anti-inflammatory agents possessingadvantages over the glucocorticoid ligands with respect to side-effects,efficacy, and toxicity. PCT International Publication No. WO 03/086294discloses 1H-benzo[f]indazol-5-yl derivatives as selectiveglucocorticoid receptor modulators potentially useful in treating forthe treatment of many inflammatory diseases, including rheumatoidarthritis and Crohn's disease. PCT International Publication No. WO03/061651 and the corresponding U.S. Application Publication No.2005/0054700 disclose non-steroidal ligands for the glucocorticoidreceptor, potentially useful in treating metabolic and inflammatorydiseases. PCT International Publication No. WO 99/33786 disclosestriphenylpropanamide compounds with potential use in treatinginflammatory diseases. PCT International Publication No. WO 00/66522describes non-steroidal compounds as selective modulators of theglucocorticoid receptor potentially useful in treating metabolic andinflammatory diseases. PCT International Publication No. WO 99/41256describes tetracyclic modulators of the glucocorticoid receptorpotentially useful in treating immune, autoimmune, and inflammatorydiseases. U.S. Pat. No. 5,688,810 describes various non-steroidalcompounds as modulators of glucocorticoid and other steroid receptors.PCT International Publication No. WO 99/63976 describes a non-steroidal,liver-selective glucocorticoid antagonist potentially useful in thetreatment of diabetes. PCT International Publication No. WO 00/32584discloses non-steroidal compounds having anti-inflammatory activity withdissociation between anti-inflammatory and metabolic effects. PCTInternational Publication No. WO 98/54159 describes non-steroidalcyclically substituted acylanilides with mixed gestagen and androgenactivity. U.S. Pat. No. 4,880,839 describes acylanilides havingprogestational activity and EP 253503 discloses acylanilides withantiandrogenic properties. PCT International Publication No. WO 97/27852describes amides that are inhibitors of farnesyl-protein transferase.

2,2,2-Trifluoro-1,1-bis-[1-(1-propylbutyl)-1H-indol-5-yl]ethanol hasbeen reported as a by-product of the condensation of5-bromo-1-(1-propylbutyl)-1H-indole and trifluoroacetyl anhydride undermetal halogen exchange conditions (H. Takami et al., Heterocycles, 1999,51, pp. 1119-1124). The4,4,4-trifluoro-3-hydroxy-3-[1-(1-propylbutyl)-1H-indol-5-yl]butyricacid ethyl ester has been disclosed as a product of a Reformatskyreaction between bromoacetic acid ethyl ester and2,2,2-trifluoro-1-[1-(1-propylbutyl)-1H-indol-5-yl]ethanone (H. Takamiet al., Med. Chem. Res. EN, 1999, 9(4), pp. 239-248).

A compound that is found to interact with the glucocorticoid receptor ina binding assay could be an agonist or an antagonist. The agonistproperties of the compound could be evaluated in the transactivation ortransrepression assays described above. Given the efficacy demonstratedby available glucocorticoid drugs in inflammatory and immune diseasesand their adverse side effects, there remains a need for novelglucocorticoid receptor agonists with selectivity over other members ofthe steroid receptor family and a dissociation of the transactivationand transrepression activities. Alternatively, the compound may be foundto have antagonist activity. As mentioned above, glucocorticoidsstimulate glucose production in the liver. Increased glucose productioninduced by glucocorticoid excess can exacerbate existing diabetes ortrigger latent diabetes. Thus, a ligand for the glucocorticoid receptorthat is found to be an antagonist may be useful, inter alia, fortreating or preventing diabetes.

SUMMARY OF THE INVENTION

The instant invention is directed to compounds of Formula (IA)

wherein:

-   R¹ is aryl, heteroaryl, or C₃-C₇ cycloalkyl each optionally    independently substituted with one to three substituent groups    selected from C₁-C₃ alkyl, hydroxy, halogen, oxo, methoxy, amino    wherein the nitrogen atom is optionally independently mono- or    disubstituted with a methyl group; or thiomethyl wherein the sulfur    atom is optionally oxidized to a sulfoxide or sulfone;-   R² is hydrogen or a halogen;-   A and B are each independently CH or N;-   C and E are each independently a bond or a —CH₂—;-   D is —CR⁴R⁵—, where R⁴ is —CF₃ and R⁵ is —OH; and-   R³ is C₁-C₆ alkyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl,    heterocyclyl, NR⁶R⁷, OR⁸, or SR⁹, each optionally independently    substituted with one to three substituent groups,    -   wherein each substituent group of R³ is independently aryl,        heteroaryl, heterocyclyl, C₁-C₅ alkyl, C₁-C₅ alkenyl,        cycloalkyl, cycloalkenyl, acyl, alkoxycarbonyl, C₁-C₅        alkanoyloxy, C₁-C₅ alkanoyl, aroyl, C₁-C₅ alkanoylamino,        alkylaminocarbonyl, dialkylaminocarbonyl, aminocarbonyloxy,        C₁-C₅ alkylaminocarbonyloxy, C₁-C₅ dialkylaminocarbonyloxy,        C₁-C₅ alkanoylamino, C₁-C₅ alkoxycarbonylamino, C₁-C₅        alkylsulfonylamino, aminosulfonyl, C₁-C₅ alkylaminosulfonyl,        C₁-C₅ dialkylaminosulfonyl, C₁-C₅ alkyloxy, aryloxy, halogen,        hydroxy, oxo, cyano, trifluoromethyl, nitro, carboxyl,        aminocarbonyl, amino wherein the nitrogen atom is optionally        independently mono- or disubstituted with a C₁-C₅ alkyl, or        C₁-C₅ alkylthio wherein the sulfur atom is optionally oxidized        to a sulfoxide or sulfone,        -   wherein each substituent group of R³ is optionally            independently substituted with one to three substituents            selected from aryl, heteroaryl, heterocyclyl, acyl, C₁-C₅            alkyl, C₁-C₅ alkanoyloxy, C₁-C₅ alkanoyl, C₁-C₅            alkanoylamino, alkylaminocarbonyl, dialkylaminocarbonyl,            C₁-C₅ alkylsulfonylamino, aminosulfonyl, C₁-C₅            alkylaminosulfonyl, C₁-C₅ dialkylaminosulfonyl, C₁-C₅            alkyloxy, C₁-C₅ cycloalkyl, aryloxy, halogen, hydroxy, oxo,            cyano, trifluoromethyl, nitro, aminocarbonyl, amino wherein            the nitrogen atom is optionally independently mono- or            disubstituted with a C₁-C₅ alkyl, or C₁-C₅ alkylthio wherein            the sulfur atom is optionally oxidized to a sulfoxide or            sulfone,    -   wherein R⁶ is a hydrogen or C₁-C₃ alkyl, and    -   R⁷, R⁸, and R⁹ are each independently C₁-C₅ alkyl, C₁-C₅        alkenyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, or        heterocyclyl optionally independently substituted with one to        three substituent groups,        -   wherein each substituent group of R⁷, R⁸, and R⁹ is            independently heteroaryl, heterocyclyl, C₁-C₅ alkyl,            cycloalkyl, cycloalkenyl, acyl, alkoxycarbonyl, C₁-C₅            alkanoyloxy, C₁-C₅ alkanoyl, aroyl, C₁-C₅ alkanoylamino,            alkylaminocarbonyl, dialkylaminocarbonyl, aminocarbonyloxy,            C₁-C₅ alkylaminocarbonyloxy, C₁-C₅ dialkylaminocarbonyloxy,            C₁-C₅ alkanoylamino, C₁-C₅ alkoxycarbonylamino, C₁-C₅            alkylsulfonylamino, aminosulfonyl, C₁-C₅ alkylaminosulfonyl,            C₁-C₅ dialkylaminosulfonyl, C₁-C₅ alkyloxy, aryloxy,            halogen, hydroxy, oxo, cyano, trifluoromethyl, nitro,            aminocarbonyl, amino wherein the nitrogen atom is optionally            independently mono- or disubstituted with a C₁-C₅ alkyl, or            C₁-C₅ alkylthio wherein the sulfur atom is optionally            oxidized to a sulfoxide or sulfone,            -   wherein each substituent group of R⁷, R⁸, and R⁹ is                optionally independently substituted with one to three                substituent groups selected from heteroaryl,                heterocyclyl, acyl, C₁-C₅ alkyl, C₁-C₅ alkanoylamino,                alkylaminocarbonyl, dialkylaminocarbonyl, C₁-C₅                alkylsulfonylamino, aminosulfonyl, C₁-C₅                alkylaminosulfonyl, C₁-C₅ dialkylaminosulfonyl, C₁-C₅                alkyloxy, aryloxy, halogen, hydroxy, oxo, cyano,                trifluoromethyl, nitro, aminocarbonyl, amino wherein the                nitrogen atom is optionally independently mono- or                disubstituted with a C₁-C₅ alkyl, or C₁-C₅ alkylthio                wherein the sulfur atom is optionally oxidized to a                sulfoxide or sulfone,                or a tautomer, prodrug, solvate, or salt thereof.

One aspect of the invention includes compounds of Formula (IA), wherein:

-   R¹ is aryl or heteroaryl optionally independently substituted with    one to three substituent groups selected from hydroxy, halogen, or    oxo;-   R² is hydrogen; and-   C is a bond and E is a bond or —CH₂—,    or a tautomer, prodrug, solvate, or salt thereof.

One aspect of the invention includes compounds of Formula (IA), wherein:

-   R¹ is a phenyl optionally substituted with one to three halogen    groups;-   A is N;-   B is CH; and-   R³ is a phenyl, naphthyl, pyridyl, quinoline, isoquinoline, indole,    azaindole, benzothiophene, benzofuran, 2,3-dihydro-1,4-benzodioxin,    1,3-benzodioxole, 3,4-dihydro-2H-1,4-benzoxazine,    1,2,3,4-tetrahydroisoquinoline,    N-ethyl-N′-methylbenzene-1,2-diamine, 1,2,3,4-tetrahydroquinoline,    NR⁶R⁷, OR⁸, or SR⁹ group, each optionally independently substituted    with one to three substituent groups,    -   wherein each substituent group of R³ is independently C₁-C₅        alkyl, heteroaryl, heterocyclyl, acyl, C₁-C₅ alkyloxy, halogen,        hydroxy, oxo, cyano, trifluoromethyl, aminocarbonyl, amino        wherein the nitrogen atom is optionally independently mono- or        disubstituted with a C₁-C₅ alkyl, C₁-C₅ alkenyl, carboxyl, or        C₁-C₅ alkylthio wherein the sulfur atom is optionally oxidized        to a sulfoxide or sulfone,        -   wherein each substituent group of R³ is optionally            independently substituted with one to three substituents            selected from heterocyclyl, C₁-C₅ alkyl, C₁-C₅ alkyloxy,            halogen, hydroxy, oxo, cyano, trifluoromethyl,            aminocarbonyl, amino wherein the nitrogen atom is optionally            independently mono- or disubstituted with a C₁-C₅ alkyl, or            C₁-C₅ alkylthio wherein the sulfur atom is optionally            oxidized to a sulfoxide or sulfone,    -   wherein R⁶ is a hydrogen or a methyl group, and    -   R⁷, R⁸, and R⁹ are each independently a phenyl, naphthyl,        pyridyl, pyrimidyl, quinoline, isoquinoline, or indolyl        optionally independently substituted with one to three        substituent groups,        -   wherein each substituent group of R⁷, R⁸, and R⁹ is            independently heterocyclyl, C₁-C₅ alkyl, cycloalkyl, acyl,            C₁-C₅ alkyloxy, halogen, hydroxy, oxo, cyano,            trifluoromethyl, aminocarbonyl, amino wherein the nitrogen            atom is optionally independently mono- or disubstituted with            a C₁-C₅ alkyl, or C₁-C₅ alkylthio wherein the sulfur atom is            optionally oxidized to a sulfoxide or sulfone,

One aspect of the above embodiment includes compounds of Formula (IA),wherein:

-   R³ is a phenyl, naphthyl, pyridyl, quinoline, isoquinoline, indole,    azaindole, benzothiophene, benzofuran, 2,3-dihydro-1,4-benzodioxin,    1,3-benzodioxole, 3,4-dihydro-2H-1,4-benzoxazine,    1,2,3,4-tetrahydroisoquinoline,    N-ethyl-N′-methylbenzene-1,2-diamine, or    1,2,3,4-tetrahydroquinoline,    -   wherein each substituent group of R³ is independently C₁-C₅        alkyl, C₁-C₅ alkenyl, carboxyl, acyl, C₁-C₅ alkyloxy, halogen,        hydroxy, oxo, cyano, trifluoromethyl, aminocarbonyl, amino        wherein the nitrogen atom is optionally independently mono- or        disubstituted with a C₁-C₅ alkyl, or C₁-C₅ alkylthio wherein the        sulfur atom is optionally oxidized to a sulfoxide or sulfone,        -   wherein each substituent group of R³ is optionally            independently substituted with one to three substituents            selected from C₁-C₅ alkyl, halogen, hydroxy, oxo, cyano,            trifluoromethyl, aminocarbonyl, amino wherein the nitrogen            atom is optionally independently mono- or disubstituted with            a C₁-C₅ alkyl, or C₁-C₅ alkylthio wherein the sulfur atom is            optionally oxidized to a sulfoxide or sulfone,            or a tautomer, prodrug, solvate, or salt thereof.

Representative compounds of Formula (IA) according to the invention areappended hereto as Table IA, where column A is the compound nameaccording to standard nomenclature and column B is the correspondingchemical structure.

Preferred compounds of Formula (IA) include the following:

-   1-Biphenyl-3-yl-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   1-(3,4-Difluorophenyl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   1-(3,5-Difluorophenyl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   1-(3-Chloro-5-fluorophenyl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   1-(4-Chloro-3-methylphenyl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   1-(3-Chlorophenyl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   1-(3-Chloro-4-fluorophenyl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   1-(4-Chloro-3-fluorophenyl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   1-(3,5-Dichlorophenyl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   2,2,2-Trifluoro-1-naphthalen-1-yl-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   2,2,2-Trifluoro-1-(3-fluorophenyl)-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   2,2,2-Trifluoro-1-(4-methylnaphthalen-1-yl)-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   1-(2,3-Dihydrobenzo[1,4]dioxin-6-yl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   1-(3,4-Dichlorophenyl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   2,2,2-Trifluoro-1-(4-fluorophenyl)-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   2,2,2-Trifluoro-1-(3-fluoro-4-methylphenyl)-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   1-Benzo[1,3]dioxol-5-yl-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   1-1,3-Benzodioxol-4-yl-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   1-(2,2-Difluoro-1,3-benzodioxol-4-yl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   1-(2,2-Difluoro-1,3-benzodioxol-4-yl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   1-(4-Chlorophenyl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   2,2,2-Trifluoro-1-phenyl-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   2,2,2-Trifluoro-1-(1-phenyl-1H-indazol-5-yl)-1-(2,4,5-trimethylphenyl)ethanol;-   2,2,2-Trifluoro-1-(1-phenyl-1H-indazol-5-yl)-1-(2,4,6-trimethylphenyl)ethanol;-   1-(4-tert-Butyl-2,6-dimethylphenyl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   2,2,2-Trifluoro-1-(3-methoxyphenyl)-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   1-(3,5-Dimethylphenyl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   2,2,2-Trifluoro-1-(4-methoxy-3,5-dimethylphenyl)-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   2,2,2-Trifluoro-1-(4-methoxyphenyl)-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   1-(3,4-Dimethylphenyl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   2,2,2-Trifluoro-1-(3-fluoro-4-methoxyphenyl)-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   2,2,2-Trifluoro-1-(5-fluoro-2-methoxyphenyl)-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   1-(2,5-Dimethoxyphenyl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   2,2,2-Trifluoro-1-(2-morpholin-4-ylmethylphenyl)-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   1-Biphenyl-2-yl-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   2,2,2-Trifluoro-1-(3-fluoro-4-methylphenyl)-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   2,2,2-Trifluoro-1-(4-fluoronaphthalen-1-yl)-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   1-(4-Dimethylaminonaphthalen-1-yl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   2,2,2-Trifluoro-1-(2-methylnaphthalen-1-yl)-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   2,2,2-Trifluoro-1-(2-methoxynaphthalen-1-yl)-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   2,2,2-Trifluoro-1-naphthalen-2-yl-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   2,2,2-Trifluoro-1-(1-phenyl-1H-indazol-5-yl)-1-quinolin-4-ylethanol;-   2,2,2-Trifluoro-1-(1H-indol-4-yl)-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   1,1,1-Trifluoro-3-indol-1-yl-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1-[3,3,3-Trifluoro-2-hydroxy-2-(1-phenyl-1H-indazol-5-yl)propyl]-1H-indole-3-carbonitrile;-   3-(3,4-Dihydro-2H-quinoxalin-1-yl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(3,4-Dihydro-2H-quinolin-1-yl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-3-(3-fluorophenyl)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-3-phenyl-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-2-phenyl-3-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-phenylsulfanylpropan-2-ol;-   1,1,1-Trifluoro-3-(4-fluorophenylsulfanyl)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-3-phenoxy-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(3,5-Difluorophenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(3,5-Dimethoxyphenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1-Benzo[b]thiophen-3-yl-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   2,2,2-Trifluoro-1-(1-phenyl-1H-indazol-5-yl)-1-quinolin-4-ylethanol;-   2,2,2-Trifluoro-1-isoquinolin-1-yl-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   1-Benzo[b]thiophen-3-yl-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-phenylethanol;-   1-(3-Chloro-4-fluorophenyl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-naphthalen-1-ylethanol;-   2,2,2-Trifluoro-1-(4-fluoronaphthalen-1-yl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(4-methylnaphthalen-1-yl)ethanol;-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1-methyl-1H-indol-4-yl)ethanol;-   1-Benzo[b]thiophen-3-yl-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;-   1-1,3-Benzodioxol-4-yl-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;-   1-(2,2-Difluoro-1,3-benzodioxol-4-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;-   2,2,2-Trifluoro-1-phenyl-1-(1-phenyl-1H-benzotriazol-5-yl)ethanol;-   2,2,2-Trifluoro-1-(6-fluoropyridin-2-yl)-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   3-(3-Chloro-2-fluorophenyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(4-Chloro-3-fluorophenyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(4-Chloro-2-fluorophenyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1-(2,2-Difluoro-1,3-benzodioxol-4-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;-   1-1,3-Benzodioxol-4-yl-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1H-indol-7-yl)ethanol;-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1-methyl-1H-indol-7-yl)ethanol;-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1-methyl-1H-indol-5-yl)ethanol;-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1-methyl-1H-indol-6-yl)ethanol;-   4-{2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}indole-1-carboxylic    acid tert-butyl ester;-   1-(3-Aminophenyl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   N-{3-[2,2,2-Trifluoro-1-hydroxy-1-(1-phenyl-1H-indazol-5-yl)ethyl]phenyl}acetamide;-   1-Methyl-4-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-quinolin-2-one;-   1-(1-Allyl-1H-indol-4-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;-   3-(4-{2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}indol-1-yl)propane-1,2-diol;-   3-Hydroxy-4-(4-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}indol-1-yl)butyronitrile;-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-[1-(2-hydroxyethyl)-1H-indol-4-yl]ethanol;-   2-(4-{2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}indol-1-yl)acetamide;-   N-Methyl-2-(4-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}indol-1-yl)acetamide;-   1-[1-(2-Cyclopropyl-2-hydroxyethyl)-1H-indol-4-yl]-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;-   1-(7-Bromo-1-methyl-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;-   1-Methyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylic    acid methyl ester;-   1-Methyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylic    acid;-   1-Methyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylic    acid amide;-   1-Methyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylic    acid methylamide;-   1-Methyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylic    acid (2-cyanoethyl)amide;-   1-Methyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylic    acid (2-methoxyethyl)amide;-   1-Methyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylic    acid (2-methoxyethyl)methylamide;-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1-methyl-7-nitro-1H-indol-3-yl)ethanol;-   1-(7-Amino-1-methyl-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;-   1-Methyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylic    acid carbamoylmethylamide;-   1-Methyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylic    acid cyanomethylamide;-   1-(1-Allyl-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;-   N-(1-Methyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indol-7-yl)methanesulfonamide;-   3-(3-{2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}indol-1-yl)propane-1,2-diol;-   1-Benzyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylic    acid methyl ester;-   2-(3-{2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}indol-1-yl)acetamide;-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-[1-(2-hydroxyethyl)-1H-indol-3-yl]ethanol;-   N-Methyl-2-(3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}indol-1-yl)acetamide;-   N-Cyanomethyl-2-(3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}indol-1-yl)acetamide;-   N-Carbamoylmethyl-2-(3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}indol-1-yl)acetamide;-   1-Morpholin-4-yl-2-(3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}indol-1-yl)ethanone;-   1-Allyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylic    acid methyl ester;-   1-Allyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylic    acid amide;-   1-(2,3-Dihydroxypropyl)-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylic    acid amide;-   1-(1-Allyl-1H-indol-3-yl)-2,2,2-trifluoro-1-(1-p-tolyl-1H-indazol-5-yl)ethanol;-   3-{3-[2,2,2-Trifluoro-1-hydroxy-1-(1-p-tolyl-1H-indazol-5-yl)ethyl]indol-1-yl}propane-1,2-diol;-   2,2,2-Trifluoro-1-(4-fluoronaphthalen-1-yl)-1-(1-phenyl-1H-indol-5-yl)ethanol;-   2,2,2-Trifluoro-1-naphthalen-1-yl-1-(1-phenyl-1H-indol-5-yl)ethanol;-   1-(3,4-Dichlorophenyl)-2,2,2-trifluoro-1-(1-pyridin-2-yl-1H-indazol-5-yl)ethanol;-   1-(3-Chlorophenyl)-2,2,2-trifluoro-1-(1-pyridin-2-yl-1H-indazol-5-yl)ethanol;-   1-(3,4-Difluorophenyl)-2,2,2-trifluoro-1-(1-pyridin-2-yl-1H-indazol-5-yl)ethanol;-   2,2,2-Trifluoro-1-phenyl-1-(1-pyridin-2-yl-1H-indazol-5-yl)ethanol;-   2,2,2-Trifluoro-1-[1-(2-fluorophenyl)-1H-indazol-5-yl]-1-phenylethanol;-   2,2,2-Trifluoro-1-[1-(2-fluorophenyl)-1H-indazol-5-yl]-1-naphthalen-1-ylethanol;-   2,2,2-Trifluoro-1-(4-fluoronaphthalen-1-yl)-1-[1-(2-fluorophenyl)-1H-indazol-5-yl]ethanol;-   2,2,2-Trifluoro-1-phenyl-1-(1-p-tolyl-1H-indazol-5-yl)ethanol;-   2,2,2-Trifluoro-1-[1-(4-methoxyphenyl)-1H-indazol-5-yl]-1-phenylethanol;-   2,2,2-Trifluoro-1-phenyl-1-(1-o-tolyl-1H-indazol-5-yl)ethanol;-   2,2,2-Trifluoro-1-naphthalen-1-yl-1-(1-o-tolyl-1H-indazol-5-yl)ethanol;-   2,2,2-Trifluoro-1-(4-fluoronaphthalen-1-yl)-1-(1-o-tolyl-1H-indazol-5-yl)ethanol;-   2,2,2-Trifluoro-1-(5-fluoro-1H-indol-3-yl)-1-(1-p-tolyl-1H-indazol-5-yl)ethanol;-   2,2,2-Trifluoro-1-(5-fluoro-1H-indol-3-yl)-1-[1-(2-fluorophenyl)-1H-indazol-5-yl]ethanol;-   2,2,2-Trifluoro-1-(5-fluoro-1H-indol-3-yl)-1-[1-(4-methoxyphenyl)-1H-indazol-5-yl]ethanol;-   2,2,2-Trifluoro-1-(5-fluoro-1H-indol-3-yl)-1-(1-pyridin-2-yl-1H-indazol-5-yl)ethanol;-   3-[2,2,2-Trifluoro-1-hydroxy-1-(1-phenyl-1H-indazol-5-yl)ethyl]phenol;-   2,2,2-Trifluoro-1-(4-fluoro-3-hydroxymethylphenyl)-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   4-[2,2,2-Trifluoro-1-hydroxy-1-(1-phenyl-1H-indazol-5-yl)ethyl]phenol;-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(5-methoxy-4-methyl-1H-indol-3-yl)ethanol;-   1-(4-Chloro-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(6-methoxy-1H-indol-3-yl)ethanol;-   1-(2,5-Dimethyl-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(7-methoxy-1H-indol-3-yl)ethanol;-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1H-indol-3-yl)ethanol;-   1-(6-Bromo-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;-   1-(7-Bromo-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;-   1-(5-Bromo-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(5-methyl-1H-indol-3-yl)ethanol;-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(2-methyl-1H-indol-3-yl)ethanol;-   1-(6-Chloro-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;-   1-(5-Chloro-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;-   1-(4-Bromo-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;-   2,2,2-Trifluoro-1-(5-fluoro-1H-indol-3-yl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;-   2,2,2-Trifluoro-1-(4-fluoro-1H-indol-3-yl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;-   2,2,2-Trifluoro-1-(6-fluoro-1H-indol-3-yl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(5-methoxy-1H-indol-3-yl)ethanol;-   2,2,2-Trifluoro-1-(7-fluoro-1H-indol-3-yl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(6-methyl-1H-indol-3-yl)ethanol;-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(7-methyl-1H-indol-3-yl)ethanol;-   3-{2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-5-carbonitrile;-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1-methyl-1H-indol-3-yl)ethanol;-   1-(6-Bromo-1-methyl-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;-   1-Methyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-6-carbonitrile;-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1-methyl-6-pyridin-3-yl-1H-indol-3-yl)ethanol;-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1-methyl-6-pyridin-4-yl-1H-indol-3-yl)ethanol;-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1-methyl-6-morpholin-4-yl-1H-indol-3-yl)ethanol;-   1-Methyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-6-carboxylic    acid methyl ester;-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(6-furan-2-yl-1-methyl-1H-indol-3-yl)ethanol;-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1-methyl-6-pyrimidin-5-yl-1H-indol-3-yl)ethanol;-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-{6-[(2-methoxyethyl)methylamino]-1-methyl-1H-indol-3-yl}ethanol;-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-[6-(2-methoxyethylamino)-1-methyl-1H-indol-3-yl]ethanol;-   1-{6-[(2-Dimethylaminoethyl)methylamino]-1-methyl-1H-indol-3-yl}-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1-methyl-5-morpholin-4-yl-1H-indol-3-yl)ethanol;-   1-[6-(2-Dimethylaminoethylamino)-1-methyl-1H-indol-3-yl]-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;-   1-[5-(2-Dimethylaminoethylamino)-1-methyl-1H-indol-3-yl]-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1-methyl-6-pyrrolidin-1-yl-1H-indol-3-yl)ethanol;-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1-methyl-5-pyrrolidin-1-yl-1H-indol-3-yl)ethanol;-   1-[6-Bromo-1-(4-methoxybenzyl)-1H-indol-3-yl]-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;-   N-Carbamoylmethyl-N-methyl-2-{3-[2,2,2-trifluoro-1-hydroxy-1-(1-p-tolyl-1H-indazol-5-yl)ethyl]indol-1-yl}acetamide;-   N-Carbamoylmethyl-2-{3-[2,2,2-trifluoro-1-hydroxy-1-(1-p-tolyl-1H-indazol-5-yl)ethyl]indol-1-yl}acetamide;-   N-(2-Methoxyethyl)-N-methyl-2-{3-[2,2,2-trifluoro-1-hydroxy-1-(1-p-tolyl-1H-indazol-5-yl)ethyl]indol-1-yl}acetamide;-   N-(2-Methoxyethyl)-2-{3-[2,2,2-trifluoro-1-hydroxy-1-(1-p-tolyl-1H-indazol-5-yl)ethyl]indol-1-yl}acetamide;-   N-Cyanomethyl-2-{3-[2,2,2-trifluoro-1-hydroxy-1-(1-p-tolyl-1H-indazol-5-yl)ethyl]indol-1-yl}acetamide;-   N-Methyl-2-{3-[2,2,2-trifluoro-1-hydroxy-1-(1-p-tolyl-1H-indazol-5-yl)ethyl]indol-1-yl}acetamide;-   2-{3-[2,2,2-Trifluoro-1-hydroxy-1-(1-p-tolyl-1H-indazol-5-yl)ethyl]indol-1-yl}acetamide;-   2,2,2-Trifluoro-1-[1-(2-hydroxyethyl)-1H-indol-3-yl]-1-(1-p-tolyl-1H-indazol-5-yl)ethanol;-   3-{3-[2,2,2-Trifluoro-1-hydroxy-1-(1-p-tolyl-1H-indazol-5-yl)ethyl]indol-1-yl}propane-1,2-diol;-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(2-trifluoromethylphenoxy)propan-2-ol;-   3-(2-Chloro-3,5-difluorophenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(5-Chloro-2-methylphenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(4-Bromophenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-3-(indan-5-yloxy)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(2,4,6-trichlorophenoxy)propan-2-ol;-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(2,4,6-trimethylphenoxy)propan-2-ol;-   3-(3-Bromophenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(2,4-Dichlorophenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(2-Bromophenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(3-trifluoromethylphenoxy)propan-2-ol;-   3-(2-Chloro-5-methylphenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(4-trifluoromethylphenoxy)propan-2-ol;-   1,1,1-Trifluoro-3-(naphthalen-2-yloxy)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(2-Chlorophenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(4-Chlorophenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(2-Chloro-4-methylphenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(4-Chloro-2-fluorophenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-3-(4-fluoro-2-methylphenoxy)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(2,3,4-trifluorophenoxy)propan-2-ol;-   3-(2-Chloro-3,5-difluorophenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-3-(7-methoxynaphthalen-2-yloxy)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(2-Bromo-5-fluorophenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-3-(2-fluoro-5-trifluoromethylphenoxy)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(4-Bromo-3-methylphenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-3-(2-fluoro-5-methylphenoxy)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-3-(4-methylsulfanylphenoxy)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(4-Bromophenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(3-Chlorophenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-o-tolyloxypropan-2-ol;-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-m-tolyloxypropan-2-ol;-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-p-tolyloxypropan-2-ol;-   3-(2,6-Dimethylphenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(2,6-Dichlorophenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(3,5-Dichlorophenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-3-(naphthalen-1-yloxy)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-3-(isoquinolin-7-yloxy)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(2-trifluoromethoxyphenoxy)propan-2-ol;-   1,1,1-Trifluoro-3-(4-phenylaminophenoxy)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(3-Chloro-4-methylphenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-3-(3-fluoro-5-trifluoromethylphenoxy)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-3-(2-methylsulfanylphenoxy)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(4-Chloro-3-trifluoromethylphenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(2,4-Dichloro-6-methylphenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(2,6-Dichloro-4-methylphenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-Methoxy-4-[3,3,3-trifluoro-2-hydroxy-2-(1-phenyl-1H-indazol-5-yl)propoxy]benzoic    acid ethyl ester;-   1,1,1-Trifluoro-3-(4-imidazol-1-ylphenoxy)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(3-Chloro-5-trifluoromethylpyridin-2-yloxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(5,6,7,8-tetrahydronaphthalen-1-yloxy)propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(5,6,7,8-tetrahydronaphthalen-2-yloxy)propan-2-ol;-   2-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropoxy}benzonitrile;-   3-(2-Bromophenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   3-(2-Chlorophenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   3-(2,4-Dichlorophenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(2,4,6-trichlorophenoxy)propan-2-ol;-   3-(2-Chloro-5-methylphenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   3-(2,6-Dichlorophenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(2-trifluoromethylphenoxy)propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-o-tolyloxypropan-2-ol;-   3-(2,4-Dimethylphenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(2,4,6-trimethylphenoxy)propan-2-ol;-   3-(2,6-Dimethylphenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   3-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropoxy}benzonitrile;-   3-(3-Bromophenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   1,1,1-Trifluoro-3-(3-fluorophenoxy)-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   3-(3,5-Difluorophenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   3-(3-Chlorophenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   3-(3,5-Dichlorophenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-m-tolyloxypropan-2-ol;-   3-(3,5-Dimethylphenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   4-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropoxy}benzonitrile;-   3-(4-Bromophenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   1,1,1-Trifluoro-3-(4-fluorophenoxy)-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   3-(4-Chlorophenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(4-trifluoromethylphenoxy)propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-p-tolyloxypropan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(indan-5-yloxy)propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(naphthalen-1-yloxy)propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(naphthalen-2-yloxy)propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(quinolin-5-yloxy)propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(quinolin-8-yloxy)propan-2-ol;-   3-(2,4-Difluorophenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(quinolin-7-yloxy)propan-2-ol;-   3-Methoxy-4-{3,3,3-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropoxy}benzoic    acid ethyl ester;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(4-phenylaminophenoxy)propan-2-ol;-   N-(4-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropoxy}phenyl)butyramide;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(4-trifluoromethylsulfanylphenoxy)propan-2-ol;-   5-Acetyl-2-{3,3,3-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropoxy}benzoic    acid methyl ester;-   3-(2-Bromo-5-fluorophenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(2,3,4-trifluorophenoxy)propan-2-ol;-   3-(2,5-Difluorophenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   3-(4-Chloro-3-trifluoromethylphenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   3-(Acridin-4-yloxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(3-morpholin-4-ylphenoxy)propan-2-ol;-   2-Chloro-4-{3,3,3-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropoxy}benzonitrile;-   3-(4-Bromo-2-methylphenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   3-(3-Chloro-4-methylphenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   3-(5-Chloro-2-methylphenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(2,3,6-trifluorophenoxy)propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(2,4,5-trifluorophenoxy)propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(2,4,6-trifluorophenoxy)propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(2-fluoro-5-trifluoromethylphenoxy)propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(3-fluoro-5-trifluoromethylphenoxy)propan-2-ol;-   3-(2-Chloro-4-methylphenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   3-(4-Chloro-2-fluorophenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   1,1,1-Trifluoro-3-(4-fluoro-2-methylphenoxy)-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   1,1,1-Trifluoro-3-(2-fluoro-6-methoxyphenoxy)-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   3-(2-Chloro-3,5-difluorophenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(2,3,5-trifluorophenoxy)propan-2-ol;-   4-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropoxy}benzonitrile;-   3-(4-Bromo-3-methylphenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(6-methoxynaphthalen-2-yloxy)propan-2-ol;-   3-(2,6-Dichloro-4-methylphenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   4-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropoxy}indan-1-one;-   5-Bromo-2-{3,3,3-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropoxy}benzonitrile;-   1,1,1-Trifluoro-3-(2-fluoro-5-methylphenoxy)-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   5-Chloro-2-{3,3,3-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropoxy}benzonitrile;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(2-trifluoromethoxyphenoxy)propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(isoquinolin-7-yloxy)propan-2-ol;-   3-(3,4-Dimethoxyphenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(3-trifluoromethoxyphenoxy)propan-2-ol;-   3-(2,4-Dichloro-6-methylphenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   1,1,1-Trifluoro-3-(2-isopropylphenylsulfanyl)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(pyridin-2-ylsulfanyl)propan-2-ol;-   3-(4-Ethylphenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   4-Methyl-7-[3,3,3-trifluoro-2-hydroxy-2-(1-phenyl-1H-indazol-5-yl)propylsulfanyl]-1-benzopyran-2-one;-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(3-trifluoromethylphenylsulfanyl)propan-2-ol;-   3-(2,3-Dichlorophenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(4-trifluoromethylphenylsulfanyl)propan-2-ol;-   1,1,1-Trifluoro-3-(naphthalen-1-ylsulfanyl)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(4-thiophen-2-ylpyrimidin-2-ylsulfanyl)propan-2-ol;-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(4-phenylpyrimidin-2-ylsulfanyl)propan-2-ol;-   3-[4-(4-Chlorophenyl)pyrimidin-2-ylsulfanyl]-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   6-Methyl-2-[3,3,3-trifluoro-2-hydroxy-2-(1-phenyl-1H-indazol-5-yl)propylsulfanyl]-4-trifluoromethylnicotinonitrile;-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(5-trifluoromethylpyridin-2-ylsulfanyl)propan-2-ol;-   3-(2-Chloro-4-fluorophenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(4-trifluoromethoxyphenylsulfanyl)propan-2-ol;-   3-(4-Bromo-2-trifluoromethoxyphenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-3-(4-methoxyphenylsulfanyl)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(quinolin-2-ylsulfanyl)propan-2-ol;-   3-(4-Chlorophenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(pyrimidin-2-ylsulfanyl)propan-2-ol;-   3-(4,6-Dimethylpyrimidin-2-ylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(3,4-Dichlorophenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(2,5-Dichlorophenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(pyridin-4-ylsulfanyl)propan-2-ol;-   1,1,1-Trifluoro-3-(3-methoxyphenylsulfanyl)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-3-(2-methoxyphenylsulfanyl)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(3-Chlorophenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(2,6-Dichlorophenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(2,6-Dichlorophenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(3-Bromophenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(3,4-Dimethylphenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-3-(naphthalen-2-ylsulfanyl)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-3-(2-fluorophenylsulfanyl)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-3-(3-fluorophenylsulfanyl)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(2,5-Dimethoxyphenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(2,4-Dimethylphenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(2,5-Dimethylphenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(2,6-Dimethylphenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(2-Ethylphenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   2-[3,3,3-Trifluoro-2-hydroxy-2-(1-phenyl-1H-indazol-5-yl)propylsulfanyl]benzoic    acid methyl ester;-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(4-trifluoromethylpyrimidin-2-ylsulfanyl)propan-2-ol;-   3-(3,5-Dimethylphenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(3,5-Bis-trifluoromethylphenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(2,4-Difluorophenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-3-(4-isopropylphenylsulfanyl)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(2,4-Dichlorophenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(3,5-Dichlorophenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(2-trifluoromethylphenylsulfanyl)propan-2-ol;-   3-(3,4-Difluorophenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(3-Ethoxyphenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(4-tert-Butylphenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   N-{4-[3,3,3-Trifluoro-2-hydroxy-2-(1-phenyl-1H-indazol-5-yl)propylsulfanyl]phenyl}acetamide;-   3-(4-Bromophenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-3-(4-fluorophenylsulfanyl)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-3-(2-isopropylphenylsulfanyl)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(pyridin-2-ylsulfanyl)propan-2-ol;-   1,1,1-Trifluoro-3-(4-nitrophenylsulfanyl)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-o-tolylsulfanylpropan-2-ol;-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-m-tolylsulfanylpropan-2-ol;-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-p-tolylsulfanylpropan-2-ol;-   3-(3-Chloro-4-fluorophenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(3,4-Dimethoxyphenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(5-tert-Butyl-2-methylphenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(2,4,6-trimethylphenylsulfanyl)propan-2-ol;-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(3-trifluoromethylphenylsulfanyl)propan-2-ol;-   1,1,1-Trifluoro-3-(4-methylsulfanylphenylsulfanyl)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(2-Chloro-6-methylphenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(2-tert-Butylphenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(3-trifluoromethylpyridin-2-ylsulfanyl)propan-2-ol;-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(3-trifluoromethoxyphenylsulfanyl)propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(4-methylindol-1-yl)propan-2-ol;-   3-[2-(4-Chlorophenyl)indol-1-yl]-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   (1-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H-indol-3-yl)acetonitrile;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(6-methoxyindol-1-yl)propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(5-methylindol-1-yl)propan-2-ol;-   3-(4-Benzyloxyindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   3-(4-Chloroindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   3-(6-Chloroindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(6-methylindol-1-yl)propan-2-ol;-   1-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H-indole-4-carboxylic    acid methyl ester;-   1,1,1-Trifluoro-3-(6-fluoroindol-1-yl)-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   1-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H-indole-3-carboxylic    acid methyl ester;-   2,2,2-Trifluoro-1-(1-{3,3,3-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H-indol-3-yl)ethanone;-   1,1,1-Trifluoro-3-(4-fluoroindol-1-yl)-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   N-[2-(5-Methoxy-1-{3,3,3-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H-indol-3-yl)ethyl]acetamide;-   3-(7-Bromoindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   3-(7-Chloroindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   (2-Methyl-1-{3,3,3-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H-indol-3-yl)acetic    acid ethyl ester;-   1-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H-indole-5-carboxylic    acid methyl ester;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(2-methyl-5-nitroindol-1-yl)propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-[2-(4-fluorophenyl)indol-1-yl]propan-2-ol;-   3-(4-Bromoindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   3-(6-Bromoindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   3-(3-Dimethylaminomethyl-6-methoxyindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   (5-Methoxy-1-{3,3,3-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H-indol-3-yl)acetonitrile;-   (5-Benzyloxy-1-{3,3,3-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H-indol-3-yl)acetonitrile;-   1-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H-indole-6-carboxylic    acid methyl ester;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(7-nitroindol-1-yl)propan-2-ol;-   1-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H-indole-4-carbonitrile;-   3-(5-Benzyloxyindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   1-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H-indole-5-carbonitrile;-   3-(3-Dimethylaminomethyl-5-methoxyindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(5-methoxy-2-methylindol-1-yl)propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(2-methylindol-1-yl)propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(3-methylindol-1-yl)propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(7-methylindol-1-yl)propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(5-nitroindol-1-yl)propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(2-phenylindol-1-yl)propan-2-ol;-   (2-Phenyl-1-{3,3,3-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H-indol-3-yl)acetonitrile;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-pyrrolo[2,3-c]pyridin-1-ylpropan-2-ol;-   3-(7-Ethylindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   3-(2,3-Dimethyl-5-nitroindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(6-trifluoromethylindol-1-yl)propan-2-ol;-   1,1,1-Trifluoro-3-(7-fluoroindol-1-yl)-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   1-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H-indole-6-carbonitrile;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-indol-1-ylpropan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-pyrrolo[2,3-b]pyridin-1-ylpropan-2-ol;-   1-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H-indole-2-carboxylic    acid ethyl ester;-   3-(2,3-Dimethylindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   1-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H-indole-3-carbonitrile;-   1-(1-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H-indol-3-yl)ethanone;-   3-(3-Dimethylaminomethylindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   3-(3-Dimethylaminomethyl-5-methoxyindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   (1-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H-indol-3-yl)acetic    acid ethyl ester;-   2-(1-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H-indol-3-yl)acetamide;-   3-(5-Bromoindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   1,1,1-Trifluoro-3-(5-fluoroindol-1-yl)-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   3-(5-Chloroindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(5-methoxyindol-1-yl)propan-2-ol;-   3-(5,6-Dimethoxyindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(4-nitroindol-1-yl)propan-2-ol;    and-   5-Methyl-1-{3,3,3-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H-indole-2-carboxylic    acid ethyl ester,    or a tautomer, prodrug, solvate, or salt thereof.

More preferred compounds of Formula (IA) include the following:

-   1-Biphenyl-3-yl-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   1-(3,4-Difluorophenyl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   1-(3,5-Difluorophenyl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   1-(3-Chloro-5-fluorophenyl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   1-(4-Chloro-3-methylphenyl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   1-(3-Chlorophenyl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   1-(3-Chloro-4-fluorophenyl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   1-(4-Chloro-3-fluorophenyl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   2,2,2-Trifluoro-1-naphthalen-1-yl-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   2,2,2-Trifluoro-1-(3-fluorophenyl)-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   2,2,2-Trifluoro-1-(4-methylnaphthalen-1-yl)-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   1-(2,3-Dihydrobenzo[1,4]dioxin-6-yl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   1-(3,4-Dichlorophenyl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   2,2,2-Trifluoro-1-(4-fluorophenyl)-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   2,2,2-Trifluoro-1-(3-fluoro-4-methylphenyl)-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   1-Benzo[1,3]dioxol-5-yl-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   1-(4-Chlorophenyl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   2,2,2-Trifluoro-1-(3-methoxyphenyl)-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   2,2,2-Trifluoro-1-(3-fluoro-4-methylphenyl)-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   1-(2,2-Difluoro-1,3-benzodioxol-4-yl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   2,2,2-Trifluoro-1-(4-fluoronaphthalen-1-yl)-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   1-(4-Dimethylaminonaphthalen-1-yl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   2,2,2-Trifluoro-1-(2-methoxynaphthalen-1-yl)-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   2,2,2-Trifluoro-1-(1-phenyl-1H-indazol-5-yl)-1-quinolin-4-ylethanol;-   2,2,2-Trifluoro-1-(1H-indol-4-yl)-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   1,1,1-Trifluoro-3-(3-fluorophenyl)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-3-phenyl-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(3,5-Difluorophenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1-Benzo[b]thiophen-3-yl-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   2,2,2-Trifluoro-1-(1-phenyl-1H-indazol-5-yl)-1-quinolin-4-ylethanol;-   2,2,2-Trifluoro-1-isoquinolin-1-yl-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   1-Benzo[b]thiophen-3-yl-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-phenylethanol;-   1-(3-Chloro-4-fluorophenyl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-naphthalen-1-ylethanol;-   2,2,2-Trifluoro-1-(4-fluoronaphthalen-1-yl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(4-methylnaphthalen-1-yl)ethanol;-   1-Benzo[b]thiophen-3-yl-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;-   1-1,3-Benzodioxol-4-yl-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;-   1-(2,2-Difluoro-1,3-benzodioxol-4-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;-   2,2,2-Trifluoro-1-(6-fluoropyridin-2-yl)-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   3-(3-Chloro-2-fluorophenyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(4-Chloro-3-fluorophenyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(4-Chloro-2-fluorophenyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1-(2,2-Difluoro-1,3-benzodioxol-4-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;-   1-1,3-Benzodioxol-4-yl-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1H-indol-7-yl)ethanol;-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1-methyl-1H-indol-7-yl)ethanol;-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1-methyl-1H-indol-5-yl)ethanol;-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1-methyl-1H-indol-6-yl)ethanol;-   4-{2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}indole-1-carboxylic    acid tert-butyl ester;-   1-(3-Aminophenyl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   N-{3-[2,2,2-Trifluoro-1-hydroxy-1-(1-phenyl-1H-indazol-5-yl)ethyl]phenyl}acetamide;-   1-Methyl-4-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-quinolin-2-one;-   1-(1-Allyl-1H-indol-4-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;-   3-(4-{2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}indol-1-yl)propane-1,2-diol;-   3-Hydroxy-4-(4-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}indol-1-yl)butyronitrile;-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-[1-(2-hydroxyethyl)-1H-indol-4-yl]ethanol;-   2-(4-{2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}indol-1-yl)acetamide;-   N-Methyl-2-(4-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}indol-1-yl)acetamide;-   1-[1-(2-Cyclopropyl-2-hydroxyethyl)-1H-indol-4-yl]-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;-   1-(7-Bromo-1-methyl-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;-   1-Methyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylic    acid methyl ester;-   1-Methyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylic    acid;-   1-Methyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylic    acid amide;-   1-Methyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylic    acid methylamide;-   1-Methyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylic    acid (2-cyanoethyl)amide;-   1-Methyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylic    acid (2-methoxyethyl)amide;-   1-Methyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylic    acid (2-methoxyethyl)methylamide;-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1-methyl-7-nitro-1H-indol-3-yl)ethanol;-   1-(7-Amino-1-methyl-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;-   1-Methyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylic    acid carbamoylmethylamide;-   1-Methyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylic    acid cyanomethylamide;-   1-(1-Allyl-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;-   N-(1-Methyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indol-7-yl)methanesulfonamide;-   3-(3-{2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}indol-1-yl)propane-1,2-diol;-   1-Benzyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylic    acid methyl ester;-   2-(3-{2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}indol-1-yl)acetamide;-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-[1-(2-hydroxyethyl)-1H-indol-3-yl]ethanol;-   N-Methyl-2-(3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}indol-1-yl)acetamide;-   N-Cyanomethyl-2-(3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}indol-1-yl)acetamide;-   N-Carbamoylmethyl-2-(3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}indol-1-yl)acetamide;-   1-Morpholin-4-yl-2-(3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}indol-1-yl)ethanone;-   1-Allyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylic    acid methyl ester;-   1-Allyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylic    acid amide;-   1-(2,3-Dihydroxypropyl)-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylic    acid amide;-   1-(1-Allyl-1H-indol-3-yl)-2,2,2-trifluoro-1-(1-p-tolyl-1H-indazol-5-yl)ethanol;-   3-{3-[2,2,2-Trifluoro-1-hydroxy-1-(1-p-tolyl-1H-indazol-5-yl)ethyl]indol-1-yl}propane-1,2-diol;-   2,2,2-Trifluoro-1-(4-fluoronaphthalen-1-yl)-1-(1-phenyl-1H-indol-5-yl)ethanol;-   2,2,2-Trifluoro-1-naphthalen-1-yl-1-(1-phenyl-1H-indol-5-yl)ethanol;-   1-(3,4-Dichlorophenyl)-2,2,2-trifluoro-1-(1-pyridin-2-yl-1H-indazol-5-yl)ethanol;-   1-(3-Chlorophenyl)-2,2,2-trifluoro-1-(1-pyridin-2-yl-1H-indazol-5-yl)ethanol;-   1-(3,4-Difluorophenyl)-2,2,2-trifluoro-1-(1-pyridin-2-yl-1H-indazol-5-yl)ethanol;-   2,2,2-Trifluoro-1-phenyl-1-(1-pyridin-2-yl-1H-indazol-5-yl)ethanol;-   2,2,2-Trifluoro-1-[1-(2-fluorophenyl)-1H-indazol-5-yl]-1-phenylethanol;-   2,2,2-Trifluoro-1-[1-(2-fluorophenyl)-1H-indazol-5-yl]-1-naphthalen-1-ylethanol;-   2,2,2-Trifluoro-1-(4-fluoronaphthalen-1-yl)-1-[1-(2-fluorophenyl)-1H-indazol-5-yl]ethanol;-   2,2,2-Trifluoro-1-phenyl-1-(1-p-tolyl-1H-indazol-5-yl)ethanol;-   2,2,2-Trifluoro-1-[1-(4-methoxyphenyl)-1H-indazol-5-yl]-1-phenylethanol;-   2,2,2-Trifluoro-1-phenyl-1-(1-o-tolyl-1H-indazol-5-yl)ethanol;-   2,2,2-Trifluoro-1-naphthalen-1-yl-1-(1-o-tolyl-1H-indazol-5-yl)ethanol;-   2,2,2-Trifluoro-1-(4-fluoronaphthalen-1-yl)-1-(1-o-tolyl-1H-indazol-5-yl)ethanol;-   2,2,2-Trifluoro-1-(5-fluoro-1H-indol-3-yl)-1-(1-p-tolyl-1H-indazol-5-yl)ethanol;-   2,2,2-Trifluoro-1-(5-fluoro-1H-indol-3-yl)-1-[1-(2-fluorophenyl)-1H-indazol-5-yl]ethanol;-   2,2,2-Trifluoro-1-(5-fluoro-1H-indol-3-yl)-1-[1-(4-methoxyphenyl)-1H-indazol-5-yl]ethanol;-   2,2,2-Trifluoro-1-(5-fluoro-1H-indol-3-yl)-1-(1-pyridin-2-yl-1H-indazol-5-yl)ethanol;-   3-[2,2,2-Trifluoro-1-hydroxy-1-(1-phenyl-1H-indazol-5-yl)ethyl]phenol;-   2,2,2-Trifluoro-1-(4-fluoro-3-hydroxymethylphenyl)-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   4-[2,2,2-Trifluoro-1-hydroxy-1-(1-phenyl-1H-indazol-5-yl)ethyl]phenol;-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(5-methoxy-4-methyl-1H-indol-3-yl)ethanol;-   1-(4-Chloro-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(6-methoxy-1H-indol-3-yl)ethanol;-   1-(2,5-Dimethyl-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(7-methoxy-1H-indol-3-yl)ethanol;-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1H-indol-3-yl)ethanol;-   1-(6-Bromo-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;-   1-(7-Bromo-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;-   1-(5-Bromo-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(5-methyl-1H-indol-3-yl)ethanol;-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(2-methyl-1H-indol-3-yl)ethanol;-   1-(6-Chloro-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;-   1-(5-Chloro-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;-   1-(4-Bromo-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;-   2,2,2-Trifluoro-1-(5-fluoro-1H-indol-3-yl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;-   2,2,2-Trifluoro-1-(4-fluoro-1H-indol-3-yl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;-   2,2,2-Trifluoro-1-(6-fluoro-1H-indol-3-yl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(5-methoxy-1H-indol-3-yl)ethanol;-   2,2,2-Trifluoro-1-(7-fluoro-1H-indol-3-yl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(6-methyl-1H-indol-3-yl)ethanol;-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(7-methyl-1H-indol-3-yl)ethanol;-   3-{2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-5-carbonitrile;-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1-methyl-1H-indol-3-yl)ethanol;-   1-(6-Bromo-1-methyl-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;-   1-Methyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-6-carbonitrile;-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1-methyl-6-pyridin-3-yl-1H-indol-3-yl)ethanol;-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1-methyl-6-pyridin-4-yl-1H-indol-3-yl)ethanol;-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1-methyl-6-morpholin-4-yl-1H-indol-3-yl)ethanol;-   1-Methyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-6-carboxylic    acid methyl ester;-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(6-furan-2-yl-1-methyl-1H-indol-3-yl)ethanol;-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1-methyl-6-pyrimidin-5-yl-1H-indol-3-yl)ethanol;-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-{6-[(2-methoxyethyl)methylamino]-1-methyl-1H-indol-3-yl}ethanol;-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-[6-(2-methoxyethylamino)-1-methyl-1H-indol-3-yl]ethanol;-   1-{6-[(2-Dimethylaminoethyl)methylamino]-1-methyl-1H-indol-3-yl}-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1-methyl-5-morpholin-4-yl-1H-indol-3-yl)ethanol;-   1-[6-(2-Dimethylaminoethylamino)-1-methyl-1H-indol-3-yl]-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;-   1-[5-(2-Dimethylaminoethylamino)-1-methyl-1H-indol-3-yl]-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1-methyl-6-pyrrolidin-1-yl-1H-indol-3-yl)ethanol;-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1-methyl-5-pyrrolidin-1-yl-1H-indol-3-yl)ethanol;-   1-[6-Bromo-1-(4-methoxybenzyl)-1H-indol-3-yl]-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;-   N-Carbamoylmethyl-N-methyl-2-{3-[2,2,2-trifluoro-1-hydroxy-1-(1-p-tolyl-1H-indazol-5-yl)ethyl]indol-1-yl}acetamide;-   N-Carbamoylmethyl-2-{3-[2,2,2-trifluoro-1-hydroxy-1-(1-p-tolyl-1H-indazol-5-yl)ethyl]indol-1-yl}acetamide;-   N-(2-Methoxyethyl)-N-methyl-2-{3-[2,2,2-trifluoro-1-hydroxy-1-(1-p-tolyl-1H-indazol-5-yl)ethyl]indol-1-yl}acetamide;-   N-(2-Methoxyethyl)-2-{3-[2,2,2-trifluoro-1-hydroxy-1-(1-p-tolyl-1H-indazol-5-yl)ethyl]indol-1-yl}acetamide;-   N-Cyanomethyl-2-{3-[2,2,2-trifluoro-1-hydroxy-1-(1-p-tolyl-1H-indazol-5-yl)ethyl]indol-1-yl}acetamide;-   N-Methyl-2-{3-[2,2,2-trifluoro-1-hydroxy-1-(1-p-tolyl-1H-indazol-5-yl)ethyl]indol-1-yl}acetamide;-   2-{3-[2,2,2-Trifluoro-1-hydroxy-1-(1-p-tolyl-1H-indazol-5-yl)ethyl]indol-1-yl}acetamide;-   2,2,2-Trifluoro-1-[1-(2-hydroxyethyl)-1H-indol-3-yl]-1-(1-p-tolyl-1H-indazol-5-yl)ethanol;-   3-{3-[2,2,2-Trifluoro-1-hydroxy-1-(1-p-tolyl-1H-indazol-5-yl)ethyl]indol-1-yl}propane-1,2-diol;-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(2-trifluoromethylphenoxy)propan-2-ol;-   3-(2-Chloro-3,5-difluorophenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(5-Chloro-2-methylphenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(4-Bromophenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-3-(indan-5-yloxy)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(2,4,6-trichlorophenoxy)propan-2-ol;-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(2,4,6-trimethylphenoxy)propan-2-ol;-   3-(3-Bromophenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(2,4-Dichlorophenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(2-Bromophenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(3-trifluoromethylphenoxy)propan-2-ol;-   3-(2-Chloro-5-methylphenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(4-trifluoromethylphenoxy)propan-2-ol;-   1,1,1-Trifluoro-3-(naphthalen-2-yloxy)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(2-Chlorophenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(4-Chlorophenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(2-Chloro-4-methylphenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(4-Chloro-2-fluorophenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-3-(4-fluoro-2-methylphenoxy)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(2,3,4-trifluorophenoxy)propan-2-ol;-   3-(2-Chloro-3,5-difluorophenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-3-(7-methoxynaphthalen-2-yloxy)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(2-Bromo-5-fluorophenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-3-(2-fluoro-5-trifluoromethylphenoxy)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(4-Bromo-3-methylphenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-3-(2-fluoro-5-methylphenoxy)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-3-(4-methylsulfanylphenoxy)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(4-Bromophenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(3-Chlorophenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-o-tolyloxypropan-2-ol;-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-m-tolyloxypropan-2-ol;-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-p-tolyloxypropan-2-ol;-   3-(2,6-Dimethylphenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(2,6-Dichlorophenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(3,5-Dichlorophenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-3-(naphthalen-1-yloxy)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-3-(isoquinolin-7-yloxy)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(2-trifluoromethoxyphenoxy)propan-2-ol;-   1,1,1-Trifluoro-3-(4-phenylaminophenoxy)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(3-Chloro-4-methylphenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-3-(3-fluoro-5-trifluoromethylphenoxy)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-3-(2-methylsulfanylphenoxy)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(4-Chloro-3-trifluoromethylphenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(2,4-Dichloro-6-methylphenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(2,6-Dichloro-4-methylphenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-Methoxy-4-[3,3,3-trifluoro-2-hydroxy-2-(1-phenyl-1H-indazol-5-yl)propoxy]benzoic    acid ethyl ester;-   1,1,1-Trifluoro-3-(4-imidazol-1-ylphenoxy)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(3-Chloro-5-trifluoromethylpyridin-2-yloxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(5,6,7,8-tetrahydronaphthalen-1-yloxy)propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(5,6,7,8-tetrahydronaphthalen-2-yloxy)propan-2-ol;-   2-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropoxy}benzonitrile;-   3-(2-Bromophenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   3-(2-Chlorophenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   3-(2,4-Dichlorophenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(2,4,6-trichlorophenoxy)propan-2-ol;-   3-(2-Chloro-5-methylphenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   3-(2,6-Dichlorophenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(2-trifluoromethylphenoxy)propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-o-tolyloxypropan-2-ol;-   3-(2,4-Dimethylphenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(2,4,6-trimethylphenoxy)propan-2-ol;-   3-(2,6-Dimethylphenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   3-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropoxy}benzonitrile;-   3-(3-Bromophenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   1,1,1-Trifluoro-3-(3-fluorophenoxy)-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   3-(3,5-Difluorophenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   3-(3-Chlorophenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   3-(3,5-Dichlorophenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-m-tolyloxypropan-2-ol;-   3-(3,5-Dimethylphenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   4-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropoxy}benzonitrile;-   3-(4-Bromophenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   1,1,1-Trifluoro-3-(4-fluorophenoxy)-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   3-(4-Chlorophenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(4-trifluoromethylphenoxy)propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-p-tolyloxypropan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(indan-5-yloxy)propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(naphthalen-1-yloxy)propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(naphthalen-2-yloxy)propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(quinolin-5-yloxy)propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(quinolin-8-yloxy)propan-2-ol;-   3-(2,4-Difluorophenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(quinolin-7-yloxy)propan-2-ol;-   3-Methoxy-4-{3,3,3-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropoxy}benzoic    acid ethyl ester;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(4-phenylaminophenoxy)propan-2-ol;-   N-(4-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropoxy}phenyl)butyramide;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(4-trifluoromethylsulfanylphenoxy)propan-2-ol;-   5-Acetyl-2-{3,3,3-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropoxy}benzoic    acid methyl ester;-   3-(2-Bromo-5-fluorophenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(2,3,4-trifluorophenoxy)propan-2-ol;-   3-(2,5-Difluorophenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   3-(4-Chloro-3-trifluoromethylphenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   3-(Acridin-4-yloxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(3-morpholin-4-ylphenoxy)propan-2-ol;-   2-Chloro-4-{3,3,3-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropoxy}benzonitrile;-   3-(4-Bromo-2-methylphenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   3-(3-Chloro-4-methylphenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   3-(5-Chloro-2-methylphenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(2,3,6-trifluorophenoxy)propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(2,4,5-trifluorophenoxy)propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(2,4,6-trifluorophenoxy)propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(2-fluoro-5-trifluoromethylphenoxy)propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(3-fluoro-5-trifluoromethylphenoxy)propan-2-ol;-   3-(2-Chloro-4-methylphenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   3-(4-Chloro-2-fluorophenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   1,1,1-Trifluoro-3-(4-fluoro-2-methylphenoxy)-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   1,1,1-Trifluoro-3-(2-fluoro-6-methoxyphenoxy)-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   3-(2-Chloro-3,5-difluorophenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(2,3,5-trifluorophenoxy)propan-2-ol;-   4-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropoxy}benzonitrile;-   3-(4-Bromo-3-methylphenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(6-methoxynaphthalen-2-yloxy)propan-2-ol;-   3-(2,6-Dichloro-4-methylphenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   4-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropoxy}indan-1-one;-   5-Bromo-2-{3,3,3-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropoxy}benzonitrile;-   1,1,1-Trifluoro-3-(2-fluoro-5-methylphenoxy)-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   5-Chloro-2-{3,3,3-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropoxy}benzonitrile;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(2-trifluoromethoxyphenoxy)propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(isoquinolin-7-yloxy)propan-2-ol;-   3-(3,4-Dimethoxyphenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(3-trifluoromethoxyphenoxy)propan-2-ol;-   3-(2,4-Dichloro-6-methylphenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   1,1,1-Trifluoro-3-(2-isopropylphenylsulfanyl)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(pyridin-2-ylsulfanyl)propan-2-ol;-   3-(4-Ethylphenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   4-Methyl-7-[3,3,3-trifluoro-2-hydroxy-2-(1-phenyl-1H-indazol-5-yl)propylsulfanyl]-1-benzopyran-2-one;-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(3-trifluoromethylphenylsulfanyl)propan-2-ol;-   3-(2,3-Dichlorophenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(4-trifluoromethylphenylsulfanyl)propan-2-ol;-   1,1,1-Trifluoro-3-(naphthalen-1-ylsulfanyl)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(4-thiophen-2-ylpyrimidin-2-ylsulfanyl)propan-2-ol;-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(4-phenylpyrimidin-2-ylsulfanyl)propan-2-ol;-   3-[4-(4-Chlorophenyl)pyrimidin-2-ylsulfanyl]-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   6-Methyl-2-[3,3,3-trifluoro-2-hydroxy-2-(1-phenyl-1H-indazol-5-yl)propylsulfanyl]-4-trifluoromethylnicotinonitrile;-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(5-trifluoromethylpyridin-2-ylsulfanyl)propan-2-ol;-   3-(2-Chloro-4-fluorophenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(4-trifluoromethoxyphenylsulfanyl)propan-2-ol;-   3-(4-Bromo-2-trifluoromethoxyphenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-3-(4-methoxyphenylsulfanyl)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(quinolin-2-ylsulfanyl)propan-2-ol;-   3-(4-Chlorophenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(pyrimidin-2-ylsulfanyl)propan-2-ol;-   3-(4,6-Dimethylpyrimidin-2-ylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(3,4-Dichlorophenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(2,5-Dichlorophenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(pyridin-4-ylsulfanyl)propan-2-ol;-   1,1,1-Trifluoro-3-(3-methoxyphenylsulfanyl)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-3-(2-methoxyphenylsulfanyl)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(3-Chlorophenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(2,6-Dichlorophenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(2,6-Dichlorophenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(3-Bromophenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(3,4-Dimethylphenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-3-(naphthalen-2-ylsulfanyl)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-3-(2-fluorophenylsulfanyl)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-3-(3-fluorophenylsulfanyl)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(2,5-Dimethoxyphenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(2,4-Dimethylphenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(2,5-Dimethylphenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(2,6-Dimethylphenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(2-Ethylphenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   2-[3,3,3-Trifluoro-2-hydroxy-2-(1-phenyl-1H-indazol-5-yl)propylsulfanyl]benzoic    acid methyl ester;-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(4-trifluoromethylpyrimidin-2-ylsulfanyl)propan-2-ol;-   3-(3,5-Dimethylphenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(3,5-Bis-trifluoromethylphenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(2,4-Difluorophenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-3-(4-isopropylphenylsulfanyl)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(2,4-Dichlorophenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(3,5-Dichlorophenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(2-trifluoromethylphenylsulfanyl)propan-2-ol;-   3-(3,4-Difluorophenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(3-Ethoxyphenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(4-tert-Butylphenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   N-{4-[3,3,3-Trifluoro-2-hydroxy-2-(1-phenyl-1H-indazol-5-yl)propylsulfanyl]phenyl}acetamide;-   3-(4-Bromophenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-3-(4-fluorophenylsulfanyl)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-3-(2-isopropylphenylsulfanyl)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(pyridin-2-ylsulfanyl)propan-2-ol;-   1,1,1-Trifluoro-3-(4-nitrophenylsulfanyl)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-o-tolylsulfanylpropan-2-ol;-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-m-tolylsulfanylpropan-2-ol;-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-p-tolylsulfanylpropan-2-ol;-   3-(3-Chloro-4-fluorophenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(3,4-Dimethoxyphenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(5-tert-Butyl-2-methylphenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(2,4,6-trimethylphenylsulfanyl)propan-2-ol;-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(3-trifluoromethylphenylsulfanyl)propan-2-ol;-   1,1,1-Trifluoro-3-(4-methylsulfanylphenylsulfanyl)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(2-Chloro-6-methylphenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(2-tert-Butylphenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(3-trifluoromethylpyridin-2-ylsulfanyl)propan-2-ol;-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(3-trifluoromethoxyphenylsulfanyl)propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(4-methylindol-1-yl)propan-2-ol;-   3-[2-(4-Chlorophenyl)indol-1-yl]-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   (1-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H-indol-3-yl)acetonitrile;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(6-methoxyindol-1-yl)propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(5-methylindol-1-yl)propan-2-ol;-   3-(4-Benzyloxyindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   3-(4-Chloroindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   3-(6-Chloroindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(6-methylindol-1-yl)propan-2-ol;-   1-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H-indole-4-carboxylic    acid methyl ester;-   1,1,1-Trifluoro-3-(6-fluoroindol-1-yl)-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   1-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H-indole-3-carboxylic    acid methyl ester;-   2,2,2-Trifluoro-1-(1-{3,3,3-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H-indol-3-yl)ethanone;-   1,1,1-Trifluoro-3-(4-fluoroindol-1-yl)-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   N-[2-(5-Methoxy-1-{3,3,3-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H-indol-3-yl)ethyl]acetamide;-   3-(7-Bromoindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   3-(7-Chloroindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   (2-Methyl-1-{3,3,3-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H-indol-3-yl)acetic    acid ethyl ester;-   1-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H-indole-5-carboxylic    acid methyl ester;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(2-methyl-5-nitroindol-1-yl)propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-[2-(4-fluorophenyl)indol-1-yl]propan-2-ol;-   3-(4-Bromoindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   3-(6-Bromoindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   3-(3-Dimethylaminomethyl-6-methoxyindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   (5-Methoxy-1-{3,3,3-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H-indol-3-yl)acetonitrile;-   (5-Benzyloxy-1-{3,3,3-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H-indol-3-yl)acetonitrile;-   1-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H-indole-6-carboxylic    acid methyl ester;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(7-nitroindol-1-yl)propan-2-ol;-   1-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H-indole-4-carbonitrile;-   3-(5-Benzyloxyindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   1-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H-indole-5-carbonitrile;-   3-(3-Dimethylaminomethyl-5-methoxyindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(5-methoxy-2-methylindol-1-yl)propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(2-methylindol-1-yl)propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(3-methylindol-1-yl)propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(7-methylindol-1-yl)propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(5-nitroindol-1-yl)propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(2-phenylindol-1-yl)propan-2-ol;-   (2-Phenyl-1-{3,3,3-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H-indol-3-yl)acetonitrile;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-pyrrolo[2,3-c]pyridin-1-ylpropan-2-ol;-   3-(7-Ethylindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   3-(2,3-Dimethyl-5-nitroindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(6-trifluoromethylindol-1-yl)propan-2-ol;-   1,1,1-Trifluoro-3-(7-fluoroindol-1-yl)-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   1-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H-indole-6-carbonitrile;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-indol-1-ylpropan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-pyrrolo[2,3-b]pyridin-1-ylpropan-2-ol;-   1-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H-indole-2-carboxylic    acid ethyl ester;-   3-(2,3-Dimethylindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   1-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H-indole-3-carbonitrile;-   1-(1-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H-indol-3-yl)ethanone;-   3-(3-Dimethylaminomethylindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   3-(3-Dimethylaminomethyl-5-methoxyindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   (1-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H-indol-3-yl)acetic    acid ethyl ester;-   2-(1-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H-indol-3-yl)acetamide;-   3-(5-Bromoindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   1,1,1-Trifluoro-3-(5-fluoroindol-1-yl)-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   3-(5-Chloroindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(5-methoxyindol-1-yl)propan-2-ol;-   3-(5,6-Dimethoxyindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol;-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(4-nitroindol-1-yl)propan-2-ol;-   5-Methyl-1-{3,3,3-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H-indole-2-carboxylic    acid ethyl ester,    or a tautomer, prodrug, solvate, or salt thereof.

The invention also provides a method of making a compound of Formula(IA)

wherein: C is CH₂, D is CR⁴R⁵ (where R⁴ is CF₃ and R⁵ is OH), E is abond, and A, B, R¹, R², and R³ are as defined above, the methodcomprising:

-   -   (a) reacting the nitrile of Formula (II) with a suitable        reducing agent, such as diisopropyl aluminum hydride, in a        suitable solvent, such as dichloromethane, to provide an        aldehyde of Formula (III)

-   -   (b) reacting the aldehyde of Formula (III) with        [1,3]dithian-2-yltrimethylsilane (IV) in the presence of a        suitable base, such as n-butyl lithium, in a suitable solvent,        such as THF, to provide a thioketene acetal of Formula (V)

-   -   (c) reacting the thioketene acetal of Formula (V) with        triethylsilane in the presence of an acid, such as TFA, in a        solvent, such as dichloromethane, to give a thioketal of Formula        (VI)

-   -   (d) reacting the thioketal of Formula (VI) with methyl iodide in        a solvent, such as acetonitrile, to provide an aldehyde of        Formula (VII)

-   -   (e) reacting the aldehyde of Formula (VII) with        (trifluoromethyl)trimethylsilane in the presence of a suitable        source of fluoride, such as tetrabutylammonium fluoride, in a        suitable solvent, such as THF, to provide the alcohol of Formula        (VIII)

-   -   (f) oxidizing the alcohol of Formula (VIII) in the presence of        Dess-Martin periodinane in a suitable solvent, such as        dichloromethane, to form a ketone of Formula (IX)

and

-   -   (g) reacting the ketone of Formula (IX) with an organometallic        reagent R³M, such as a Grignard reagent where M is MgBr, MgCl,        or MgI, or an organolithium reagent where M is Li, in a suitable        solvent, such as ether or THF, to form the compound of Formula        (IA)

Alternatively, a compound of Formula (IA), wherein C is a bond, and A,B, D, E, R¹, R², and R³ are as defined above may be prepared by startingfrom the aldehyde of Formula (III) and following steps (e), (f), and(g).

The invention also provides a method for making a compound of Formula(IA), wherein R³ is NR⁶R⁷, OR⁸, or SR⁹, C is CH₂, D is CR⁴R⁵ (where R⁴is CF₃ and R⁵ is OH), E is CH₂, and A, B, R¹, and R² are as definedabove, the method comprising:

-   -   (a′) reacting a ketone of Formula (IX) with a sulfur ylide of        Formula (XI) in the presence of a suitable base, such as sodium        hydride, in a suitable solvent, such as THF, to provide an        epoxide of Formula (XII)

and

-   -   (b′) reacting the epoxide of Formula (XII) with a compound R³H        of Formula (XIII), optionally in the presence of a base, such as        sodium hydride, in a suitable solvent, such as DMF, to provide        the compound of Formula (IA). Alternatively, a compound of        Formula (IA), wherein C is a bond and A, B, D, E, R¹, R², and R³        are as defined above may be prepared by starting from the        aldehyde of Formula (III) and following steps (e), (f), (a′),        and (b′)

Alternatively, a compound of Formula (IA), wherein C is CH₂, D is CR⁴R⁵(where R⁴ is CF₃ and R⁵ is OH), and E is a bond, may be made by startingfrom the aldehyde of Formula (VII) using the following process:

-   -   (a″) reacting the aldehyde of Formula (VII) with an        organometallic reagent R³M of Formula (X) such as a Grignard        reagent (M is MgBr, MgCl, or MgI), or an organolithium reagent        (M is Li), in a suitable solvent such as ether or THF, to form        an alcohol of

-   -   (b″) oxidizing the alcohol of the Formula (XIV) with Dess        Martin's periodinane reagent in a suitable solvent such as        dichloromethane or THF, to provide a ketone of Formula (XV)

-   -   (c″) reacting the ketone of Formula (XIV) with        (trifluoromethyl)trimethylsilane in the presence of a suitable        source of fluoride such tetrabutylammonium fluoride, in a        suitable solvent such as THF to provide the compound of Formula        (IA). Alternatively, a compound of Formula (IA), wherein C is a        bond and A, B, D, E, R¹, R², and R³ are as defined above, may be        prepared by starting from the aldehyde of Formula (III) and        following steps (a″), (b″), and (c″)

The instant invention is also directed to compounds of Formula (IB)

wherein:

-   R¹ is aryl, heteroaryl or C₃-C₇ cycloalkyl each optionally    independently substituted with one to three substituent groups    selected from C₁-C₃ alkyl, hydroxy, halogen, oxo, methoxy, amino    wherein the nitrogen atom is optionally independently mono- or    disubstituted with a methyl group, or thiomethyl wherein the sulfur    atom is optionally oxidized to a sulfoxide or sulfone;-   R² is hydrogen or a halogen;-   A and B are each independently CH or N;-   C and E are each independently a bond or a —CH₂—;-   D is —CR⁴R⁵—, wherein:    -   R⁴ is C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, carbocycle,        heterocyclyl, aryl, heteroaryl, carbocycle-C₁-C₈ alkyl,        aryl-C₁-C₈ alkyl, aryl-C₁-C₈ haloalkyl, heterocyclyl-C₁-C₈        alkyl, heteroaryl-C₁-C₈ alkyl, carbocycle-C₂-C₈ alkenyl,        aryl-C₂-C₈ alkenyl, heterocyclyl-C₂-C₈ alkenyl, or        heteroaryl-C₂-C₈ alkenyl, each optionally independently        substituted with one to three substituent groups,        -   wherein each substituent group of R⁴ is independently C₁-C₃            alkyl, C₂-C₃ alkenyl, C₂-C₃ alkynyl, C₁-C₃ alkoxy,            aminocarbonyl, C₁-C₃ alkylaminocarbonyl, C₁-C₃            dialkylaminocarbonyl, halogen, hydroxy, carboxy, cyano,            trifluoromethyl, nitro, or C₁-C₃ alkylthio wherein the            sulfur atom is optionally oxidized to a sulfoxide or            sulfone, wherein R⁴ cannot be trifluoromethyl,    -   R⁵ is —OH;-   R³ is C₁-C₆ alkyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl,    heterocyclyl, NR⁶R⁷, OR⁸, or SR⁹, each optionally independently    substituted with one to three substituent groups,    -   wherein each substituent group of R³ is independently aryl,        heteroaryl, heterocyclyl, C₁-C₅ alkyl, C₁-C₅ alkenyl,        cycloalkyl, cycloalkenyl, acyl, alkoxycarbonyl, C₁-C₅        alkanoyloxy, C₁-C₅ alkanoyl, aroyl, C₁-C₅ alkanoylamino,        alkylaminocarbonyl, dialkylaminocarbonyl, aminocarbonyloxy,        C₁-C₅ alkylaminocarbonyloxy, C₁-C₅ dialkylaminocarbonyloxy,        C₁-C₅ alkanoylamino, C₁-C₅ alkoxycarbonylamino, C₁-C₅        alkylsulfonylamino, aminosulfonyl, C₁-C₅ alkylaminosulfonyl,        C₁-C₅ dialkylaminosulfonyl, C₁-C₅ alkyloxy, aryloxy, halogen,        hydroxy, oxo, cyano, trifluoromethyl, nitro, carboxyl,        aminocarbonyl, amino wherein the nitrogen atom is optionally        independently mono- or disubstituted with a C₁-C₅ alkyl, or        C₁-C₅ alkylthio wherein the sulfur atom is optionally oxidized        to a sulfoxide or sulfone,        -   wherein each substituent group of R³ is optionally            independently substituted with one to three substituents            selected from aryl, heteroaryl, heterocyclyl, acyl, C₁-C₅            alkyl, C₁-C₅ alkanoyloxy, C₁-C₅ alkanoyl, C₁-C₅            alkanoylamino, alkylaminocarbonyl, dialkylaminocarbonyl,            C₁-C₅ alkylsulfonylamino, aminosulfonyl, C₁-C₅            alkylaminosulfonyl, C₁-C₅ dialkylaminosulfonyl, C₁-C₅            alkyloxy, aryloxy, halogen, hydroxy, oxo, cyano,            trifluoromethyl, nitro, aminocarbonyl, amino wherein the            nitrogen atom is optionally independently mono- or            disubstituted with a C₁-C₅ alkyl, C₁-C₅ cycloalkyl, or C₁-C₅            alkylthio wherein the sulfur atom is optionally oxidized to            a sulfoxide or sulfone,    -   wherein R⁶ is a hydrogen or C₁-C₃ alkyl, and    -   R⁷, R⁸, and R⁹ are each independently C₁-C₅ alkyl, C₁-C₅        alkenyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, or        heterocyclyl optionally independently substituted with one to        three substituent groups,    -   wherein each substituent group of R⁷, R⁸, and R⁹ is        independently heteroaryl, heterocyclyl, C₁-C₅ alkyl, cycloalkyl,        cycloalkenyl, acyl, alkoxycarbonyl, C₁-C₅ alkanoyloxy, C₁-C₅        alkanoyl, aroyl, C₁-C₅ alkanoylamino, alkylaminocarbonyl,        dialkylaminocarbonyl, aminocarbonyloxy, C₁-C₅        alkylaminocarbonyloxy, C₁-C₅ dialkylaminocarbonyloxy, C₁-C₅        alkanoylamino, C₁-C₅ alkoxycarbonylamino, C₁-C₅        alkylsulfonylamino, aminosulfonyl, C₁-C₅ alkylaminosulfonyl,        C₁-C₅ dialkylaminosulfonyl, C₁-C₅ alkyloxy, aryloxy, halogen,        hydroxy, oxo, cyano, trifluoromethyl, nitro, aminocarbonyl,        amino wherein the nitrogen atom is optionally independently        mono- or disubstituted with a C₁-C₅ alkyl, or C₁-C₅ alkylthio        wherein the sulfur atom is optionally oxidized to a sulfoxide or        sulfone,        -   wherein each substituent group of R⁷, R⁸, and R⁹ is            optionally independently substituted with one to three            substituent groups selected from heteroaryl, heterocyclyl,            acyl, C₁-C₅ alkyl, C₁-C₅ alkanoylamino, alkylaminocarbonyl,            dialkylaminocarbonyl, C₁-C₅ alkylsulfonylamino,            aminosulfonyl, C₁-C₅ alkylaminosulfonyl, C₁-C₅            dialkylaminosulfonyl, C₁-C₅ alkyloxy, aryloxy, halogen,            hydroxy, oxo, cyano, trifluoromethyl, nitro, aminocarbonyl,            amino wherein the nitrogen atom is optionally independently            mono- or disubstituted with a C₁-C₅ alkyl, or C₁-C₅            alkylthio wherein the sulfur atom is optionally oxidized to            a sulfoxide or sulfone,            or a tautomer, prodrug, solvate, or salt thereof.

One aspect of the invention includes compounds of Formula (IB), wherein:

-   R¹ is aryl or heteroaryl optionally substituted with one to three    substituent groups selected from hydroxy, halogen, or oxo;-   R² is hydrogen;-   C is a bond;-   E is a bond or —CH₂—; and-   D is —CR⁴R⁵—, wherein:    -   R⁴ is C₁-C₅ alkyl, C₂-C₅ alkenyl, C₃-C₆ cycloalkyl, phenyl,        C₃-C₆ cycloalkyl-C₁-C₃ alkyl, phenyl-C₁-C₃ alkyl, phenyl-C₁-C₃        haloalkyl, C₃-C₆ cycloalkyl-C₂-C₃ alkenyl, phenyl-C₂-C₃ alkenyl,        each optionally independently substituted with one to three        substituent groups,        -   wherein each substituent group of R⁴ is independently C₁-C₃            alkyl, C₂-C₃ alkenyl, C₂-C₃ alkynyl, C₁-C₃ alkoxy,            aminocarbonyl, C₁-C₃ alkylaminocarbonyl, C₁-C₃            dialkylaminocarbonyl, halogen, hydroxy, carboxy, cyano,            trifluoromethyl, nitro, or C₁-C₃ alkylthio wherein the            sulfur atom is optionally oxidized to a sulfoxide or            sulfone, wherein R⁴ cannot be trifluoromethyl, and    -   R⁵ is —OH,        or a tautomer, prodrug, solvate, or salt thereof.

One aspect of the invention includes compounds of Formula (IB), wherein:

-   R¹ is a phenyl optionally substituted with one to three halogen    groups;-   A is N;-   B is CH;-   D is —CR⁴R⁵—, wherein:    -   R⁴ is C₁-C₅ alkyl, C₃-C₆ cycloalkyl, C₃-C₆ cycloalkyl-methyl-,        or benzyl, each optionally independently substituted with one to        three substituent groups, wherein each substituent group of R⁴        is independently methyl, methoxy, fluoro, chloro, bromo, cyano,        trifluoromethyl, or hydroxy, wherein R⁴ cannot be        trifluoromethyl, and    -   R⁵ is —OH; and-   R³ is a phenyl, naphthyl, pyridyl, quinoline, isoquinoline, indole,    azaindole, benzothiophene, benzofuran, 2,3-dihydro-1,4-benzodioxin,    1,3-benzodioxole, 3,4-dihydro-2H-1,4-benzoxazine,    1,2,3,4-tetrahydroisoquinoline, or    N-ethyl-N′-methylbenzene-1,2-diamine, 1,2,3,4-tetrahydroquinoline,    NR⁶R⁷, OR⁸, or SR⁹; each optionally independently substituted with    one to three substituent groups,    -   wherein each substituent group of R³ is independently C₁-C₅        alkyl, heteroaryl, heterocyclyl, acyl, C₁-C₅ alkyloxy, halogen,        hydroxy, oxo, cyano, trifluoromethyl, aminocarbonyl, amino        wherein the nitrogen atom is optionally independently mono- or        disubstituted with a C₁-C₅ alkyl, C₁-C₅ alkenyl, carboxyl, or        C₁-C₅ alkylthio wherein the sulfur atom is optionally oxidized        to a sulfoxide or sulfone,    -   wherein each substituent group of R³ is optionally independently        substituted with one to three substituents selected from        heterocyclyl, C₁-C₅ alkyl, C₁-C₅ alkyloxy, halogen, hydroxy,        oxo, cyano, trifluoromethyl, aminocarbonyl, amino wherein the        nitrogen atom is optionally independently mono- or disubstituted        with a C₁-C₅ alkyl, or C₁-C₅ alkylthio wherein the sulfur atom        is optionally oxidized to a sulfoxide or sulfone,    -   wherein R⁶ is a hydrogen or a methyl group, and    -   R⁷, R⁸, and R⁹ are each independently a phenyl, naphthyl,        pyridyl, pyrimidyl, quinoline, isoquinoline, or indolyl        optionally independently substituted with one to three        substituent groups,        -   wherein each substituent group of R⁷, R⁸, and R⁹ is            independently heterocyclyl, C₁-C₅ alkyl, cycloalkyl, acyl,            C₁-C₅ alkyloxy, halogen, hydroxy, oxo, cyano,            trifluoromethyl, aminocarbonyl, amino wherein the nitrogen            atom is optionally independently mono- or disubstituted with            a C₁-C₅ alkyl, or C₁-C₅ alkylthio wherein the sulfur atom is            optionally oxidized to a sulfoxide or sulfone,            or a tautomer, prodrug, solvate, or salt thereof.

One aspect of the above embodiment includes compounds of Formula (IB),wherein:

-   R³ is a phenyl, naphthyl, pyridyl, quinoline, isoquinoline, indole,    azaindole, benzothiophene, benzofuran, 2,3-dihydro-1,4-benzodioxin,    1,3-benzodioxole, 3,4-dihydro-2H-1,4-benzoxazine,    1,2,3,4-tetrahydroisoquinoline, or    N-ethyl-N′-methylbenzene-1,2-diamine, 1,2,3,4-tetrahydroquinoline,    -   wherein each substituent group of R³ is independently C₁-C₅        alkyl, acyl, C₁-C₅ alkyloxy, halogen, hydroxy, oxo, cyano,        trifluoromethyl, aminocarbonyl, amino wherein the nitrogen atom        is optionally independently mono- or disubstituted with a C₁-C₅        alkyl, C₁-C₅ alkenyl, carboxyl, or C₁-C₅ alkylthio wherein the        sulfur atom is optionally oxidized to a sulfoxide or sulfone,        -   wherein each substituent group of R³ is optionally            independently substituted with one to three substituents            selected from heterocyclyl, C₁-C₅ alkyl, halogen, hydroxy,            oxo, cyano, trifluoromethyl, aminocarbonyl, amino wherein            the nitrogen atom is optionally independently mono- or            disubstituted with a C₁-C₅ alkyl, or C₁-C₅ alkylthio wherein            the sulfur atom is optionally oxidized to a sulfoxide or            sulfone,            or a tautomer, prodrug, solvate, or salt thereof.

Representative compounds of Formula (IB) according to the invention areappended hereto as Table IB, where column A is the compound nameaccording to standard nomenclature and column B is the correspondingchemical structure.

Preferred compounds of Formula (IB) include the following:

-   Cyclopropylphenyl-(1-phenyl-1H-indazol-5-yl)methanol;-   Cyclopropyl-(3,5-dichlorophenyl)-(1-phenyl-1H-indazol-5-yl)methanol;-   1-Cyclopropyl-2-phenyl-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   1-Cyclopropyl-2-(3,5-dichlorophenyl)-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   1-Cyclopropyl-1-(1-phenyl-1H-indazol-5-yl)-2-p-tolylethanol;-   1-Cyclopropyl-1-(1-phenyl-1H-indazol-5-yl)-2-m-tolylethanol;-   Cyclopropylphenyl-(1-phenyl-1H-benzotriazol-5-yl)methanol;-   Cyclopropyl-[1-(4-fluorophenyl)-1H-benzotriazol-5-yl]phenylmethanol;-   1-(1-Phenyl-1H-indazol-5-yl)-1-quinolin-4-ylethanol;-   1-(1-Phenyl-1H-indazol-5-yl)-1-quinolin-4-ylpropan-1-ol;-   1-(4-Fluoronaphthalen-1-yl)-1-(1-phenyl-1H-indazol-5-yl)propan-1-ol;-   1-(1-Allyl-1H-indol-3-yl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-methylpropan-1-ol;    and-   1-(1-Allyl-1H-indol-3-yl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-1-ol,    or a tautomer, prodrug, solvate, or salt thereof.

The invention also provides a method of making a compound of Formula(IB)

wherein: A, B, C, D, E, R¹, R², and R³ are as defined above, the methodcomprising:

-   -   (a) reacting a nitrile of Formula (II) with an organometallic        reagent R⁴—M of Formula (XVI) such as a Grignard reagent (M is        MgBr, MgCl, or MgI), in a suitable solvent, such as THF or        ether, to obtain the ketone of Formula (XVII)

-   -   (b) reacting the ketone of Formula (XVII) with an organometallic        reagent R³M of Formula (X) such as a Grignard reagent (M is        MgBr, MgCl, or MgI), or an organolithium reagent (M is Li), in a        suitable solvent, such as ether or THF, to provide the compound        of Formula (IB)

Alternatively, a compound of Formula (IB), wherein C is a bond or CH₂, Dis CR⁴R⁵ (where R⁵ is OH), and E is a bond, and A, B, R¹, R², R³, and R⁴are as defined above may be prepared by starting from the ketone ofFormula (XV) using the following step:

-   -   (a′) reacting the ketone of Formula (XV) with an organometallic        reagent R⁴M of Formula (XVI) such as a Grignard reagent (M is        MgBr, MgCl, or MgI), or an organolithium reagent (M is Li), in a        suitable solvent, such as ether or THF, to provide the compound        of Formula (IB)

Alternatively, a compound of Formula (IB), wherein R³ is NR⁶R⁷, OR⁸, orSR⁹, C is a bond or CH₂, D is CR⁴R⁵ (where R⁵ is OH), and E is CH₂, andA, B, R¹, R², and R⁴ are as defined above, may be prepared by startingfrom the aldehyde of Formula (III) or (VII):

-   -   (a″) reacting the aldehyde of Formula (III) or (VII) with an        organometallic reagent R⁴M of Formula (XVI), such as a Grignard        reagent (M is MgBr, MgCl, or MgI), or an organolithium reagent        (M is Li), in a suitable solvent, such as THF or ether, to        obtain the alcohol of Formula (XVIII)

-   -   (b″) oxidizing the alcohol of Formula (XVIII) in the presence of        Dess-Martin periodinane in a suitable solvent, such as        dichloromethane, to form a ketone of Formula (XIX)

-   -   (c″) reacting the ketone of Formula (XIX) with the sulfur ylide        of Formula (XI) in the presence of a suitable base such as        sodium hydride in a suitable solvent, such as THF, to provide an        epoxide of Formula (XX)

and

-   -   (d″) reacting the epoxide of the Formula (XX) with a compound        R³H of Formula (XIII), either without or with a base such as        sodium hydride, in a suitable solvent, such as DMF, to provide a        compound of Formula (IB)

In another aspect of the invention, the compounds according to theinvention are formulated into pharmaceutical compositions comprising aneffective amount, preferably a pharmaceutically effective amount, of acompound according to the invention or a tautomer, prodrug, solvate, orsalt thereof, and a pharmaceutically acceptable excipient or carrier.

The invention also provides a method of modulating the glucocorticoidreceptor function in a patient, the method comprising administering tothe patient an effective amount of a compound according to the inventionor a tautomer, prodrug, solvate, or salt thereof.

The invention further provides a method of treating a disease-state orcondition mediated by the glucocorticoid receptor function in a patientin need of such treatment, the method comprising administering to thepatient an effective amount of a pharmaceutically acceptable compoundaccording to the invention or a tautomer, prodrug, solvate, or saltthereof.

In addition, the invention also provides a method of treating adisease-state or condition selected from: type II diabetes, obesity,cardiovascular diseases, hypertension, arteriosclerosis, neurologicaldiseases, adrenal and pituitary tumors, and glaucoma, in a patient inneed of such treatment, the method comprising administering to thepatient an effective amount of a pharmaceutically acceptable compoundaccording to the invention or a tautomer, prodrug, solvate, or saltthereof.

The invention provides a method of treating a disease characterized byinflammatory, allergic, or proliferative processes, in a patient in needof such treatment, the method comprising administering to the patient aneffective amount of a pharmaceutically acceptable compound according tothe invention or a tautomer, prodrug, solvate, or salt thereof. In apreferred embodiment of the invention, the disease characterized byinflammatory, allergic, or proliferative processes is selected from: (i)lung diseases (ii) rheumatic diseases or autoimmune diseases or jointdiseases (iii) allergic diseases (iv) vasculitis diseases (v)dermatological diseases (vi) renal diseases (vii) hepatic diseases(viii) gastrointestinal diseases (ix) proctological diseases (x) eyediseases (xi) diseases of the ear, nose, and throat (ENT) area (xii)neurological diseases (xiii) blood diseases (xiv) tumor diseases (xv)endocrine diseases (xvi) organ and tissue transplantations andgraft-versus-host diseases (xvii) severe states of shock (xviii)substitution therapy; and (xix) pain of inflammatory genesis. In anotherpreferred embodiment of the invention, the disease characterized byinflammatory, allergic, or proliferative processes is selected from:type I diabetes, osteoarthritis, Guillain-Barre syndrome, restenosisfollowing percutaneous transluminal coronary angioplasty, Alzheimerdisease, acute and chronic pain, atherosclerosis, reperfusion injury,bone resorption diseases, congestive heart failure, myocardialinfarction, thermal injury, multiple organ injury secondary to trauma,acute purulent meningitis, necrotizing enterocolitis, and syndromesassociated with hemodialysis, leukopheresis, and granulocytetransfusion.

The invention further provides methods of treating the disease-states orconditions mentioned above, in a patient in need of such treatment, themethods comprising sequentially or simultaneously administering to thepatient: (a) an effective amount of a pharmaceutically acceptablecompound according to the invention or a tautomer, prodrug, solvate, orsalt thereof; and (b) a pharmaceutically acceptable glucocorticoid.

The invention further provides a method of assaying the glucocorticoidreceptor function in a sample, comprising: (a) contacting the samplewith a selected amount of a compound according to the invention or atautomer, prodrug, solvate, or salt thereof; and (b) detecting theamount of the compound according to the invention or a tautomer,prodrug, solvate, or salt thereof bound to glucocorticoid receptors inthe sample. In a preferred embodiment of the invention, the compoundaccording to the invention or a tautomer, prodrug, solvate, or saltthereof is labeled with a detectable marker selected from: a radiolabel,fluorescent tag, a chemiluminescent tag, a chromophore, and a spinlabel.

The invention also provides a method of imaging the glucocorticoidreceptor distribution in a sample or patient, the method comprising: (a)contacting the sample or administering to a patient a compound accordingto the invention or a tautomer, prodrug, solvate, or salt thereof havinga detectable marker (b) detecting the spatial distribution and amount ofthe compound according to the invention or a tautomer, prodrug, solvate,or salt thereof having a detectable marker bound to glucocorticoidreceptors in the sample or patient using an imaging means to obtain animage; and (c) displaying an image of the spatial distribution andamount of the compound according to the invention or a tautomer,prodrug, solvate, or salt thereof having a detectable marker bound toglucocorticoid receptors in the sample. In a preferred embodiment of theinvention, the imaging means is selected from: radioscintigraphy,nuclear magnetic resonance imaging (MRI), computed tomography (CT scan),or positron emission tomography (PET).

The invention also provides a kit for the in vitro diagnosticdetermination of the glucocorticoid receptor function in a sample,comprising: (a) a diagnostically effective amount of a compoundaccording to the invention or a tautomer, prodrug, solvate, or saltthereof; and (b) instructions for use of the diagnostic kit.

DEFINITION OF TERMS AND CONVENTIONS USED

Terms not specifically defined herein should be given the meanings thatwould be given to them by one of skill in the art in light of thedisclosure and the context. As used in the specification and appendedclaims, however, unless specified to the contrary, the following termshave the meaning indicated and the following conventions are adhered to

A. Chemical Nomenclature, Terms, and Conventions

In the groups, radicals, or moieties defined below, the number of carbonatoms is often specified preceding the group, for example, C₁-C₁₀ alkylmeans an alkyl group or radical having 1 to 10 carbon atoms. The term“lower” applied to any carbon-containing group means a group containingfrom 1 to 8 carbon atoms, as appropriate to the group (i.e., a cyclicgroup must have at least 3 atoms to constitute a ring). In general, forgroups comprising two or more subgroups, the last named group is theradical attachment point, for example, “alkylaryl” means a monovalentradical of the formula Alk-Ar—, while “arylalkyl” means a monovalentradical of the formula Ar-Alk- (where Alk is an alkyl group and Ar is anaryl group). Furthermore, the use of a term designating a monovalentradical where a divalent radical is appropriate shall be construed todesignate the respective divalent radical and vice versa. Unlessotherwise specified, conventional definitions of terms control andconventional stable atom valences are presumed and achieved in allformulas and groups.

The terms “alkyl” or “alkyl group” mean a branched or straight-chainsaturated aliphatic hydrocarbon monovalent radical. This term isexemplified by groups such as methyl, ethyl, n-propyl, 1-methylethyl(isopropyl), n-butyl, n-pentyl, 1,1-dimethylethyl (tert-butyl), and thelike. It may be abbreviated “Alk”.

The terms “alkenyl” or “alkenyl group” mean a branched or straight-chainaliphatic hydrocarbon monovalent radical containing at least onecarbon-carbon double bond. This term is exemplified by groups such asethenyl, propenyl, n-butenyl, isobutenyl, 3-methylbut-2-enyl,n-pentenyl, heptenyl, octenyl, decenyl, and the like.

The terms “alkynyl” or “alkynyl group” mean a branched or straight-chainaliphatic hydrocarbon monovalent radical containing at least onecarbon-carbon triple bond. This term is exemplified by groups such asethynyl, propynyl, n-butynyl, 2-butynyl, 3-methylbutynyl, n-pentynyl,heptynyl, octynyl, decynyl, and the like.

The terms “alkylene” or “alkylene group” mean a branched orstraight-chain saturated aliphatic hydrocarbon divalent radical havingthe specified number of carbon atoms. This term is exemplified by groupssuch as methylene, ethylene, propylene, n-butylene, and the like, andmay alternatively and equivalently be denoted herein as -(alkyl)-.

The terms “alkenylene” or “alkenylene group” mean a branched orstraight-chain aliphatic hydrocarbon divalent radical having thespecified number of carbon atoms and at least one carbon-carbon doublebond. This term is exemplified by groups such as ethenylene,propenylene, n-butenylene, and the like, and may alternatively andequivalently be denoted herein as -(alkylenyl)-.

The terms “alkynylene” or “alkynylene group” mean a branched orstraight-chain aliphatic hydrocarbon divalent radical containing atleast one carbon-carbon triple bond. This term is exemplified by groupssuch as ethynylene, propynylene, n-butynylene, 2-butynylene,3-methylbutynylene, n-pentynylene, heptynylene, octynylene, decynylene,and the like, and may alternatively and equivalently be denoted hereinas -(alkynyl)-.

The terms “alkoxy” or “alkoxy group” mean a monovalent radical of theformula AlkO—, where Alk is an alkyl group. This term is exemplified bygroups such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butoxy,tert-butoxy, pentoxy, and the like.

The terms “aryloxy”, “aryloxy group”, mean a monovalent radical of theformula ArO—, where Ar is aryl. This term is exemplified by groups suchas phenoxy, naphthoxy, and the like.

The terms “alkylcarbonyl”, “alkylcarbonyl group”, “alkanoyl”, or“alkanoyl group” mean a monovalent radical of the formula AlkC(O)—,where Alk is alkyl or hydrogen.

The terms “arylcarbonyl”, “arylcarbonyl group”, “aroyl” or “aroyl group”mean a monovalent radical of the formula ArC(O)—, where Ar is aryl.

The terms “acyl” or “acyl group” mean a monovalent radical of theformula RC(O)—, where R is a substituent selected from hydrogen or anorganic substituent. Exemplary substituents include alkyl, aryl,arylalkyl, cycloalkyl, heterocyclyl, heteroaryl, heteroarylalkyl, andthe like. As such, the terms comprise alkylcarbonyl groups andarylcarbonyl groups.

The terms “acylamino” or “acylamino group” mean a monovalent radical ofthe formula RC(O)N(R)—, where each R is a substituent selected fromhydrogen or a substituent group.

The terms “alkoxycarbonyl” or “alkoxycarbonyl group” mean a monovalentradical of the formula AlkO-C(O)—, where Alk is alkyl. Exemplaryalkoxycarbonyl groups include methoxycarbonyl, ethoxycarbonyl,tert-butyloxycarbonyl, and the like.

The terms “aryloxycarbonyl” or “aryloxycarbonyl group” mean a monovalentradical of the formula ArO—C(O)—, where Ar is aryl.

The terms “alkylcarbonyloxy” or “alkylcarbonyloxy group” or“alkanoyloxy” or “alkanoyloxy group” mean a monovalent radical of theformula AlkC(O)O—, where Alk is alkyl.

The terms “arylcarbonyloxy” or “arylcarbonyloxy group” or “aroyloxy” or“aroyloxy group” mean a monovalent radical of the formula ArC(O)O—,where Ar is aryl.

The terms “alkylaminocarbonyloxy” or “alkylaminocarbonyloxy group” meana monovalent radical of the formula R₂NC(O)O—, where each R isindependently hydrogen or lower alkyl.

The term “alkoxycarbonylamino” or “alkoxycarbonylamino group” mean amonovalent radical of the formula ROC(O)NH—, where R is lower alkyl.

The terms “alkylcarbonylamino” or “alkylcarbonylamino group” or“alkanoylamino” or “alkanoylamino groups” mean a monovalent radical ofthe formula AlkC(O)NH—, where Alk is alkyl. Exemplary alkylcarbonylaminogroups include acetamido (CH₃C(O)NH—).

The terms “alkylaminocarbonyloxy” or “alkylaminocarbonyloxy group” meana monovalent radical of the formula AlkNHC(O)O—, where Alk is alkyl.

The terms “amino” or “amino group” mean an —NH₂ group.

The terms “alkylamino” or “alkylamino group” mean a monovalent radicalof the formula (Alk)NH—, where Alk is alkyl. Exemplary alkylamino groupsinclude methylamino, ethylamino, propylamino, butylamino,tert-butylamino, and the like.

The terms “dialkylamino” or “dialkylamino group” mean a monovalentradical of the formula (Alk)(Alk)N—, where each Alk is independentlyalkyl. Exemplary dialkylamino groups include dimethylamino,methylethylamino, diethylamino, dipropylamino, ethylpropylamino, and thelike.

The terms “substituted amino” or “substituted amino group” mean amonovalent radical of the formula —NR₂, where each R is independently asubstituent selected from hydrogen or the specified substituents (butwhere both Rs cannot be hydrogen). Exemplary substituents include alkyl,alkanoyl, aryl, arylalkyl, cycloalkyl, heterocyclyl, heteroaryl,heteroarylalkyl, and the like.

The terms “alkoxycarbonylamino” or “alkoxycarbonylamino group” mean amonovalent radical of the formula AlkOC(O)NH—, where Alk is alkyl.

The terms “ureido” or “ureido group” mean a monovalent radical of theformula R₂NC(O)NH—, where each R is independently hydrogen or alkyl.

The terms “halogen” or “halogen group” mean a fluoro, chloro, bromo, oriodo group.

The term “halo” means one or more hydrogen atoms of the group arereplaced by halogen groups.

The terms “haloalkyl” or “haloalkyl group” mean a branched orstraight-chain saturated aliphatic hydrocarbon monovalent radical,wherein one or more hydrogen atoms thereof are each independentlyreplaced with halogen atoms. This term is exemplified by groups such aschloromethyl, 1,2-dibromoethyl, 1,1,1-trifluoropropyl, 2-iodobutyl,1-chloro-2-bromo-3-fluoropentyl, and the like.

The terms “sulfanyl”, “sulfanyl group”, “thioether”, or “thioethergroup” mean a divalent radical of the formula —S—.

The terms “alkylthio” or “alkylthio group” mean a monovalent radical ofthe formula AlkS—, where Alk is alkyl. Exemplary groups includemethylthio, ethylthio, n-propylthio, isopropylthio, n-butylthio, and thelike.

The terms “arylthio” or “arylthio group” mean a monovalent radical ofthe formula ArS—, where Ar is aryl.

The terms “sulfinyl”, “sulfinyl group”, “thionyl”, or “thionyl group”mean a divalent radical of the formula —SO—.

The terms “sulfonyl” or “sulfonyl group” mean a divalent radical of theformula —SO₂—.

The terms “sulfonylamino” or “sulfonylamino group” mean a divalentradical of the formula —SO₂NR—, where R is a hydrogen or a substituentgroup.

The terms “aminosulfonyl” or “aminosulfonyl group” mean a monovalentradical of the formula NR₂SO₂—, where R is each independently a hydrogenor a substituent group.

The terms “carbocycle” or “carbocyclic group” mean a stable aliphatic 3-to 15-membered monocyclic or polycyclic monovalent or divalent radicalconsisting solely of carbon and hydrogen atoms which may comprise one ormore fused or bridged ring(s), preferably a 5- to 7-membered monocyclicor 7- to 10-membered bicyclic ring. Unless otherwise specified, thecarbocycle may be attached at any carbon atom which results in a stablestructure and, if substituted, may be substituted at any suitable carbonatom which results in a stable structure. The term comprises cycloalkyl(including spiro cycloalkyl), cycloalkylene, cycloalkenyl,cycloalkenylene, cycloalkynyl, and cycloalkynylene, and the like.

The terms “cycloalkyl” or “cycloalkyl group” mean a stable aliphaticsaturated 3- to 15-membered monocyclic or polycyclic monovalent radicalconsisting solely of carbon and hydrogen atoms which may comprise one ormore fused or bridged ring(s), preferably a 5- to 7-membered monocyclicor 7- to 10-membered bicyclic ring. Unless otherwise specified, thecycloalkyl ring may be attached at any carbon atom which results in astable structure and, if substituted, may be substituted at any suitablecarbon atom which results in a stable structure. Exemplary cycloalkylgroups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl,cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, norbornane, adamantyl,tetrahydronaphthyl (tetralin), 1-decalinyl, bicyclo[2.2.2]octanyl,1-methylcyclopropyl, 2-methylcyclopentyl, 2-methylcyclooctyl, and thelike.

The terms “cycloalkenyl” or “cycloalkenyl group” mean a stable aliphatic5- to 15-membered monocyclic or polycyclic monovalent radical having atleast one carbon-carbon double bond and consisting solely of carbon andhydrogen atoms which may comprise one or more fused or bridged ring(s),preferably a 5- to 7-membered monocyclic or 7- to 10-membered bicyclicring. Unless otherwise specified, the cycloalkenyl ring may be attachedat any carbon atom which results in a stable structure and, ifsubstituted, may be substituted at any suitable carbon atom whichresults in a stable structure. Exemplary cycloalkenyl groups includecyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, cyclononenyl,cyclodecenyl, norbornenyl, 2-methylcyclopentenyl, 2-methylcyclooctenyl,and the like.

The terms “cycloalkynyl” or “cycloalkynyl group” mean a stable aliphatic8- to 15-membered monocyclic or polycyclic monovalent radical having atleast one carbon-carbon triple bond and consisting solely of carbon andhydrogen atoms which may comprise one or more fused or bridged ring(s),preferably a 8- to 10-membered monocyclic or 12- to 15-membered bicyclicring. Unless otherwise specified, the cycloalkynyl ring may be attachedat any carbon atom which results in a stable structure and, ifsubstituted, may be substituted at any suitable carbon atom whichresults in a stable structure. Exemplary cycloalkynyl groups include,cyclooctynyl, cyclononynyl, cyclodecynyl, 2-methylcyclooctynyl, and thelike.

The terms “cycloalkylene” or “cycloalkylene group” mean a stablesaturated aliphatic 3- to 15-membered monocyclic or polycyclic divalentradical consisting solely of carbon and hydrogen atoms which maycomprise one or more fused or bridged ring(s), preferably a 5- to7-membered monocyclic or 7- to 10-membered bicyclic ring. Unlessotherwise specified, the cycloalkyl ring may be attached at any carbonatom which results in a stable structure and, if substituted, may besubstituted at any suitable carbon atom which results in a stablestructure. Exemplary cycloalkylene groups include cyclopentylene, andthe like.

The terms “cycloalkenylene” or “cycloalkenylene group” mean a stablealiphatic 5- to 15-membered monocyclic or polycyclic divalent radicalhaving at least one carbon-carbon double bond and consisting solely ofcarbon and hydrogen atoms which may comprise one or more fused orbridged ring(s), preferably a 5- to 7-membered monocyclic or 7- to10-membered bicyclic ring. Unless otherwise specified, thecycloalkenylene ring may be attached at any carbon atom which results ina stable structure and, if substituted, may be substituted at anysuitable carbon atom which results in a stable structure. Exemplarycycloalkenylene groups include cyclopentenylene, cyclohexenylene,cycloheptenylene, cyclooctenylene, cyclononenylene, cyclodecenylene,norbornenylene, 2-methylcyclopentenylene, 2-methylcyclooctenylene, andthe like.

The terms “aryl” or “aryl group” mean an aromatic carbocyclic monovalentor divalent radical of from 6 to 14 carbon atoms having a single ring(e.g., phenyl or phenylene) or multiple condensed rings (e.g., naphthylor anthranyl). Unless otherwise specified, the aryl ring may be attachedat any suitable carbon atom which results in a stable structure and, ifsubstituted, may be substituted at any suitable carbon atom whichresults in a stable structure. Exemplary aryl groups include phenyl,naphthyl, anthryl, phenanthryl, indanyl, indenyl, biphenyl, and thelike. It may be abbreviated “Ar”.

The terms “heteroaryl” or “heteroaryl group” mean a stable aromatic 5-to 14-membered, monocyclic or polycyclic monovalent or divalent radicalwhich may comprise one or more fused or bridged ring(s), preferably a 5-to 7-membered monocyclic or 7- to 10-membered bicyclic radical, havingfrom one to four heteroatoms in the ring(s) independently selected fromnitrogen, oxygen, and sulfur, wherein any sulfur heteroatoms mayoptionally be oxidized and any nitrogen heteroatom may optionally beoxidized or be quaternized. Unless otherwise specified, the heteroarylring may be attached at any suitable heteroatom or carbon atom whichresults in a stable structure and, if substituted, may be substituted atany suitable heteroatom or carbon atom which results in a stablestructure. Exemplary and preferred heteroaryls include furanyl, thienyl,pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl,isothiazolyl, oxadiazolyl, triazolyl, tetrazolyl, thiadiazolyl,pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, indolyl,azaindolyl, dihydroindolyl, isoindolyl, benzofuranyl,dihydrobenzofuranyl, benzothienyl, dihydrobenzothienyl, indazolyl,benzimidazolyl, benzthiazolyl, benzoxazolyl, benzisoxazolyl,benzpyrazolyl, benzopyranone, purinyl, quinolizinyl, quinolinyl,dihydroquinolinyl, tetrahydroquinolinyl, tetrahydroquinoxalinyl,isoquinolinyl, dihydroisoquinolinyl, tetrahydroisoquinolinyl,cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, naphthyridinyl,pteridinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, andphenoxazinyl, acridine, and the like.

The terms “heterocycle”, “heterocycle group”, “heterocyclyl”, or“heterocyclyl group” mean a stable non-aromatic 5- to 14-memberedmonocyclic or polycyclic, monovalent or divalent, ring which maycomprise one or more fused or bridged ring(s), preferably a 5- to7-membered monocyclic or 7- to 10-membered bicyclic ring, having fromone to three heteroatoms in the ring(s) independently selected fromnitrogen, oxygen, and sulfur, wherein any sulfur heteroatoms mayoptionally be oxidized and any nitrogen heteroatom may optionally beoxidized or be quaternized. Unless otherwise specified, the heterocyclylring may be attached at any suitable heteroatom or carbon atom whichresults in a stable structure and, if substituted, may be substituted atany suitable heteroatom or carbon atom which results in a stablestructure. Exemplary and preferred heterocycles include pyrrolinyl,pyrrolidinyl, pyrazolinyl, pyrazolidinyl, piperidinyl, morpholinyl,thiomorpholinyl, piperazinyl, tetrahydropyranyl, tetrahydrothiopyranyl,tetrahydrofuranyl, hexahydropyrimidinyl, hexahydropyridazinyl,2,3-dihydro-1,4-benzodioxin, 1,3-benzodioxole,3,4-dihydro-2H-1,4-benzoxazine, 1,2,3,4-tetrahydroisoquinoline,N-ethyl-N′-methylbenzene-1,2-diamine, 1,2,3,4-tetrahydroquinoline andthe like.

The term “compounds of the invention” and equivalent expressions aremeant to embrace compounds of Formula (I) as herein described, includingthe tautomers, the prodrugs, the salts, particularly thepharmaceutically acceptable salts, and the solvates and hydratesthereof, where the context so permits. In general and preferably, thecompounds of the invention and the formulas designating the compounds ofthe invention are understood to only include the stable compoundsthereof and exclude unstable compounds, even if an unstable compoundmight be considered to be literally embraced by the compound formula.Similarly, reference to intermediates, whether or not they themselvesare claimed, is meant to embrace their salts and solvates, where thecontext so permits. For the sake of clarity, particular instances whenthe context so permits are sometimes indicated in the text, but theseinstances are purely illustrative and it is not intended to excludeother instances when the context so permits.

The terms “optional” or “optionally” mean that the subsequentlydescribed event or circumstances may or may not occur, and that thedescription includes instances where the event or circumstance occursand instances in which it does not. For example, “optionally substitutedaryl” means that the aryl radical may or may not be substituted and thatthe description includes both substituted aryl radicals and arylradicals having no substitution.

The terms “stable compound” or “stable structure” mean a compound thatis sufficiently robust to survive isolation to a useful degree of purityfrom a reaction mixture, and formulation into an efficacious therapeuticor diagnostic agent. For example, a compound which would have a“dangling valency” or is a carbanion is not a compound contemplated bythe invention.

The term “substituted” means that any one or more hydrogens on an atomof a group or moiety, whether specifically designated or not, isreplaced with a selection from the indicated group of substituents,provided that the atom's normal valency is not exceeded and that thesubstitution results in a stable compound. If a bond to a substituent isshown to cross the bond connecting two atoms in a ring, then suchsubstituent may be bonded to any atom on the ring. When a substituent islisted without indicating the atom via which such substituent is bondedto the rest of the compound, then such substituent may be bonded via anyatom in such substituent. For example, when the substituent ispiperazinyl, piperidinyl, or tetrazolyl, unless specified otherwise,such piperazinyl, piperidinyl, or tetrazolyl group may be bonded to therest of the compound of the invention via any atom in such piperazinyl,piperidinyl, or tetrazolyl group. Generally, when any substituent orgroup occurs more than one time in any constituent or compound, itsdefinition on each occurrence is independent of its definition at everyother occurrence. Thus, for example, if a group is shown to besubstituted with 0 to 2 R⁵, then such group is optionally substitutedwith up to two R⁵ groups and R⁵ at each occurrence is selectedindependently from the defined list of possible R⁵. Such combinations ofsubstituents and/or variables, however, are permissible only if suchcombinations result in stable compounds.

In a specific embodiment, the term “about” or “approximately” meanswithin 20%, preferably within 10%, and more preferably within 5% of agiven value or range.

The yield of each of the reactions described herein is expressed as apercentage of the theoretical yield.

B. Salt, Prodrug, Derivative, and Solvate Terms and Conventions

The terms “prodrug” or “prodrug derivative” mean a covalently-bondedderivative or carrier of the parent compound or active drug substancewhich undergoes at least some biotransformation prior to exhibiting itspharmacological effect(s). In general, such prodrugs have metabolicallycleavable groups and are rapidly transformed in vivo to yield the parentcompound, for example, by hydrolysis in blood, and generally includeesters and amide analogs of the parent compounds. The prodrug isformulated with the objectives of improved chemical stability, improvedpatient acceptance and compliance, improved bioavailability, prolongedduration of action, improved organ selectivity, improved formulation(e.g., increased hydrosolubility), and/or decreased side effects (e.g.,toxicity). In general, prodrugs themselves have weak or no biologicalactivity and are stable under ordinary conditions. Prodrugs can bereadily prepared from the parent compounds using methods known in theart, such as those described in A Textbook of Drug Design andDevelopment, Krogsgaard-Larsen and H. Bundgaard (eds.), Gordon & Breach,1991, particularly Chapter 5: “Design and Applications of Prodrugs”;Design of Prodrugs, H. Bundgaard (ed.), Elsevier, 1985; Prodrugs:Topical and Ocular Drug Delivery, K. B. Sloan (ed.), Marcel Dekker,1998; Methods in Enzymology, K. Widder et al. (eds.), Vol. 42, AcademicPress, 1985, particularly pp. 309-396; Burger's Medicinal Chemistry andDrug Discovery, 5th Ed., M. Wolff (ed.), John Wiley & Sons, 1995,particularly Vol. 1 and pp. 172-178 and pp. 949-982; Pro-Drugs as NovelDelivery Systems, T. Higuchi and V. Stella (eds.), Am. Chem. Soc., 1975;and Bioreversible Carriers in Drug Design, E. B. Roche (ed.), Elsevier,1987, each of which is incorporated herein by reference in theirentireties.

The term “pharmaceutically acceptable prodrug” as used herein means aprodrug of a compound of the invention which is, within the scope ofsound medical judgment, suitable for use in contact with the tissues ofhumans and lower animals without undue toxicity, irritation, allergicresponse, and the like, commensurate with a reasonable benefit/riskratio, and effective for their intended use, as well as the zwitterionicforms, where possible.

The term “salt” means an ionic form of the parent compound or theproduct of the reaction between the parent compound with a suitable acidor base to make the acid salt or base salt of the parent compound. Saltsof the compounds of the present invention can be synthesized from theparent compounds which contain a basic or acidic moiety by conventionalchemical methods. Generally, the salts are prepared by reacting the freebase or acid parent compound with stoichiometric amounts or with anexcess of the desired salt-forming inorganic or organic acid or base ina suitable solvent or various combinations of solvents.

The term “pharmaceutically acceptable salt” means a salt of a compoundof the invention which is, within the scope of sound medical judgment,suitable for use in contact with the tissues of humans and lower animalswithout undue toxicity, irritation, allergic response, and the like,commensurate with a reasonable benefit/risk ratio, generally water oroil-soluble or dispersible, and effective for their intended use. Theterm includes pharmaceutically-acceptable acid addition salts andpharmaceutically-acceptable base addition salts. As the compounds of thepresent invention are useful in both free base and salt form, inpractice, the use of the salt form amounts to use of the base form.Lists of suitable salts are found in, e.g., S. M. Birge et al., J.Pharm. Sci., 1977, 66, pp. 1-19, which is hereby incorporated byreference in its entirety.

The term “pharmaceutically-acceptable acid addition salt” means thosesalts which retain the biological effectiveness and properties of thefree bases and which are not biologically or otherwise undesirable,formed with inorganic acids such as hydrochloric acid, hydrobromic acid,hydroiodic acid, sulfuric acid, sulfamic acid, nitric acid, phosphoricacid, and the like, and organic acids such as acetic acid,trichloroacetic acid, trifluoroacetic acid, adipic acid, alginic acid,ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid,2-acetoxybenzoic acid, butyric acid, camphoric acid, camphorsulfonicacid, cinnamic acid, citric acid, digluconic acid, ethanesulfonic acid,glutamic acid, glycolic acid, glycerophosphoric acid, hemisulfic acid,heptanoic acid, hexanoic acid, formic acid, fumaric acid,2-hydroxyethanesulfonic acid (isethionic acid), lactic acid, maleicacid, hydroxymaleic acid, malic acid, malonic acid, mandelic acid,mesitylenesulfonic acid, methanesulfonic acid, naphthalenesulfonic acid,nicotinic acid, 2-naphthalenesulfonic acid, oxalic acid, pamoic acid,pectinic acid, phenylacetic acid, 3-phenylpropionic acid, picric acid,pivalic acid, propionic acid, pyruvic acid, pyruvic acid, salicylicacid, stearic acid, succinic acid, sulfanilic acid, tartaric acid,p-toluenesulfonic acid, undecanoic acid, and the like.

The term “pharmaceutically-acceptable base addition salt” means thosesalts which retain the biological effectiveness and properties of thefree acids and which are not biologically or otherwise undesirable,formed with inorganic bases such as ammonia or hydroxide, carbonate, orbicarbonate of ammonium or a metal cation such as sodium, potassium,lithium, calcium, magnesium, iron, zinc, copper, manganese, aluminum,and the like. Particularly preferred are the ammonium, potassium,sodium, calcium, and magnesium salts. Salts derived frompharmaceutically-acceptable organic nontoxic bases include salts ofprimary, secondary, and tertiary amines, quaternary amine compounds,substituted amines including naturally occurring substituted amines,cyclic amines and basic ion-exchange resins, such as methylamine,dimethylamine, trimethylamine, ethylamine, diethylamine, triethylamine,isopropylamine, tripropylamine, tributylamine, ethanolamine,diethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol,dicyclohexylamine, lysine, arginine, histidine, caffeine, hydrabamine,choline, betaine, ethylenediamine, glucosamine, methylglucamine,theobromine, purines, piperazine, piperidine, N-ethylpiperidine,tetramethylammonium compounds, tetraethylammonium compounds, pyridine,N,N-dimethylaniline, N-methylpiperidine, N-methylmorpholine,dicyclohexylamine, dibenzylamine, N,N-dibenzylphenethylamine,1-ephenamine, N,N-dibenzylethylenediamine, polyamine resins, and thelike. Particularly preferred organic nontoxic bases are isopropylamine,diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline,and caffeine.

The term “solvate” means a physical association of a compound with oneor more solvent molecules or a complex of variable stoichiometry formedby a solute (for example, a compound of Formula (I)) and a solvent, forexample, water, ethanol, or acetic acid. This physical association mayinvolve varying degrees of ionic and covalent bonding, includinghydrogen bonding. In certain instances, the solvate will be capable ofisolation, for example, when one or more solvent molecules areincorporated in the crystal lattice of the crystalline solid. Ingeneral, the solvents selected do not interfere with the biologicalactivity of the solute. Solvates encompasses both solution-phase andisolatable solvates. Representative solvates include hydrates,ethanolates, methanolates, and the like.

The term “hydrate” means a solvate wherein the solvent molecule(s)is/are H₂O.

The compounds of the present invention as discussed below include thefree base or acid thereof, their salts, solvates, and prodrugs and mayinclude oxidized sulfur atoms or quaternized nitrogen atoms in theirstructure, although not explicitly stated or shown, particularly thepharmaceutically acceptable forms thereof. Such forms, particularly thepharmaceutically acceptable forms, are intended to be embraced by theappended claims.

C. Isomer Terms and Conventions

The term “isomers” means compounds having the same number and kind ofatoms, and hence the same molecular weight, but differing with respectto the arrangement or configuration of their atoms in space. The termincludes stereoisomers and geometric isomers.

The terms “stereoisomer” or “optical isomer” means a stable isomer thathas at least one chiral atom or restricted rotation giving rise toperpendicular dissymmetric planes (e.g., certain biphenyls, allenes, andspiro compounds) and can rotate plane-polarized light. Becauseasymmetric centers and other chemical structure exist in the compoundsof the invention which may give rise to stereoisomerism, the inventioncontemplates stereoisomers and mixtures thereof. The compounds of theinvention and their salts include asymmetric carbon atoms and maytherefore exist as single stereoisomers, racemates, and as mixtures ofenantiomers and diastereomers. Typically, such compounds will beprepared as a racemic mixture. If desired, however, such compounds canbe prepared or isolated as pure stereoisomers, i.e., as individualenantiomers or diastereomers, or as stereoisomer-enriched mixtures. Asdiscussed in more detail below, individual stereoisomers of compoundsare prepared by synthesis from optically active starting materialscontaining the desired chiral centers or by preparation of mixtures ofenantiomeric products followed by separation or resolution, such asconversion to a mixture of diastereomers followed by separation orrecrystallization, chromatographic techniques, use of chiral resolvingagents, or direct separation of the enantiomers on chiralchromatographic columns. Starting compounds of particularstereochemistry are either commercially available or are made by themethods described below and resolved by techniques well-known in theart.

The term “enantiomers” means a pair of stereoisomers that arenon-superimposable mirror images of each other.

The terms “diastereoisomers” or “diastereomers” mean stereoisomers whichare not mirror images of each other.

The terms “racemic mixture” or “racemate” mean a mixture containingequal parts of individual enantiomers.

The term “non-racemic mixture” means a mixture containing unequal partsof individual enantiomers.

The term “geometrical isomer” means a stable isomer which results fromrestricted freedom of rotation about double bonds (e.g., cis-2-buteneand trans-2-butene) or in a cyclic structure (e.g.,cis-1,3-dichlorocyclobutane and trans-1,3-dichlorocyclobutane). Becausecarbon-carbon double (olefinic) bonds, C═N double bonds, cyclicstructures, and the like may be present in the compounds of theinvention, the invention contemplates each of the various stablegeometric isomers and mixtures thereof resulting from the arrangement ofsubstituents around these double bonds and in these cyclic structures.The substituents and the isomers are designated using the cis/transconvention or using the E or Z system, wherein the term “E” means higherorder substituents on opposite sides of the double bond, and the term“Z” means higher order substituents on the same side of the double bond.A thorough discussion of E and Z isomerism is provided in J. March,Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 4thed., John Wiley & Sons, 1992, which is hereby incorporated by referencein its entirety. Several of the following examples represent single Eisomers, single Z isomers, and mixtures of E/Z isomers. Determination ofthe E and Z isomers can be done by analytical methods such as X-raycrystallography, ¹H NMR, and ¹³C NMR.

Some of the compounds of the invention can exist in more than onetautomeric form. As mentioned above, the compounds of the inventioninclude all such tautomers.

It is well-known in the art that the biological and pharmacologicalactivity of a compound is sensitive to the stereochemistry of thecompound. Thus, for example, enantiomers often exhibit strikinglydifferent biological activity including differences in pharmacokineticproperties, including metabolism, protein binding, and the like, andpharmacological properties, including the type of activity displayed,the degree of activity, toxicity, and the like. Thus, one skilled in theart will appreciate that one enantiomer may be more active or mayexhibit beneficial effects when enriched relative to the otherenantiomer or when separated from the other enantiomer. Additionally,one skilled in the art would know how to separate, enrich, orselectively prepare the enantiomers of the compounds of the inventionfrom this disclosure and the knowledge of the prior art.

Thus, although the racemic form of drug may be used, it is often lesseffective than administering an equal amount of enantiomerically puredrug; indeed, in some cases, one enantiomer may be pharmacologicallyinactive and would merely serve as a simple diluent. For example,although ibuprofen had been previously administered as a racemate, ithas been shown that only the S-isomer of ibuprofen is effective as ananti-inflammatory agent (in the case of ibuprofen, however, although theR-isomer is inactive, it is converted in vivo to the S-isomer, thus, therapidity of action of the racemic form of the drug is less than that ofthe pure S-isomer). Furthermore, the pharmacological activities ofenantiomers may have distinct biological activity. For example,S-penicillamine is a therapeutic agent for chronic arthritis, whileR-penicillamine is toxic. Indeed, some purified enantiomers haveadvantages over the racemates, as it has been reported that purifiedindividual isomers have faster transdermal penetration rates compared tothe racemic mixture. See U.S. Pat. Nos. 5,114,946 and 4,818,541.

Thus, if one enantiomer is pharmacologically more active, less toxic, orhas a preferred disposition in the body than the other enantiomer, itwould be therapeutically more beneficial to administer that enantiomerpreferentially. In this way, the patient undergoing treatment would beexposed to a lower total dose of the drug and to a lower dose of anenantiomer that is possibly toxic or an inhibitor of the otherenantiomer.

Preparation of pure enantiomers or mixtures of desired enantiomericexcess (ee) or enantiomeric purity are accomplished by one or more ofthe many methods of (a) separation or resolution of enantiomers, or (b)enantioselective synthesis known to those of skill in the art, or acombination thereof. These resolution methods generally rely on chiralrecognition and include, for example, chromatography using chiralstationary phases, enantioselective host-guest complexation, resolutionor synthesis using chiral auxiliaries, enantioselective synthesis,enzymatic and nonenzymatic kinetic resolution, or spontaneousenantioselective crystallization. Such methods are disclosed generallyin Chiral Separation Techniques: A Practical Approach (2nd Ed.), G.Subramanian (ed.), Wiley-VCH, 2000; T. E. Beesley and R. P. W. Scott,Chiral Chromatography, John Wiley & Sons, 1999; and Satinder Ahuja,Chiral Separations by Chromatography, Am. Chem. Soc., 2000. Furthermore,there are equally well-known methods for the quantitation ofenantiomeric excess or purity, for example, GC, HPLC, CE, or NMR, andassignment of absolute configuration and conformation, for example, CDORD, X-ray crystallography, or NMR.

In general, all tautomeric forms and isomeric forms and mixtures,whether individual geometric isomers or stereoisomers or racemic ornon-racemic mixtures, of a chemical structure or compound is intended,unless the specific stereochemistry or isomeric form is specificallyindicated in the compound name or structure.

D. Pharmaceutical Administration and Diagnostic and Treatment Terms andConventions

The term “patient” includes both human and non-human mammals.

The term “effective amount” means an amount of a compound according tothe invention which, in the context of which it is administered or used,is sufficient to achieve the desired effect or result. Depending on thecontext, the term effective amount may include or be synonymous with apharmaceutically effective amount or a diagnostically effective amount.

The terms “pharmaceutically effective amount” or “therapeuticallyeffective amount” means an amount of a compound according to theinvention which, when administered to a patient in need thereof, issufficient to effect treatment for disease-states, conditions, ordisorders for which the compounds have utility. Such an amount would besufficient to elicit the biological or medical response of a tissue,system, or patient that is sought by a researcher or clinician. Theamount of a compound of according to the invention which constitutes atherapeutically effective amount will vary depending on such factors asthe compound and its biological activity, the composition used foradministration, the time of administration, the route of administration,the rate of excretion of the compound, the duration of treatment, thetype of disease-state or disorder being treated and its severity, drugsused in combination with or coincidentally with the compounds of theinvention, and the age, body weight, general health, sex, and diet ofthe patient. Such a therapeutically effective amount can be determinedroutinely by one of ordinary skill in the art having regard to their ownknowledge, the prior art, and this disclosure.

The term “diagnostically effective amount” means an amount of a compoundaccording to the invention which, when used in a diagnostic method,apparatus, or assay, is sufficient to achieve the desired diagnosticeffect or the desired biological activity necessary for the diagnosticmethod, apparatus, or assay. Such an amount would be sufficient toelicit the biological or medical response in a diagnostic method,apparatus, or assay, which may include a biological or medical responsein a patient or in a in vitro or in vivo tissue or system, that issought by a researcher or clinician. The amount of a compound accordingto the invention which constitutes a diagnostically effective amountwill vary depending on such factors as the compound and its biologicalactivity, the diagnostic method, apparatus, or assay used, thecomposition used for administration, the time of administration, theroute of administration, the rate of excretion of the compound, theduration of administration, drugs and other compounds used incombination with or coincidentally with the compounds of the invention,and, if a patient is the subject of the diagnostic administration, theage, body weight, general health, sex, and diet of the patient. Such adiagnostically effective amount can be determined routinely by one ofordinary skill in the art having regard to their own knowledge, theprior art, and this disclosure.

The term “modulate” means the ability of a compound to alter thefunction of the glucocorticoid receptor by, for example, binding to andstimulating or inhibiting the glucocorticoid receptor functionalresponses.

The term “modulator” in the context of describing compounds according tothe invention means a compound that modulates the glucocorticoidreceptor function. As such, modulators include, but are not limited to,agonists, partial agonists, antagonists, and partial antagonists.

The term “agonist” in the context of describing compounds according tothe invention means a compound that, when bound to the glucocorticoidreceptor, enhances or increases the glucocorticoid receptor function. Assuch, agonists include partial agonists and full agonists.

The term “full agonist” in the context of describing compounds accordingto the invention means a compound that evokes the maximal stimulatoryresponse from the glucocorticoid receptor, even when there are spare(unoccupied) glucocorticoid receptors present.

The term “partial agonist” in the context of describing compoundsaccording to the invention means a compound that is unable to evoke themaximal stimulatory response from the glucocorticoid receptor, even atconcentrations sufficient to saturate the glucocorticoid receptorspresent.

The term “antagonist” in the context of describing compounds accordingto the invention means a compound that directly or indirectly inhibitsor suppresses the glucocorticoid receptor function. As such, antagonistsinclude partial antagonists and full antagonists.

The term “full antagonist” in the context of describing compoundsaccording to the invention means a compound that evokes the maximalinhibitory response from the glucocorticoid receptor, even when thereare spare (unoccupied) glucocorticoid receptors present.

The term “partial antagonist” in the context of describing compoundsaccording to the invention means a compound that is unable to evoke themaximal inhibitory response from the glucocorticoid receptor, even atconcentrations sufficient to saturate the glucocorticoid receptorspresent.

The terms “treating” or “treatment” mean the treatment of adisease-state in a patient, and include:

-   -   (i) preventing the disease-state from occurring in a patient, in        particular, when such patient is genetically or otherwise        predisposed to the disease-state but has not yet been diagnosed        as having it;    -   (ii) inhibiting or ameliorating the disease-state in a patient,        i.e., arresting or slowing its development; or    -   (iii) relieving the disease-state in a patient, i.e., causing        regression or cure of the disease-state.        General Synthetic Methods for Making Compounds of Formula (IA)        and (IB)

The invention also provides processes for making compounds of Formula(IA) and (IB). In all schemes, unless specified otherwise, A, B, C, D,E, R¹, R², and R³ in the formulas below shall have the meaning of A, B,C, D, E, R¹, R², and R³ in the Formula (IA) and (IB) of the inventiondescribed hereinabove. Intermediates used in the preparation ofcompounds of the invention are either commercially available or readilyprepared by methods known to those skilled in the art.

Optimum reaction conditions and reaction times may vary depending on theparticular reactants used. Unless otherwise specified, solvents,temperatures, pressures, and other reaction conditions may be readilyselected by one of ordinary skill in the art. Specific procedures areprovided in the Synthetic Examples section. Typically, reaction progressmay be monitored by thin layer chromatography (TLC), if desired, andintermediates and products may be purified by chromatography on silicagel and/or by recrystallization.

Compounds of Formula (IA) may be prepared by the method outlined inScheme I.

As illustrated in Scheme I, nitrile is reduced with a suitable reducingagent, such as diisopropyl aluminum hydride, in a suitable solvent, suchas dichloromethane or THF, to produce an aldehyde (III). Condensationsof aldehydes are well known in the art and the[1,3]dithian-2-yltrimethylsilane anion can be condensed with thealdehyde (III) in a suitable solvent, such as THF or diethyl ether, toprovide a thioketene acetal (V). Reduction of the double bond of thethioketene acetal (V) in the presence of triethylsilane and a suitableacid, such as TFA, in a suitable solvent, such as dichloromethane,provides thioacetal (VI). Deprotection of the thioacetal (VI) in thepresence of iodomethane in a suitable solvent, such as acetonitrile,provides an aldehyde (VII). Nucleophilic additions to aldehydes is wellknown in the art and the trifluoromethyl anion can be added to thealdehyde (VII) in a suitable solvent, such as THF, or diethyl ether, toprovide a secondary alcohol (VIII). Oxidation of the alcohol (VIII) inthe presence of a suitable oxidizing reagent, such as Dess-Martin'speriodinane or manganese dioxide, in a suitable solvent, such asdichloromethane or acetone, provides a ketone (IX). Reaction of theketone (IX) with a suitable organometallic reagent R³M, such as aGrignard reagent (M is MgBr or MgCl) or an organolithium reagent (M isLi), in a suitable solvent, such as THF or diethyl ether, provides thedesired compound of Formula (IA) wherein C is CH₂, D is CR⁴R⁵ (where R⁴is CF₃ and R⁵ is OH), and E is a bond. Alternatively, a compound ofFormula (IA), when C is a bond, D is CR⁴R⁵ (where R⁴ is CF₃ and R⁵ isOH), and E is a bond, may be prepared by starting from the aldehyde(III) and following steps (f), (g), and (h) shown in Scheme I.

Reaction of the ketone (IX) with a sulfur ylide in a suitable solvent,such as THF or diethyl ether, provides an epoxide (XII). Cleavage ofepoxides is well known in the art, and may be achieved by the additionof nucleophiles or organometallic reagents. The epoxide (XII) can becleaved by the addition of organometallic reagents R³M, such as aGrignard reagent (M is MgBr or MgCl) or an organolithium reagent (M isLi), in a suitable solvent, such as THF or diethyl ether. Cleavage ofthe epoxide (XII) may also be achieved by reacting with nucleophiles R³Hsuch as amines (where R³ is NR⁶R⁷), alcohols (where R³ is OR⁸), orthiols (where R³ is SR⁹) either with or without a base in a suitablesolvent, such as DMF or DMSO, to provide the compound of Formula (IA),where C is CH₂, D is CR⁴R⁵ (where R⁴ is CF₃ and R⁵ is OH), and E is aCH₂. Alternatively, compound of Formula (IA) where C is a bond, D isCR⁴R⁵ (where R⁴ is CF₃ and R⁵ is OH), and E is a CH₂, may be obtained bystarting with the aldehyde (III) and following the steps (f), (g), (i),and (j) shown in Scheme I.

Reaction of the aldehyde (VII) with a suitable organometallic reagentR³M, such as a Grignard reagent (M is MgBr or MgCl) or an organolithiumreagent (M is Li), in a suitable solvent, such as THF or diethyl ether,provides a secondary alcohol (XIV). Oxidation of the alcohol (XIV) inthe presence of a suitable oxidizing reagent, such as Dess-Martin'speriodinane, in a suitable solvent, such as dichloromethane or acetone,provides a ketone (XV). Reaction of the ketone (XV) with(trifluoromethyl)trimethylsilane in the presence of a suitable source offluoride, such as tetrabutylammonium fluoride, in a suitable solvent,such as THF or diethyl ether, provides the compound of Formula (IA)where C is CH₂, D is CR⁴R⁵ (where R⁴ is CF₃ and R⁵ is OH), and E is abond. Alternatively, the compound of Formula (IA) where C is a bond, Dis CR⁴R⁵ (where R⁴ is CF₃ and R⁵ is OH), and E is a bond, may beobtained by starting with the aldehyde (III) and following steps (e),(k), and (l) of Scheme I.

Compounds of Formula (IB) may be prepared by the method outlined inScheme II.

Reaction of nitrites with Grignard reagents is well known in the art. Asillustrated in Scheme II, reacting a nitrile (II) with a Grignardreagent R⁴M (M is MgBr or MgCl) in a suitable solvent, such as THF orether, provides a ketone (XVII). Reaction of the ketone (XVII) withorganometallic reagents R³M, such as a Grignard reagent (M is MgBr orMgCl) or an organolithium reagent (M is Li), in a suitable solvent, suchas THF or ether, provides the compound of Formula (IB).

Compounds of Formula (IB) may also be prepared by the method outlined inScheme III.

As shown in Scheme III, reaction of an aldehyde (VII) with a suitableorganometallic reagent R⁴M, such as a Grignard reagent (M is MgBr orMgCl), in a suitable solvent, such as THF or diethyl ether, provides asecondary alcohol (XVIII). Oxidation of the alcohol (XVIII) in thepresence of a suitable oxidizing reagent, such as Dess-Martin'speriodinane, in a suitable solvent, such as dichloromethane or acetone,provides a ketone (XIX). Reaction of the ketone (XIX) with a suitableorganometallic reagent R³M, such as a Grignard reagent (M is MgBr orMgCl) or an organolithium reagent (M is Li), in a suitable solvent, suchas THF or diethyl ether, provides the compound of Formula (IB) where Cis CH₂, D is CR⁴R⁵ (R⁵ is OH), and E is a bond.

Reaction of the ketone (XIX) with a sulfur ylide in a suitable solvent,such as THF or diethyl ether, provides an epoxide (XX). The epoxide (XX)can be cleaved by the addition of organometallic reagents R³M, such as aGrignard reagent (M is MgBr or MgCl) or an organolithium reagent (M isLi), in a suitable solvent, such as THF or diethyl ether. Cleavage ofthe epoxide (XX) may also be achieved by reacting with nucleophiles R³Hsuch as amines (where R³ is NR⁶R⁷), alcohols (where R³ is OR⁸), orthiols (where R³ is SR⁹) either with or without a base in a suitablesolvent, such as DMF or DMSO, to provide a compound of Formula (IB),where C is CH₂, D is CR⁴R⁵ (where R⁵ is OH), and E is a CH₂.Alternatively, a compound of Formula (IB) where C is a bond, D is CR⁴R⁵(where R⁵ is OH), and E is a CH₂, may be obtained by starting with theketone (XVII) and following the steps (d) and (e).

A method for making the benzotriazolonitrile (XXV) and the benzimidazolenitrile (XXVI) is outlined in Scheme IV.

As outlined in Scheme IV, an optionally substitutedchloronitrobenzonitrile (XXI) is reacted with an optionally substitutedaniline (XXII) in the presence of diisopropylethylamine in a suitablesolvent, such as DMF or DMA, to provide an optionally substitutedaminonitrobenzonitrile (XXIII). The aminonitrobenzonitrile (XXIII) isreduced under hydrogen transfer conditions to a correspondingdiaminobenzonitrile (XXIV). The optionally substituteddiaminobenzonitrile (XXIV) is reacted with sodium nitrate in acetic acidto provide an optionally substituted benzotriazole (XXV). The optionallysubstituted diaminobenzonitrile (XXIV) is heated with trimethylorthoformate in the presence of a suitable acid, such as p-toluenesulfonic acid, to provide an optionally substituted benzimidazole(XXVI).

An indazole nitrile (II), wherein A is N and B is CH, is preparedaccording to the known procedure of Halley et al., Syn. Commun., 1997,27(7), pp. 1199-1207. An indolonitrile (II), wherein A is CH and B isCH, is prepared according to the known procedure of Antilla et al., J.Am. Chem. Soc., 2002, 124, pp. 11684-11688.

In order that this invention be more fully understood, the followingexamples are set forth. These examples are for the purpose ofillustrating embodiments of this invention, and are not to be construedas limiting the scope of the invention in any way since, as recognizedby one skilled in the art, particular reagents or conditions could bemodified as needed for individual compounds. Starting materials used areeither commercially available or easily prepared from commerciallyavailable materials by those skilled in the art.

EXPERIMENTAL EXAMPLES Example 12,2,2-Trifluoro-1-phenyl-1-(1-phenyl-1H-indazol-5-yl)ethanol

Step (a): To a solution of 1-phenyl-1H-indazole-5-carbonitrile (12.58 g,57.38 mmol) in 300 mL of CH₂Cl₂ at 0° C. was added DIBAL-H (1M in THF,80.33 mL, 80.33 mmol). The resulting yellow suspension was stirred for 2hours and then poured into 150 mL of cold 1N HCl solution. The biphasicsystem was cooled to 0° C. and then basified to pH 8 by the addition ofsaturated aqueous sodium bicarbonate (NaHCO₃) solution. The aqueouslayer was extracted with three 100 mL portions of CH₂Cl₂. The combinedorganic phase was dried over sodium sulfate (Na₂SO₄), filtered, and thenconcentrated in vacuo. The crude material was purified by flash columnchromatography with silica gel (eluted with 100%-80% hexanes/EtOAc). Thedesired product 1-phenyl-1H-indazole-5-carbaldehyde was obtained as alight yellow solid (8.8 g, 69% yield; M+H⁺: 223).

Step (b): To a solution of 1-phenyl-1H-indazole-5-carbaldehyde (6.0 g,27.0 mmol) in 50 mL of THF at 0° C. was added a solution of TMSCF₃ inTHF (4.5 g, 31.8 mmol). The resulting light yellow solution was stirredat 0° C. for 15 minutes, then tetrabutylammonium fluoride (TBAF) (1M inTHF, 7.8 mL, 7.8 mmol) was added. The reaction mixture was allowed towarm up to room temperature and then stirred for an additional 14 hours.The THF was evaporated in vacuo and the resulting residue was dissolvedin 100 mL of EtOAc, washed with three 25 mL portions of water, and a 25mL portion of brine, dried over sodium sulfate, filtered, and thesolvent was evaporated in vacuo. The crude material was purified byflash column chromatography with silica gel (eluted with 80%hexanes/EtOAc). The desired product2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol was obtained as alight yellow solid (7.1 g, 88.0% yield; M+H⁺: 293).

Step (c): A suspension of Dess-Martin periodinane (11.9 g, 28.0 mmol)and 2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol (7.0 g, 24.0mmol) in 100 mL of CH₂Cl₂ was allowed to stir for 12 hours at roomtemperature. The reaction mixture was added to 150 mL of hexane and theresulting white precipitate was filtered through a pad of CELITE® filteraid. The combined organic solution was washed with three 25 mL portionsof aqueous saturated sodium bicarbonate solution and a 25 mL portion ofbrine, dried over sodium sulfate, filtered, and the solvent wasevaporated in vacuo. The crude material was purified by flash columnchromatography with silica gel (eluted with 85% hexanes/EtOAc) Thedesired product 2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanone wasobtained as a white solid (6.3 g, 91.0% yield; M+H⁺: 291).

Step (d): To a solution of2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanone (50.0 mg, 0.2 mmol)in 0.5 mL of THF was added phenylmagnesium bromide (1.0 M, 1.0 mL, 1.0mmol) at room temperature. The solution was stirred at this temperaturefor 12.0 hours. The reaction was quenched with 2 mL of saturated aqueousammonium chloride (NH₄Cl) solution and 3.0 mL of water. The aqueouslayer was extracted with three 5 mL portions of EtOAc and the combinedorganic layers were dried over sodium sulfate, filtered, and the solventwas evaporated in vacuo. The crude material was purified by flash columnchromatography with silica gel (eluted with 100%-85% hexanes/EtOAc). Thedesired product2,2,2-trifluoro-1-phenyl-1-(1-phenyl-1H-indazol-5-yl)ethanol wasobtained as a white solid (51.0 mg, 80% yield; M+H⁺: 369).

The following examples were synthesized following the procedureillustrated for Example 1, step (d), using the corresponding Grignard orequivalent organometallic reagent. The percent yield of the reaction andthe M+H⁺ are indicated in parentheses.

-   1-Biphenyl-3-yl-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol    (72%, M+H⁺: 445);-   1-(3,4-Difluorophenyl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol    (63%, M+H⁺: 405);-   1-(3,5-Difluorophenyl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol    (82%, M+H⁺: 405);-   1-(3-Chloro-5-fluorophenyl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol    (66%, M+H⁺: 421);-   1-(4-Chloro-3-methylphenyl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol    (72%, M+H⁺: 417);-   1-(3-Chlorophenyl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol    (69%, M+H⁺: 403);-   1-(3-Chloro-4-fluorophenyl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol    (75%, M+H⁺: 421);-   1-(4-Chloro-3-fluorophenyl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol    (68%, M+H⁺: 421);-   1-(3,5-Dichlorophenyl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol    (48%, M+H⁺: 438);-   2,2,2-Trifluoro-1-naphthalen-1-yl-1-(1-phenyl-1H-indazol-5-yl)ethanol    (80%, M+H⁺: 419);-   2,2,2-Trifluoro-1-(3-fluorophenyl)-1-(1-phenyl-1H-indazol-5-yl)ethanol    (69%, M+H⁺: 387);-   2,2,2-Trifluoro-1-(4-methylnaphthalen-1-yl)-1-(1-phenyl-1H-indazol-5-yl)ethanol    (74%, M+H⁺: 433);-   1-(2,3-Dihydrobenzo[1,4]dioxin-6-yl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol    (76%, M+H⁺: 427);-   1-(3,4-Dichlorophenyl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol    (26%, M+H⁺: 427);-   2,2,2-Trifluoro-1-(4-fluorophenyl)-1-(1-phenyl-1H-indazol-5-yl)ethanol    (55%, M+H⁺: 387);-   2,2,2-Trifluoro-1-(3-fluoro-4-methylphenyl)-1-(1-phenyl-1H-indazol-5-yl)ethanol    (83%, M+H⁺: 401);-   1-Benzo[1,3]dioxol-5-yl-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol    (39%, M+H⁺: 413);-   1-(4-Chlorophenyl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol    (76%, M+H⁺: 403);-   2,2,2-Trifluoro-1-(3-morpholin-4-ylmethylphenyl)-1-(1-phenyl-1H-indazol-5-yl)ethanol    (78%, M+H⁺: 468);-   2,2,2-Trifluoro-1-(4-morpholin-4-ylmethylphenyl)-1-(1-phenyl-1H-indazol-5-yl)ethanol    (59%, M+H⁺: 468);-   2,2,2-Trifluoro-1-(1-phenyl-1H-indazol-5-yl)-1-(2,4,5-trimethylphenyl)ethanol    (80%, M+H⁺: 411);-   2,2,2-Trifluoro-1-(1-phenyl-1H-indazol-5-yl)-1-(2,4,6-trimethylphenyl)ethanol    (83%, M+H⁺: 411);-   1-(4-tert-Butyl-2,6-dimethylphenyl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol    (20%, M+H⁺: 453);-   2,2,2-Trifluoro-1-(3-methoxyphenyl)-1-(1-phenyl-1H-indazol-5-yl)ethanol    (79%, M+H⁺: 399);-   1-(3,5-Dimethylphenyl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol    (67%, M+H⁺: 397);-   2,2,2-Trifluoro-1-(4-methoxy-3,5-dimethylphenyl)-1-(1-phenyl-1H-indazol-5-yl)ethanol    (73%, M+H⁺: 427);-   2,2,2-Trifluoro-1-(4-methoxyphenyl)-1-(1-phenyl-1H-indazol-5-yl)ethanol    (65%, M+H⁺: 399);-   1-(3,4-Dimethylphenyl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol    (73%, M+H⁺: 397);-   2,2,2-Trifluoro-1-(3-fluoro-4-methoxyphenyl)-1-(1-phenyl-1H-indazol-5-yl)ethanol    (70%, M+H⁺: 417);-   2,2,2-Trifluoro-1-(5-fluoro-2-methoxyphenyl)-1-(1-phenyl-1H-indazol-5-yl)ethanol    (77%, M+H⁺: 417);-   1-(2,5-Dimethoxyphenyl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol    (89%, M+H⁺: 429);-   2,2,2-Trifluoro-1-(2-morpholin-4-ylmethylphenyl)-1-(1-phenyl-1H-indazol-5-yl)ethanol    (76%, M+H⁺: 468);-   1-Biphenyl-2-yl-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol    (73%, M+H⁺: 445);-   1-(2,5-Dimethoxyphenyl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol    (89%, M+H⁺: 429);-   2,2,2-Trifluoro-1-(4-fluoronaphthalen-1-yl)-1-(1-phenyl-1H-indazol-5-yl)ethanol    (86%, M+H⁺: 437);-   2,2,2-Trifluoro-1-(6-methoxynaphthalen-2-yl)-1-(1-phenyl-1H-indazol-5-yl)ethanol    (82%, M+H⁺: 449);-   2,2,2-Trifluoro-1-naphthalen-2-yl-1-(1-phenyl-1H-indazol-5-yl)ethanol    (73%, M+H⁺: 419);-   2,2,2-Trifluoro-1-(2-methylnaphthalen-1-yl)-1-(1-phenyl-1H-indazol-5-yl)ethanol    (47%, M+H⁺: 433);-   1-Benzo[b]thiophen-3-yl-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol    (43%, M+H⁺: 425); and-   2,2,2-Trifluoro-1-(6-fluoropyridin-2-yl)-1-(1-phenyl-1H-indazol-5-yl)ethanol    (35%, M+H⁺: 388).

Resolution to the (+)- and (−)enantiomers was accomplished by chiralHPLC on a CHIRALCEL™ AD-H column, eluting with 20% isopropanol-hexanes.

Example 22,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-phenylethanol

Step (a): To a solution of 1-(4-fluorophenyl)-1H-indazole-5-carbonitrile(2.0 g, 8.43 mmol) in 100 mL of CH₂Cl₂ at 0° C. was added DIBAL-H (1M inTHF, 12.6 mL, 12.6 mmol). The resulting yellow suspension was stirredfor 2 hours and then poured into 25 mL of cold 1N HCl solution. Thebiphasic system was cooled to 0° C. and then basified to pH 8 by theaddition of saturated aqueous sodium bicarbonate solution. The aqueouslayer was extracted with three 50 mL portions of CH₂Cl₂. The combinedorganic phase was dried over sodium sulfate, filtered, and thenconcentrated in vacuo. The crude material was purified by flash columnchromatography with silica gel (eluted with 100%-80% EtOAc/hexanes) Thedesired product 1-(4-fluorophenyl)-1H-indazole-5-carbaldehyde wasobtained as a light yellow solid (1.4 g, 69% yield; M+H⁺: 241).

Step (b): To a solution of 1-(4-fluorophenyl)-1H-indazole-5-carbaldehyde(1.4 g, 6 mmol) in 10 mL of THF at 0° C. was added TMSCF₃ (1.3 g, 9mmol). The resulting light yellow solution was stirred at 0° C. for 15minutes then TBAF solution (15 mL, 15 mmol) was added. The reactionmixture was allowed to warm up to room temperature and then stirred foran additional 14 hours. The THF was evaporated in vacuo and theresulting residue was dissolved in 100 mL of EtOAc, washed with three 25mL portions of water and a 25 mL portion of brine, dried over sodiumsulfate, filtered, and the solvent was evaporated in vacuo. The crudematerial was purified by flash column chromatography with silica gel(eluted with 95%-70% EtOAc/hexanes). The desired product2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol wasobtained as a light yellow solid (1.3 g, 72% yield; M+H⁺: 311).

Step (c): To a suspension of Dess-Martin periodinane (360 mg, 0.85 mmol)and 2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol (217mg, 0.7 mmol) in 3 mL of CH₂Cl₂ was allowed to stir for 12 hours at roomtemperature. The reaction mixture was added to 1 mL of hexane and theresulting white precipitate was filtered through a pad of CELITE® filteraid. The combined organic solution was washed with three mL portions ofsodium bicarbonate and one 5 mL portion of brine, dried over sodiumsulfate, filtered, and the solvent was evaporated in vacuo. The crudematerial was purified by flash column chromatography with silica gel(eluted with 80% EtOAc/hexanes) The desired product2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanone wasobtained as a white solid (200 mg, 93.0 yield %; M+H⁺: 309).

Step (d): To a solution of2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanone (25.0 mg,0.07 mmol) in 0.5 mL of THF was added phenylmagnesium bromide (1.0 M,0.5 mL, 5.0 mmol) at room temperature. The solution was stirred at thistemperature for 12.0 hours. The reaction was quenched with 2 mL ofsaturated aqueous ammonium chloride solution and 3.0 mL of water. Theaqueous layer was extracted with three 5 mL portions of EtOAc and thecombined organic layers were dried over sodium sulfate, filtered, andthe solvent was evaporated in vacuo. The crude material was purified byflash column chromatography with silica gel (eluted with 100%-85%EtOAc/hexanes). The desired product2,2,2-trifluoro-1-phenyl-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanolwas obtained as a white and waxy oil (25.0 mg, 99% yield; M+H⁺: 387).

The following examples were synthesized following the procedureillustrated for Example 2 step (d), using the corresponding Grignard orequivalent organometallic reagent with suitably functionalized indazoleketones. The percent yield of the reaction and the M+H⁺ are indicated inparentheses.

-   1-(3-Chloro-4-fluorophenyl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol    (70%, M+H⁺: 439);-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-naphthalen-1-ylethanol    (97%, M+H⁺: 437);-   2,2,2-Trifluoro-1-(4-fluoronaphthalen-1-yl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol    (94%, M+H⁺: 455);-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(4-methylnaphthalen-1-yl)ethanol    (58%, M+H⁺: 451);-   1-Benzo[b]thiophen-3-yl-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol    (64%, 443);-   1-(2,2-Difluoro-1,3-benzodioxol-4-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol    (55%; M+H⁺: 467);-   1-1,3-Benzodioxol-4-yl-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol    (62%; M+H⁺: 432);-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1H-indol-7-yl)ethanol    (46%; M+H⁺: 427);-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1-methyl-1H-indol-7-yl)ethanol    (53%; M+H⁺: 440);-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1-methyl-1H-indol-5-yl)ethanol;    (62%; M+H⁺: 440);-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1-methyl-1H-indol-6-yl)ethanol;    (61%; M+H⁺: 440);-   4-{2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}indole-1-carboxylic    acid tert-butyl ester (70%; M+H⁺: 527);-   1-Methyl-4-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-quinolin-2-one    (27%; M+H⁺: 469);-   1-(3,4-Dichlorophenyl)-2,2,2-trifluoro-1-(1-pyridin-2-yl-1H-indazol-5-yl)ethanol    (79%, M+H⁺: 438);-   1-(3-Chlorophenyl)-2,2,2-trifluoro-1-(1-pyridin-2-yl-1H-indazol-5-yl)ethanol    (83%, M+H⁺: 404);-   1-(3,4-Difluorophenyl)-2,2,2-trifluoro-1-(1-pyridin-2-yl-1H-indazol-5-yl)ethanol    (75%, M+H⁺: 406);-   2,2,2-Trifluoro-1-phenyl-1-(1-pyridin-2-yl-1H-indazol-5-yl)ethanol    (87%, M+H⁺: 370);-   2,2,2-Trifluoro-1-[1-(2-fluorophenyl)-1H-indazol-5-yl]-1-phenylethanol    (87%, M+H⁺: 387);-   2,2,2-Trifluoro-1-[1-(2-fluorophenyl)-1H-indazol-5-yl]-1-naphthalen-1-ylethanol    (75%, M+H⁺: 437);-   2,2,2-Trifluoro-1-(4-fluoronaphthalen-1-yl)-1-[1-(2-fluorophenyl)-1H-indazol-5-yl]ethanol    (81%, M+H⁺: 454);-   2,2,2-Trifluoro-1-phenyl-1-(1-p-tolyl-1H-indazol-5-yl)ethanol (77%,    M+H⁺: 383);-   2,2,2-Trifluoro-1-[1-(4-methoxyphenyl)-1H-indazol-5-yl]-1-phenylethanol    (73%, M+H⁺: 399);-   2,2,2-Trifluoro-1-phenyl-1-(1-o-tolyl-1H-indazol-5-yl)ethanol (68%,    M+H⁺: 383);-   2,2,2-Trifluoro-1-naphthalen-1-yl-1-(1-o-tolyl-1H-indazol-5-yl)ethanol    (71%, M+H⁺: 433);-   2,2,2-Trifluoro-1-(4-fluoronaphthalen-1-yl)-1-(1-o-tolyl-1H-indazol-5-yl)ethanol    (65%, M+H⁺: 451); and-   1-[3-(2,5-Dimethylpyrrol-1-yl)phenyl]-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol    (70%, M+H⁺: 462).

Resolution to the (+)- and (−)enantiomers was accomplished by chiralHPLC on a CHIRALCEL™ AD-H column, eluting with 20% isopropanol-hexanes.

Example 32,2,2-Trifluoro-1-isoquinolin-1-yl-1-(1-phenyl-1H-indazol-5-yl)ethanol

Step (a): In a 250 mL flask was placed1-phenyl-1H-indazole-5-carbaldehyde (4.0 g, 1 equiv.) in 80 mL ofCH₂Cl₂. To this was added BF₃OEt₂ (2.5 mL, 1.1 equiv.) dropwise. After 5minutes, 1,3-propanedithiol (1.9 mL, 1.1 equiv.) was added and thereaction allowed to stir for 18 hours at room temperature. The volatileswere removed and the residue was triturated with minimal acetonitrileand filtered to provide the desired product5-1,3-dithian-2-yl-1-phenyl-1H-indazole as a pale yellow solid (4.1 g,72% yield; M+H⁺: 313).

Step (b): In a 25 mL round bottom flask was placed5-1,3-dithian-2-yl-1-phenyl-1H-indazole (83 mg, 1 equiv.) in 3 mL of THFunder argon. This was cooled to −78° C. where n-BuLi (2.5M in hexanes,0.12 mL, 1.1 equiv.) was added dropwise. After 10 minutes,2-chloroisoquinoline (65 mg, 1.5 equiv.) was added as a solution in 1 mLof THF. The reaction was then allowed to warm to room temperature. After20 minutes, the reaction was diluted with water and extracted withEtOAc. The combined organics were dried and evaporated in vacuo. Theresidue was purified by flash chromatography to provide desired product1-[2-(1-phenyl-1H-indazol-5-yl)-1,3-dithian-2-yl]isoquinoline as ayellow oil (113 mg, 96% yield; M+H⁺: 440).

Step (c): In a 100 mL round bottom flask was placed1-[2-(1-phenyl-1H-indazol-5-yl)-1,3-dithian-2-yl]isoquinoline (113 mg,1.0 equiv.), HgCl₂ (139 mg, 2.0 equiv.), HgO (56 mg, 1.0 equiv.) in 5 mLof 10% aqueous MeOH. This was heated at reflux for 4 hours. The reactionwas then diluted with EtOAc and the solids filtered. The solids wererinsed with EtOAc. The filtrate was transferred to a separatory funneland diluted with saturated solutions of sodium bicarbonate, sodiumchloride and EtOAc. The organic layer was removed and rinsed with brine.The combined organics were then dried, filtered, and evaporated invacuo. The residue purified by flash chromatography. The major fractionwas collected and evaporated in vacuo to provide the desired productisoquinolin-1-yl-(1-phenyl-1H-indazol-5-yl)methanone as a white solid(54 mg 59% yield; M+H⁺: 350).

Step (d): In a 50 mL round bottom flask was placedisoquinolin-1-yl-(1-phenyl-1H-indazol-5-yl)methanone (54 mg, 1 equiv.)in 2 mL of THF. This was cooled to 0° C. where trifluoromethyl trimethylsilane (38 μL, 1.6 equiv.) was added dropwise. After addition thereaction was allowed to stir at 0° C. for 30 minutes, where TBAF (1.0 Min THF, 0.23 mL, 1.5 equiv.) was added and the reaction allowed to stirat room temperature for 18 hours. The reaction was then diluted withwater and extracted with EtOAc. The organic was dried, filtered, andevaporated in vacuo and the residue was purified by flash chromatographyto provide the desired product2,2,2-trifluoro-1-isoquinolin-1-yl-1-(1-phenyl-1H-indazol-5-yl)ethanolas a pale yellow solid (52 mg, 80% yield; M+H⁺: 420).

The following example was synthesized following the procedureillustrated for Example 3 following steps b), c), and d) using thecorresponding electrophile. The percent yield of the reaction and theM+H⁺ are indicated in parentheses.

-   2,2,2-Trifluoro-1-(1-phenyl-1H-indazol-5-yl)-1-quinolin-4-ylethanol    (13%, M+H⁺: 420).

Example 41,1,1-Trifluoro-3-phenyl-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol

Step (a): To a suspension of the trimethylsulfoxonium iodide (3.2 g,14.5 mmol) in 9.0 mL of DMSO was added NaH (0.6 g, 14.5 mmol). Theresulting solution was allowed to stir for 30 minutes at roomtemperature and under an atmosphere of argon. A solution of this ylide(4.5 mL) was added to a solution of2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanone (2.0 g, 6.9 mmol)in 4.5 mL of DMSO and the resulting solution was allowed to stir at roomtemperature for 1.5 hours. The reaction mixture was poured onto 100 mLof water and extracted with three 75 mL portions of EtOAc. The combinedorganic layers were washed with 50 mL of brine, dried over sodiumsulfate, filtered, and the solvent was evaporated in vacuo. The crudematerial was purified by flash column chromatography with silica gel(eluted with 100%-85% hexanes/EtOAc). The desired product1-phenyl-5-(2-trifluoromethyloxiranyl)-1H-indazole was obtained as awhite solid (0.8 g, 36% yield; M+H⁺: 305).

Step (b): To a solution of1-phenyl-5-(2-trifluoromethyloxiranyl)-1H-indazole (50.0 mg, 0.1 mmol)in 0.5 mL of THF was added phenylmagnesium bromide (1.0 M, 1.3 mL, 1.3mmol) followed by stirring in a sealed reaction tube at 80° C. for 3days. The reaction was quenched by the addition of 2.0 mL of saturatedaqueous ammonium chloride solution, and 1 mL of water. The aqueous layerwas extracted with three 5 mL portions of EtOAc and the combined organiclayers were dried over sodium sulfate, filtered, and the solvent wasevaporated in vacuo. The crude material was purified by flash columnchromatography with silica gel (eluted with 100%-85% hexanes/EtOAc). Thedesired product1,1,1-trifluoro-3-phenyl-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol wasobtained as a white solid (17 mg, 35.0% yield; M+H⁺: 383).

Example 51,1,1-Trifluoro-3-(3-fluorophenyl)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;

To a solution of 1-phenyl-5-(2-trifluoromethyloxiranyl)-1H-indazole(50.0 mg, 0.1 mmol) in 0.5 mL of THF was added 3-fluorophenylmagnesiumbromide (1.0 M, 1.3 mL, 1.3 mmol). The reaction mixture was allowed tostir in a sealed reaction tube at 80° C. for 3 days. The reaction wasquenched by the addition of 2.0 mL of saturated aqueous ammoniumchloride solution, and 1 mL of water. The aqueous layer was extractedwith three 5 mL portions of EtOAc and the combined organic layers weredried over sodium sulfate, filtered, and the solvent was evaporated invacuo. The crude material was purified by flash column chromatographywith silica gel (eluted with 100%-85% hexanes/EtOAc). The desiredproduct1,1,1-trifluoro-3-(3-fluorophenyl)-2-(1-phenyl-1H-indazol-5-yl)propan-2-olwas obtained as a white solid (17 mg, 32.0% yield; M+H⁺: 401).

The following examples were synthesized following the procedureillustrated for Example 5. The percent yield of the reaction and theM+H⁺ are indicated in parentheses.

-   3-(3-Chloro-2-fluorophenyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (37%, M+H⁺: 435);-   3-(4-Chloro-3-fluorophenyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (29%, M+H⁺: 435); and-   3-(4-Chloro-2-fluorophenyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (33%, M+H⁺: 435).

Example 61-[3,3,3-Trifluoro-2-hydroxy-2-(1-phenyl-1H-indazol-5-yl)propyl]-1H-indole-3-carbonitrile

To a solution of 1-phenyl-5-(2-trifluoromethyloxiranyl)-1H-indazole(50.0 mg, 0.1 mmol) in 0.5 mL of THF was added indole-3-carbonitrile(45.0 mg, 0.3 mmol) and sodium ethoxide (21% wt. in ethanol, 0.13 mL,0.30 mmol). The resulting solution was allowed to stir in a sealedreaction tube at 90° C. for 12 hours. The reaction mixture was cooled toroom temperature and 2.0 mL water of water was added. The aqueous layerwas extracted with two 5 mL portions of ethyl ether. The organic layerswere combined and washed with water and brine, then dried over sodiumsulfate, and filtered. The solvents were removed by rotary evaporationin vacuo. The crude material was purified by flash column chromatographywith silica gel (eluted with 95%-90% hexanes/EtOAc). The desired product1-[3,3,3-trifluoro-2-hydroxy-2-(1-phenyl-1H-indazol-5-yl)propyl]-1H-indole-3-carbonitrilewas obtained as a white solid (20 mg, 27% yield; M+H⁺: 447).

The following examples were synthesized following the procedureillustrated for Example 5 using the corresponding amine reagents. Thepercent yield of the reactions and the M+H⁺ are indicated inparentheses.

-   1,1,1-Trifluoro-3-indol-1-yl-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (34%; M+H⁺: 422);-   3-(3,4-Dihydro-2H-quinoxalin-1-yl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (58%; M+H⁺: 439);-   3-(3,4-Dihydro-2H-quinolin-1-yl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (55%; M+H⁺: 438); and-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-pyrrolo[2,3-c]pyridin-1-ylpropan-2-ol    (17%; M+H⁺: 423).

Example 73-(3,5-Dimethoxyphenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol

A suspension of2-tert-butylimino-2-diethylamino-1,3-dimethylperhydro-1,3,2-diazaphosphorine,polymer-bound (PS-BEMP) (20 mg, 0.040 mmol) in a solution of1-phenyl-5-(2-trifluoromethyloxiranyl)-1H-indazole (5 mg, 0.016 mmol)and 3,5-dimethoxyphenol (3 mg, 0.019 mmol) in THF, was shaken and heatedto 60° C. for 48 hours. The reaction was filtered to remove the resinand washed with THF. The combined solutions were evaporated in vacuo.The crude white solid was separated by preparative reverse phase HPLC togive the desired product3-(3,5-dimethoxyphenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-olas a white solid (6 mg, 79% yield; M+H⁺: 459).

The following examples were synthesized following the procedureillustrated for Example 7 using the corresponding phenol reagent and thecorresponding epoxide. When applicable, the percent yield of thereaction and the M+H⁺ are indicated in parentheses.

-   1,1,1-Trifluoro-3-phenoxy-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (78%; M+H⁺: 399);-   3-(3,5-Difluorophenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (68%; M+H⁺: 435);-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(2-trifluoromethylphenoxy)propan-2-ol    (M+H⁺: 467);-   3-(2-Chloro-3,5-difluorophenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 469);-   3-(5-Chloro-2-methylphenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 447);-   3-(4-Bromophenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 478);-   1,1,1-Trifluoro-3-(indan-5-yloxy)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 439);-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(2,4,6-trichlorophenoxy)propan-2-ol    (M+H⁺: 501);-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(2,4,6-trimethylphenoxy)propan-2-ol    (M+H⁺: 441);-   3-(3-Bromophenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 478);-   3-(2,4-Dichlorophenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 467);-   3-(2-Bromophenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 478);-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(3-trifluoromethylphenoxy)propan-2-ol    (M+H⁺: 467);-   3-(2-Chloro-5-methylphenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 447);-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(4-trifluoromethylphenoxy)propan-2-ol    (M+H⁺: 467);-   1,1,1-Trifluoro-3-(naphthalen-2-yloxy)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 449);-   3-(2-Chlorophenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 433);-   3-(4-Chlorophenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 433);-   3-(2-Chloro-4-methylphenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 447);-   3-(4-Chloro-2-fluorophenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 451);-   1,1,1-Trifluoro-3-(4-fluoro-2-methylphenoxy)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 431);-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(2,3,4-trifluorophenoxy)propan-2-ol    (M+H⁺: 453);-   3-(2-Chloro-3,5-difluorophenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 469);-   1,1,1-Trifluoro-3-(7-methoxynaphthalen-2-yloxy)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 479);-   3-(2-Bromo-5-fluorophenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 496);-   1,1,1-Trifluoro-3-(2-fluoro-5-trifluoromethylphenoxy)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 485);-   3-(4-Bromo-3-methylphenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 492);-   1,1,1-Trifluoro-3-(2-fluoro-5-methylphenoxy)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 431);-   1,1,1-Trifluoro-3-(4-methylsulfanylphenoxy)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 445);-   3-(4-Bromophenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 478);-   3-(3-Chlorophenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 433);-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-o-tolyloxypropan-2-ol    (M+H⁺: 413);-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-m-tolyloxypropan-2-ol    (M+H⁺: 413);-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-p-tolyloxypropan-2-ol    (M+H⁺: 413);-   3-(2,6-Dimethylphenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 427);-   3-(2,6-Dichlorophenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 467);-   3-(3,5-Dichlorophenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 467);-   1,1,1-Trifluoro-3-(naphthalen-1-yloxy)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H: 449);-   1,1,1-Trifluoro-3-(isoquinolin-7-yloxy)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 450);-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(2-trifluoromethoxyphenoxy)propan-2-ol    (M+H⁺: 483);-   1,1,1-Trifluoro-3-(4-phenylaminophenoxy)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 490);-   3-(3-Chloro-4-methylphenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H: 447);-   1,1,1-Trifluoro-3-(3-fluoro-5-trifluoromethylphenoxy)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 485);-   1,1,1-Trifluoro-3-(2-methylsulfanylphenoxy)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 445);-   3-(4-Chloro-3-trifluoromethylphenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 501);-   3-(2,4-Dichloro-6-methylphenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 481);-   3-(2,6-Dichloro-4-methylphenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 481);-   3-Methoxy-4-[3,3,3-trifluoro-2-hydroxy-2-(1-phenyl-1H-indazol-5-yl)propoxy]benzoic    acid ethyl ester (M+H: 501);-   1,1,1-Trifluoro-3-(4-imidazol-1-ylphenoxy)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 465);-   3-(3-Chloro-5-trifluoromethylpyridin-2-yloxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 502);-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(5,6,7,8-tetrahydronaphthalen-1-yloxy)propan-2-ol    (M+H⁺: 411);-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(5,6,7,8-tetrahydronaphthalen-2-yloxy)propan-2-ol    (M+H⁺: 471);-   2-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropoxy}benzonitrile    (M+H⁺: 441);-   3-(2-Bromophenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H⁺: 496);-   3-(2-Chlorophenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H⁺: 451);-   3-(2,4-Dichlorophenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H⁺: 485);-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(2,4,6-trichlorophenoxy)propan-2-ol    (M+H⁺: 519);-   3-(2-Chloro-5-methylphenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H⁺: 465);-   3-(2,6-Dichlorophenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H⁺: 485);-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(2-trifluoromethylphenoxy)propan-2-ol    (M+H⁺: 485);-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-o-tolyloxypropan-2-ol    (M+H⁺: 431);-   3-(2,4-Dimethylphenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H⁺: 445);-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(2,4,6-trimethylphenoxy)propan-2-ol    (M+H⁺: 459);-   3-(2,6-Dimethylphenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H⁺: 445);-   3-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropoxy}benzonitrile    (M+H⁺: 442);-   3-(3-Bromophenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H⁺: 496);-   1,1,1-Trifluoro-3-(3-fluorophenoxy)-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H⁺: 435);-   3-(3,5-Difluorophenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H⁺: 453);-   3-(3-Chlorophenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H: 451);-   3-(3,5-Dichlorophenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H⁺: 485);-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-m-tolyloxypropan-2-ol    (M+H⁺: 431);-   3-(3,5-Dimethylphenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H⁺: 445);-   4-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropoxy}benzonitrile    (M+H⁺: 442);-   3-(4-Bromophenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H⁺: 496);-   1,1,1-Trifluoro-3-(4-fluorophenoxy)-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H⁺: 435);-   3-(4-Chlorophenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H⁺: 451);-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(4-trifluoromethylphenoxy)propan-2-ol    (M+H⁺: 485);-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-p-tolyloxypropan-2-ol    (M+H: 431);-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(indan-5-yloxy)propan-2-ol    (M+H⁺: 457);-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(naphthalen-1-yloxy)propan-2-ol    (M+H⁺: 467);-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(naphthalen-2-yloxy)propan-2-ol    (M+H: 467);-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(quinolin-5-yloxy)propan-2-ol    (M+H⁺: 468);-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(quinolin-8-yloxy)propan-2-ol    (M+H⁺: 468);-   3-(2,4-Difluorophenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H⁺: 453);-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(quinolin-7-yloxy)propan-2-ol    (M+H⁺: 468);-   3-Methoxy-4-{3,3,3-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropoxy}benzoic    acid ethyl ester (M+H⁺: 519);-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(4-phenylaminophenoxy)propan-2-ol    (M+H: 508);-   N-(4-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropoxy}phenyl)butyramide    (M+H⁺: 502);-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(4-trifluoromethylsulfanylphenoxy)propan-2-ol    (M+H⁺: 517);-   5-Acetyl-2-{3,3,3-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropoxy}benzoic    acid methyl ester (M+H: 517);-   3-(2-Bromo-5-fluorophenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H: 514);-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(2,3,4-trifluorophenoxy)propan-2-ol    (M+H⁺: 471);-   3-(2,5-Difluorophenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H⁺: 453);-   3-(4-Chloro-3-trifluoromethylphenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H⁺: 519);-   3-(Acridin-4-yloxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H⁺: 518);-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(3-morpholin-4-ylphenoxy)propan-2-ol    (M+H⁺: 502);-   2-Chloro-4-{3,3,3-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropoxy}benzonitrile    (M+H⁺: 476);-   3-(4-Bromo-2-methylphenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H⁺: 510);-   3-(3-Chloro-4-methylphenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H⁺: 465);-   3-(5-Chloro-2-methylphenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H⁺: 465);-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(2,3,6-trifluorophenoxy)propan-2-ol    (M+H⁺: 471);-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(2,4,5-trifluorophenoxy)propan-2-ol    (M+H⁺: 471);-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(2,4,6-trifluorophenoxy)propan-2-ol    (M+H⁺: 471);-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(2-fluoro-5-trifluoromethylphenoxy)propan-2-ol    (M+H⁺: 503);-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(3-fluoro-5-trifluoromethylphenoxy)propan-2-ol    (M+H⁺: 503);-   3-(2-Chloro-4-methylphenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H⁺: 465);-   3-(4-Chloro-2-fluorophenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H⁺: 469);-   1,1,1-Trifluoro-3-(4-fluoro-2-methylphenoxy)-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H⁺: 449);-   1,1,1-Trifluoro-3-(2-fluoro-6-methoxyphenoxy)-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H⁺: 465);-   3-(2-Chloro-3,5-difluorophenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H⁺: 487);-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(2,3,5-trifluorophenoxy)propan-2-ol    (M+H⁺: 471);-   4-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropoxy}benzonitrile    (M+H⁺: 497);-   3-(4-Bromo-3-methylphenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H⁺: 510);-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(6-methoxynaphthalen-2-yloxy)propan-2-ol    (M+H⁺: 497);-   3-(2,6-Dichloro-4-methylphenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H⁺: 499);-   4-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropoxy}indan-1-one    (M+H⁺: 471);-   5-Bromo-2-{3,3,3-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropoxy}benzonitrile    (M+H⁺: 521);-   1,1,1-Trifluoro-3-(2-fluoro-5-methylphenoxy)-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H⁺: 449);-   5-Chloro-2-{3,3,3-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropoxy}benzonitrile    (M+H⁺: 476);-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(2-trifluoromethoxyphenoxy)propan-2-ol    (M+H⁺: 501);-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(isoquinolin-7-yloxy)propan-2-ol    (M+H⁺: 468);-   3-(3,4-Dimethoxyphenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H⁺: 477);-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(3-trifluoromethoxyphenoxy)propan-2-ol    (M+H⁺: 501); and-   3-(2,4-Dichloro-6-methylphenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H⁺: 499).

Example 81,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-phenylsulfanylpropan-2-ol

To a solution of 1-phenyl-5-(2-trifluoromethyloxiranyl)-1H-indazole(50.0 mg, 0.2 mmol) in DMF (0.5 mL) was added benzenethiol (54.2 μL, 0.5mmol) and the resulting mixture was heated to 120° C. in a sealed tubefor 14 hours. The reaction mixture was cooled to room temperature,diluted with 5 mL of EtOAc, washed with three 10 mL portions of waterand a 10 mL portion of brine, dried over sodium sulfate, and filtered.The solvent was removed by rotary evaporation and the crude material waspurified by flash column chromatography (eluted with 85% hexanes/EtOAc).The desired product1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-phenylsulfanylpropan-2-olwas obtained as a colorless oil (44 mg, 64% yield; M+H⁺: 415).

Example 91,1,1-Trifluoro-3-(4-fluorophenylsulfanyl)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol

A suspension of 1,5,7-triazabicyclo[4.4.0]dec-5-ene bound to polystyrene(PS-TBD) (52 mg, 0.134 mmol) in a solution of1-phenyl-5-(2-trifluoromethyloxiranyl)-1H-indazole (17 mg, 0.056 mmol)and 4-fluorobenzenethiol (9 mg, 0.070 mmol) in THF was shaken at roomtemperature for 12 hours. The resin was filtered and washed with THF.The combined solutions were concentrated in vacuo to give a white solid.The crude material was purified using mass-triggered RP-HPLC, and thedesired product1,1,1-trifluoro-3-(4-fluorophenylsulfanyl)-2-(1-phenyl-1H-indazol-5-yl)propan-2-olwas obtained as a colorless oil (20 mg, 86% yield; M+H⁺: 433).

The following examples were synthesized following the procedureillustrated for Example 9 using the corresponding thiophenol reagent andthe corresponding epoxide. The M+H⁺ are indicated in parentheses.

-   1,1,1-Trifluoro-3-(2-isopropylphenylsulfanyl)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 457);-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(pyridin-2-ylsulfanyl)propan-2-ol    (M+H⁺: 416);-   3-(4-Ethylphenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;    (M+H⁺: 443);-   4-Methyl-7-[3,3,3-trifluoro-2-hydroxy-2-(1-phenyl-1H-indazol-5-yl)propylsulfanyl]-1-benzopyran-2-one    (M+H⁺: 497);-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(3-trifluoromethylphenylsulfanyl)propan-2-ol    (M+H⁺: 483);-   3-(2,3-Dichlorophenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H: 483);-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(4-trifluoromethylphenylsulfanyl)propan-2-ol    (M+H⁺: 483);-   1,1,1-Trifluoro-3-(naphthalen-1-ylsulfanyl)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 465);-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(4-thiophen-2-ylpyrimidin-2-ylsulfanyl)propan-2-ol    (M+H⁺: 499);-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(4-phenylpyrimidin-2-ylsulfanyl)propan-2-ol    (M+H⁺: 493);-   3-[4-(4-Chlorophenyl)pyrimidin-2-ylsulfanyl]-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 527);-   6-Methyl-2-[3,3,3-trifluoro-2-hydroxy-2-(1-phenyl-1H-indazol-5-yl)propylsulfanyl]-4-trifluoromethylnicotinonitrile    (M+H⁺: 523);-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(5-trifluoromethylpyridin-2-ylsulfanyl)propan-2-ol    (M+H⁺: 484);-   3-(2-Chloro-4-fluorophenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 467);-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(4-trifluoromethoxyphenylsulfanyl)propan-2-ol    (M+H⁺: 499);-   3-(4-Bromo-2-trifluoromethoxyphenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 578);-   1,1,1-Trifluoro-3-(4-methoxyphenylsulfanyl)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 445);-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(quinolin-2-ylsulfanyl)propan-2-ol    (M+H⁺: 466);-   3-(4-Chlorophenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 449);-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(pyrimidin-2-ylsulfanyl)propan-2-ol    (M+H⁺: 417);-   3-(4,6-Dimethylpyrimidin-2-ylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 445);-   3-(3,4-Dichlorophenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 483);-   3-(2,5-Dichlorophenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 483);-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(pyridin-4-ylsulfanyl)propan-2-ol    (M+H⁺: 416);-   1,1,1-Trifluoro-3-(3-methoxyphenylsulfanyl)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 445);-   1,1,1-Trifluoro-3-(2-methoxyphenylsulfanyl)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 445);-   3-(3-Chlorophenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 449);-   3-(2,6-Dichlorophenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H: 483);-   3-(2,6-Dichlorophenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 449);-   3-(3-Bromophenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 494);-   3-(3,4-Dimethylphenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 443);-   1,1,1-Trifluoro-3-(naphthalen-2-ylsulfanyl)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 465);-   1,1,1-Trifluoro-3-(2-fluorophenylsulfanyl)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 433);-   1,1,1-Trifluoro-3-(3-fluorophenylsulfanyl)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 433);-   3-(2,5-Dimethoxyphenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 474);-   3-(2,4-Dimethylphenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 443);-   3-(2,5-Dimethylphenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 443);-   3-(2,6-Dimethylphenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 443);-   3-(2-Ethylphenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 443);-   2-[3,3,3-Trifluoro-2-hydroxy-2-(1-phenyl-1H-indazol-5-yl)propylsulfanyl]benzoic    acid methyl ester (M+H⁺: 473);-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(4-trifluoromethylpyrimidin-2-ylsulfanyl)propan-2-ol    (M+H⁺: 485);-   3-(3,5-Dimethylphenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 443);-   3-(3,5-Bis-trifluoromethylphenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 551);-   3-(2,4-Difluorophenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 451);-   1,1,1-Trifluoro-3-(4-isopropylphenylsulfanyl)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 457);-   3-(2,4-Dichlorophenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 483);-   3-(3,5-Dichlorophenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 483);-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(2-trifluoromethylphenylsulfanyl)propan-2-ol    (M+H⁺: 483);-   3-(3,4-Difluorophenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 483);-   3-(3-Ethoxyphenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 459);-   3-(4-tert-Butylphenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 471);-   N-{4-[3,3,3-Trifluoro-2-hydroxy-2-(1-phenyl-1H-indazol-5-yl)propylsulfanyl]phenyl}acetamide    (M+H⁺: 472);-   3-(4-Bromophenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 494);-   1,1,1-Trifluoro-3-(4-fluorophenylsulfanyl)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 433);-   1,1,1-Trifluoro-3-(2-isopropylphenylsulfanyl)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 457);-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(pyridin-2-ylsulfanyl)propan-2-ol    (M+H⁺: 416);-   1,1,1-Trifluoro-3-(4-nitrophenylsulfanyl)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 460);-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-o-tolylsulfanylpropan-2-ol    (M+H⁺: 429);-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-m-tolylsulfanylpropan-2-ol    (M+H⁺: 429);-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-p-tolylsulfanylpropan-2-ol    (M+H⁺: 429);-   3-(3-Chloro-4-fluorophenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 467);-   3-(3,4-Dimethoxyphenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 475);-   3-(5-tert-Butyl-2-methylphenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 485);-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(2,4,6-trimethylphenylsulfanyl)propan-2-ol    (M+H⁺: 457);-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(3-trifluoromethylphenylsulfanyl)propan-2-ol    (M+H⁺: 483);-   1,1,1-Trifluoro-3-(4-methylsulfanylphenylsulfanyl)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 461);-   3-(2-Chloro-6-methylphenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 463);-   3-(2-tert-Butylphenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol    (M+H⁺: 471);-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(3-trifluoromethylpyridin-2-ylsulfanyl)propan-2-ol    (M+H⁺: 484); and-   1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(3-trifluoromethoxyphenylsulfanyl)propan-2-ol    (M+H⁺: 499).

Example 101,1,1-Trifluoro-2-phenyl-3-(1-phenyl-1H-indazol-5-yl)propan-2-ol

Step (a): In a 50 mL flask was placed 1-trimethylsilyl-1,3-dithiane (4.0equiv.) in 8 mL of THF. This solution was cooled to −78° C. and n-BuLi(2.5 M in hexanes, 3.0 equiv.) was added dropwise. After addition, thereaction was warmed up to 0° C. and allowed to stir for 15 minutes. Atthis time, the solution was cooled back to −78° C. and a solution of1-phenyl-1H-indazole-5-carbaldehyde (384 mg, 1 equiv.) in 4 mL of THFwas added and the reaction was allowed to stir at −78° C. for 30minutes. The reaction mixture was diluted with 20 mL of water andextracted with two 50 mL portions of EtOAc. The combined organics weredried over sodium sulfate, filtered, and evaporated in vacuo. Theresidue was purified by flash chromatography to provide5-(1,3-dithian-2-ylidenemethyl)-1-phenyl-1H-indazole as a pale oil (91%yield, M+H⁺: 325).

Step (b): In a 50 mL flask was placed5-(1,3-dithian-2-ylidenemethyl)-1-phenyl-1H-indazole (511 mg, 1 equiv.)in 8 mL of CH₂Cl₂. To this solution was added triethylsilane (0.8 mL,3.2 equiv.) followed by trifluoroacetic acid (0.32 mL, 2.6 equiv.). Thissolution was allowed to stir at room temperature for 18 hours. To thereaction was slowly added 20 mL of saturated sodium bicarbonatesolution. This was transferred into a separatory funnel and extractedwith two 50 mL portions of CH₂Cl₂. The organic fractions were dried,filtered, and evaporated in vacuo. The residue was adhered to silica andpurified by flash chromatography to provide5-(1,3-dithian-2-ylmethyl)-1-phenyl-1H-indazole as a pale yellow oilthat solidified upon standing (437 mg, 85% yield; M+H⁺: 327).

Step (c): To a solution of5-(1,3-dithian-2-ylmethyl)-1-phenyl-1H-indazole (437 mg, 1 equiv.) in 50mL of acetonitrile and 15 mL of water was added methyl iodide (9.8 mL,50 equiv.). The reaction was allowed to stir at room temperature. After4 hours, the reaction was poured into a separatory funnel and dilutedwith 200 mL of CH₂Cl₂ and 100 mL of saturated sodium bicarbonatesolution. The organic fractions were removed in vacuo and the aqueousextracted with CH₂Cl₂. The combined organic fractions were dried,filtered, and evaporated in vacuo. The residue was purified by flashchromatography. The desired fractions were combined and evaporated invacuo to provide (1-phenyl-1H-indazol-5-yl)acetaldehyde as a colorlessoil (277 mg, 38% yield; M+H⁺: 237).

Step (d): In a 20 mL vial at 0° C. was placed(1-phenyl-1H-indazol-5-yl)acetaldehyde (50 mg, 1.0 equiv.) in 2 mL ofTHF. To this was added phenyl magnesium bromide (1.0 M in THF, 0.64 mL,3.0 equiv.) and the reaction was allowed to warm to room temperatureovernight (18 hours). The reaction mixture was cooled to 0° C. andquenched with 1 mL of saturated aqueous ammonium chloride solution. Theaqueous layer was extracted with three 10 mL portions of EtOAc, and theorganic layers were combined and dried over sodium sulfate, filtered,and the solvents were evaporated in vacuo. The crude material waspurified by flash chromatography to provide1-phenyl-2-(1-phenyl-1H-indazol-5-yl)ethanol as a white solid (24 mg,36% yield; M+H⁺: 315).

Step (e): In a 100 mL flask was placed1-phenyl-2-(1-phenyl-1H-indazol-5-yl)ethanol (143 mg, 1 equiv.) in 10 mLof CH₂Cl₂. To this solution was added Dess-Martin's periodonane (193 mg,1 equiv.) and the reaction was allowed to stir at room temperature.After 30 minutes, the mixture was diluted with CH₂Cl₂ and rinsed withsaturated sodium bicarbonate solution. The organics were dried,filtered, and evaporated in vacuo. The residue was purified by flashchromatography. The desired fractions were combined and evaporated invacuo to provide 1-phenyl-2-(1-phenyl-1H-indazol-5-yl)ethanone as awhite solid (124 mg, 87% yield; M+H⁺: 313).

Step (f): In a 100 mL flask was placed1-phenyl-2-(1-phenyl-1H-indazol-5-yl)ethanone (100 mg, 1 equiv.) in 5 mLof THF. This was cooled to 0° C. where trifluoromethyltrimethylsilane(0.08 mL, 1.6 equiv.) was added. After 30 minutes, the reaction waswarmed to room temperature and tetrabutylammonium fluoride (TBAF) wasadded dropwise (0.51 mL, 1.6 equiv.). After 20 minutes, the reaction wasdiluted with MeOH and evaporated in vacuo. The residue was purified byflash chromatography to provide the desired product1,1,1-trifluoro-2-phenyl-3-(1-phenyl-1H-indazol-5-yl)propan-2-ol as awhite solid (21 mg, 20% yield; M+H⁺: 383).

Example 112,2,2-Trifluoro-1-phenyl-1-(1-phenyl-1H-benzotriazol-5-yl)ethanol

Step (a): To a solution of the (4-chloro-3-nitrophenyl)phenylmethanone(1.9 g, 7.26 mmol) in DMF was added aniline (1.9 mL, 20.85 mmol) andHunig's base (3.64 mL, 20.91 mmol). The resulting light brown solutionwas heated to 100° C. for 12 hours. The solution was cooled to roomtemperature and slowly poured over 100 mL of cold water to produce aprecipitate. The product (3-nitro-4-phenylaminophenyl)phenylmethanonewas collected by filtration, and then crystallized from ethanol as ayellow solid (5.0 g, 75% yield; M+H⁺: 319).

Step (b): To a slurry of (3-nitro-4-phenylaminophenyl)phenylmethanone(1.0 g, 3.14 mmol) in mL of EtOH and 6 mL of acetic acid was added ironpowder (3.5 g, 62.84 mmol). The black mixture was heated to 90° C. for 2hours. The dark red solution was filtered through a pad of CELITE®filter aid, rinsed with EtOAc, and neutralized with a saturated sodiumbicarbonate solution. The organic layer was washed with water, brine,dried over sodium sulfate, filtered, and the solvent was evaporated invacuo to give the product (3-amino-4-phenylaminophenyl)phenylmethanoneas a yellow solid which did not require purification (850 mg, 94% yield;M+H⁺: 289).

Step (c): To a pre-cooled solution of(3-amino-4-phenylaminophenyl)phenylmethanone (400 mg, 1.39 mmol) in 28mL of AcOH was added sodium nitrite (145 mg, 2.08 mmol) in portions over10 minutes with stirring. After 30 minutes, ice water was added and thedesired product phenyl-(1-phenyl-1H-benzotriazol-5-yl)methanoneprecipitated as a tan solid which was filtered and washed with water.The product was dried overnight to get as a tan solid which did notrequire purification (400 mg, 96% yield; M+H⁺: 300).

Step (d): To a pre-cooled solution ofphenyl-(1-phenyl-1H-benzotriazol-5-yl)methanone (80 mg, 0.27 mmol) at 0°C. in THF was added dropwise TMSCF₃. The resulting light yellow solutionwas stirred at 0° C. for 15 minutes, and then a solution oftetrabutylammonium fluoride (TBAF) in (1M in THF, 0.2 mL, 0.2 mmol) wasadded dropwise at 0° C. The reaction mixture was allowed to stir at roomtemperature for 12 hours. The THF was evaporated in vacuo and theresidual oil was dissolved in EtOAc then washed with water and brine.The crude material was purified by flash column chromatography withsilica gel (eluted with 95%-85% hexanes/EtOAc). The desired product2,2,2-trifluoro-1-phenyl-1-(1-phenyl-1H-benzotriazol-5-yl)ethanol wasobtained as a tan foam (32 mg, 32% yield; M+H⁺: 370).

2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-benzotriazol-5-yl]-1-phenylethanol(59%, M+H⁺: 389) was prepared starting with 4-fluoroaniline andfollowing the procedure illustrated for Example 11 steps a), b), c), andd).

Example 122,2,2-Trifluoro-1-phenyl-1-(1-phenyl-1H-benzimidazol-5-yl)ethanol

Step (a): A solution of phenyl-(1-phenyl-1H-benzotriazol-5-yl)methanone(from Example 10) trimethyl orthoformate in methanol is heated toreflux. The reaction mixture is cooled to room temperature. The methanolis evaporated in vacuo and the desiredphenyl-(1-phenyl-1H-benzimidazol-5-yl)methanone is purified by flashcolumn chromatography on silica gel.

Step (b): To a pre-cooled solution ofphenyl-(1-phenyl-1H-benzimidazol-5-yl)methanone at 0° C. in THF is addeddropwise TMSCF₃. The resulting light yellow solution is stirred at 0° C.and a solution of tetrabutylammonium fluoride (TBAF) in is addeddropwise at 0° C. The reaction mixture is allowed to stir at roomtemperature. The THF is evaporated in vacuo and the residual oil isdissolved in EtOAc then washed with water and brine. The desired product2,2,2-trifluoro-1-phenyl-1-(1-phenyl-1H-benzimidazol-5-yl)ethanol ispurified by flash column chromatography with silica gel.

Example 13 Cyclopropylphenyl-(1-phenyl-1H-indazol-5-yl)methanol

Step (a): To a solution of 1-phenyl-1H-indazole-5-carbonitrile (1.23 g,5.6 mmol) in 20.0 mL of THF at −78° C. was added cyclopropylmagnesiumbromide (33.7 mL, 0.5 M). The solution was allowed to warm up to roomtemperature then stirred for 14 hours. The reaction was cooled to 0° C.and then quenched by the addition of 20.0 mL of saturated aqueousammonium chloride solution. The aqueous layer was extracted with three30 mL portions of EtOAc, and the combined organic layer was washed withwater, brine, dried over sodium sulfate, filtered, and the solvents wereevaporated in vacuo. The desired productcyclopropyl-(1-phenyl-1H-indazol-5-yl)methanone was obtained as a yellowoil following chromatography with EtOAc/hexanes (15%) (1.22 g, 83%yield; M+H⁺: 263).

Step (b): To a solution ofcyclopropyl-(1-phenyl-1H-indazol-5-yl)methanone (0.05 g, 0.19 mmol) inTHF (0.5 mL) at 0° C., was added phenylmagnesium bromide (1M in THF,0.67 mL, 0.67 mmol). The resulting solution was allowed to stir at roomtemperature for 12 hours. The reaction mixture was cooled to 0° C. andquenched with 1 mL of saturated aqueous ammonium chloride solution. Theaqueous layer was extracted with three 10 mL portions of EtOAc, and theorganic layers were combined and dried over sodium sulfate, filtered andthe solvents were evaporated in vacuo. The desired productcyclopropylphenyl-(1-phenyl-1H-indazol-5-yl)methanol was obtained as awhite foam following column chromatography with silica gel (eluting withEtOAc/hexanes (15%) (50 mg, 65% yield; M+H⁺: 341)).

The following examples were synthesized following the procedureillustrated for Example 6 step b) using the corresponding Grignardreagents. The percent yield of the reactions and the M+H⁺ are indicatedin parentheses.

-   Cyclopropyl-(3,5-dichlorophenyl)-(1-phenyl-1H-indazol-5-yl)methanol    (32%, M+H⁺: 410);-   1-Cyclopropyl-2-(3,5-dichlorophenyl)-1-(1-phenyl-1H-indazol-5-yl)ethanol    (50%, M+H⁺: 424);-   1-Cyclopropyl-1-(1-phenyl-1H-indazol-5-yl)-2-m-tolylethanol (31%,    M+H⁺: 369); and-   1-Cyclopropyl-1-(1-phenyl-1H-indazol-5-yl)-2-p-tolylethanol (28%,    M+H⁺: 369).

Example 14 2-Phenyl-1-(1-phenyl-1H-indazol-5-yl)propan-2-ol

Step (a): To a solution of 1-phenyl-2-(1-phenyl-1H-indazol-5-yl)ethanonein THF is added a solution of methylmagnesium bromide in THF (1.2equiv.). The reaction mixture is cooled to 0° C. and quenched with 1 mLof saturated aqueous ammonium chloride solution. The aqueous layer isextracted with EtOAc and the organic layers are combined and dried oversodium sulfate, filtered, and the solvents are evaporated in vacuo. Thecrude material is purified by flash chromatography to provide thedesired product 2-phenyl-1-(1-phenyl-1H-indazol-5-yl)propan-2-ol.

Example 151-Cyclopropyl-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-phenylaminoethanol

Step (a): To a suspension of the trimethylsulfoxonium iodide in DMSO isadded NaH (1.05 equiv.). The resulting solution is allowed to stir atroom temperature under an atmosphere of argon. A solution of this ylideis added to a solution ofcyclopropyl-[1-(4-fluorophenyl)-1H-indazol-5-yl]methanone (0.9 equiv.)in DMSO and the resulting solution is allowed to stir at roomtemperature. The reaction mixture is poured onto water and extractedwith EtOAc. The combined organic layers are washed with brine, driedover sodium sulfate, filtered, and the solvent is evaporated in vacuo.The crude material is purified by flash column chromatography to obtainthe desired product5-(2-cyclopropyloxiranyl)-1-(4-fluorophenyl)-1H-indazole.

Step (b): To a solution of aniline in DMF is added NaH (1 equiv.). Tothis solution is added5-(2-cyclopropyloxiranyl)-1-(4-fluorophenyl)-1H-indazole. The resultingsolution is heated to 80° C. The reaction mixture is cooled to roomtemperature and then quenched with a saturated solution of ammoniumchloride. Ethyl acetate is added and the organic layer is washed withbrine, dried over magnesium sulfate, and filtered. The solvent isevaporated in vacuo, and the crude material is purified by flash columnchromatography to obtain the desired product1-cyclopropyl-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-phenylaminoethanol.

Example 161-Cyclopropyl-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-phenylsulfanylethanol

A solution of thiophenol and5-(2-cyclopropyloxiranyl)-1-(4-fluorophenyl)-1H-indazole in DMF isheated to 80° C. The reaction mixture is cooled to room temperature andthen quenched with a saturated solution of ammonium chloride. Ethylacetate is added and the organic layer is washed with brine, dried overmagnesium sulfate, and filtered. The solvent is evaporated in vacuo, andthe crude material is purified by flash column chromatography to obtainthe desired product1-cyclopropyl-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-phenylsulfanylethanol.

Example 171-Cyclopropyl-2-(3,5-difluorophenoxy)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol

A suspension of 1,5,7-triazabicyclo[4.4.0]dec-5-ene bound to polystyrene(PS-TBD) (52 mg, 0.134 mmol) in a solution of5-(2-cyclopropyloxiranyl)-1-(4-fluorophenyl)-1H-indazole (0.5 equiv) and3,5-difluorophenol (1.0 equiv.) in THF is shaken at room temperature.The resin is filtered and washed with THF. The combined solutions areconcentrated in vacuo and the crude material is purified by flash columnchromatography to obtain the desired productcyclopropyl-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-phenylsulfanylethanol.

Example 18 Cyclopropylphenyl-(1-phenyl-1H-benzotriazol-5-yl)methanol

To a solution of phenyl-(1-phenyl-1H-benzotriazol-5-yl)methanone (70 mg,0.23 mmol) in THF was added cyclopropyl magnesium bromide (0.5 M in THF,0.8 mL, 0.40 mmol). The resulting brown solution was stirred at roomtemperature for 6 hours. The reaction was quenched with 2 mL ofsaturated aqueous ammonium chloride solution, diluted with EtOAc, andextracted. The organic layer was washed with water and brine, dried overmagnesium sulfate (MgSO₄), then filtered and evaporated in vacuo. Thecrude material was purified by flash column chromatography (eluted with95%-85% hexanes/EtOAc) to get the desired productcyclopropylphenyl-(1-phenyl-1H-benzotriazol-5-yl)methanol as an offwhite solid (33 mg, 41%, M+H⁺: 342).

Example 19Cyclopropyl-[1-(4-fluorophenyl)-1H-benzotriazol-5-yl]phenylmethanol

To a solution [1-(4-fluorophenyl)-1H-benzotriazol-5-yl]phenylmethanone(107 mg, 0.34 mmol) in THF was added cyclopropyl magnesium bromide (0.5M in THF, 1.5 mL, 0.75 mmol). The resulting brown solution was stirredat room temperature for 6 hours. The reaction was quenched with 2 mL ofsaturated aqueous ammonium chloride solution, diluted with EtOAc, andextracted. The organic layer was washed with water and brine, dried overmagnesium sulfate, then filtered and evaporated in vacuo. The crudematerial was purified by flash column chromatography (eluted with95%-85% hexanes/EtOAc) to get the desired productcyclopropyl-[1-(4-fluorophenyl)-1H-benzotriazol-5-yl]phenylmethanol asan off white solid (70 mg, 57%, M+H⁺: 360).

Example 20 Cyclopropylphenyl-(1-phenyl-1H-indol-5-yl)methanol

Step (a): To a solution of 1-phenyl-1H-indole-5-carbonitrile in THF at−78° C. is added cyclopropylmagnesium bromide (1.2 equiv.). The solutionis allowed to warm up to room temperature. The reaction is cooled to 0°C. and then quenched by the addition of saturated aqueous ammoniumchloride solution. The aqueous layer is extracted with EtOAc and thecombined organic layer is washed with water, brine, dried over sodiumsulfate, filtered, and the solvents are evaporated in vacuo. The desiredproduct cyclopropyl-(1-phenyl-1H-indol-5-yl)methanone is obtainedfollowing purification by column chromatography.

Step (b): To a solution of cyclopropyl-(1-phenyl-1H-indol-5-yl)methanonein THF at 0° C. is added phenylmagnesium bromide (1.3 equiv.). Theresulting solution is allowed to stir at room temperature. The reactionmixture is cooled to 0° C. and quenched with saturated aqueous ammoniumchloride solution. The aqueous layer is extracted with EtOAc and theorganic layers are combined and dried over sodium sulfate, filtered, andthe solvents are evaporated in vacuo. The desired productcyclopropylphenyl-(1-phenyl-1H-indol-5-yl)methanol is obtained followingcolumn chromatography with silica gel.

Example 211,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-indol-1-ylpropan-2-ol

A solution of1-(4-fluorophenyl)-5-(2-trifluoromethyloxiranyl)-1H-indazole (24 mg,0.075 mmol) in 500 μL DMSO was added to the indoles (0.090 mmol). Themixture was shaken for 15 minutes to solubilize the indole, then asolution of sodium hexamethyldisilazide (NaHMDS) (90 μL of a 1M solutionin THF, 0.090 mmol) was added and the resultant mixtures were shaken atroom temperature for 16 hours. The reaction was then quenched with theaddition of 50 μL of water, then after shaking for 30 minutes, themixture was filtered through CELITE® filter aid. The reaction vial wasrinsed with two 300 μL portions of DMSO and was passed through theCELITE® filter aid. Finally the CELITE® filter cakes was washed with two200 μL portions of DMSO. The combined solutions were evaporated invacuo. The crude product was purified by preparative reverse phase HPLCto give the desired product (M+H⁺: 440).

The following examples were synthesized following the procedureillustrated for Example 21 using the corresponding indole reagent andthe corresponding epoxide. The M+H⁺ is indicated in parentheses.

-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(4-methylindol-1-yl)propan-2-ol    (M+H⁺: 454);-   3-[2-(4-Chlorophenyl)indol-1-yl]-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H⁺: 550);-   (1-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H-indol-3-yl)acetonitrile    (M+H⁺: 479);-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(6-methoxyindol-1-yl)propan-2-ol    (M+H⁺: 470);-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(5-methylindol-1-yl)propan-2-ol    (M+H⁺: 454);-   3-(4-Benzyloxyindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H⁺: 546);-   3-(4-Chloroindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H⁺: 474);-   3-(6-Chloroindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H⁺: 474);-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(6-methylindol-1-yl)propan-2-ol    (M+H⁺: 454);-   1-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H-indole-4-carboxylic    acid methyl ester (M+H⁺: 498);-   1,1,1-Trifluoro-3-(6-fluoroindol-1-yl)-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H⁺: 458);-   1-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H-indole-3-carboxylic    acid methyl ester (M+H⁺: 498);-   2,2,2-Trifluoro-1-(1-{3,3,3-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H-indol-3-yl)ethanone    (M+H: 536);-   1,1,1-Trifluoro-3-(4-fluoroindol-1-yl)-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H⁺: 458);-   N-[2-(5-Methoxy-1-{3,3,3-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H-indol-3-yl)ethyl]acetamide    (M+H⁺: 555);-   3-(7-Bromoindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H⁺: 519);-   3-(7-Chloroindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H⁺: 474);-   (2-Methyl-1-{3,3,3-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H-indol-3-yl)acetic    acid ethyl ester (M+H⁺: 540);-   1-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H-indole-5-carboxylic    acid methyl ester (M+H⁺: 498);-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(2-methyl-5-nitroindol-1-yl)propan-2-ol    (M+H⁺: 499);-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-[2-(4-fluorophenyl)indol-1-yl]propan-2-ol    (M+H⁺: 534);-   3-(4-Bromoindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H⁺: 519);-   3-(6-Bromoindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H⁺: 519);-   3-(3-Dimethylaminomethyl-6-methoxyindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H⁺: 527);-   (5-Methoxy-1-{3,3,3-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H-indol-3-yl)acetonitrile    (M+H⁺: 509);-   (5-Benzyloxy-1-{3,3,3-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H-indol-3-yl)acetonitrile    (M+H⁺: 585);-   1-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H-indole-6-carboxylic    acid methyl ester (M+H⁺: 498);-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(7-nitroindol-1-yl)propan-2-ol    (M+H⁺: 485);-   1-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H-indole-4-carbonitrile    (M+H⁺: 465);-   3-(5-Benzyloxyindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H⁺: 546);-   1-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H-indole-5-carbonitrile    (M+H⁺: 465);-   3-(3-Dimethylaminomethyl-5-methoxyindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H⁺: 527);-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(5-methoxy-2-methylindol-1-yl)propan-2-ol    (M+H⁺: 484);-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(2-methylindol-1-yl)propan-2-ol    (M+H⁺: 454);-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(3-methylindol-1-yl)propan-2-ol    (M+H⁺: 454);-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(7-methylindol-1-yl)propan-2-ol    (M+H⁺: 454);-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(5-nitroindol-1-yl)propan-2-ol    (M+H⁺: 485);-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(2-phenylindol-1-yl)propan-2-ol    (M+H⁺: 516);-   (2-Phenyl-1-{3,3,3-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H-indol-3-yl)acetonitrile    (M+H⁺: 554);-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-pyrrolo[2,3-c]pyridin-1-ylpropan-2-ol    (M+H⁺: 441);-   3-(7-Ethylindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H⁺: 468);-   3-(2,3-Dimethyl-5-nitroindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H⁺: 513);-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(6-trifluoromethylindol-1-yl)propan-2-ol    (M+H⁺: 508);-   1,1,1-Trifluoro-3-(7-fluoroindol-1-yl)-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H: 458);-   1-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H-indole-6-carbonitrile    (M+H⁺: 465);-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-indol-1-ylpropan-2-ol    (M+H⁺: 440);-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-pyrrolo[2,3-b]pyridin-1-ylpropan-2-ol    (M+H⁺: 441);-   1-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H-indole-2-carboxylic    acid ethyl ester (M+H⁺: 512);-   3-(2,3-Dimethylindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H: 468);-   1-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H-indole-3-carbonitrile    (M+H⁺: 465);-   1-(1-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H-indol-3-yl)ethanone    (M+H⁺: 482);-   3-(3-Dimethylaminomethylindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H⁺: 497);-   3-(3-Dimethylaminomethyl-5-methoxyindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H: 527);-   (1-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H-indol-3-yl)acetic    acid ethyl ester (M+H⁺: 526);-   2-(1-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H-indol-3-yl)acetamide    (M+H⁺: 497);-   3-(5-Bromoindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H⁺: 519);-   1,1,1-Trifluoro-3-(5-fluoroindol-1-yl)-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H⁺: 458);-   3-(5-Chloroindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H⁺: 474);-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(5-methoxyindol-1-yl)propan-2-ol    (M+H⁺: 470);-   3-(5,6-Dimethoxyindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H⁺: 500);-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(4-nitroindol-1-yl)propan-2-ol    (M+H⁺: 485); and-   5-Methyl-1-{3,3,3-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H-indole-2-carboxylic    acid ethyl ester (M+H⁺: 485).

Example 221,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-phenylaminopropan-2-ol

A solution of1-(4-fluorophenyl)-5-(2-trifluoromethyloxiranyl)-1H-indazole (24 mg,0.075 mmol) in 500 μL of MeOH was added to the aniline (0.090 mmol). Themixture was heated at 50° C. for 16 hours. The solution was evaporatedin vacuo. The crude products was purified by preparative reverse phaseHPLC to give the desired product (M+H⁺: 416).

The following examples were synthesized following the procedureillustrated for Example 22 using the corresponding aniline reagent andthe corresponding epoxide. The M+H⁺ is indicated in parentheses.

-   6-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropylamino}-3H-isobenzofuran-1-one    (M+H⁺: 472);-   N-(4-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropylamino}phenyl)acetamide    (M+H⁺: 473);-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(indan-5-ylamino)propan-2-ol    (M+H⁺: 456);-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(indan-4-ylamino)propan-2-ol    (M+H⁺: 456);-   3-(3-Bromophenylamino)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H⁺: 495);-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-o-tolylaminopropan-2-ol    (M+H⁺: 430);-   3-(4-Chlorophenylamino)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H⁺: 450);-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-m-tolylaminopropan-2-ol    (M+H⁺: 430);-   3-(4-Chloronaphthalen-1-ylamino)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H⁺: 500);-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(6-methoxypyridin-3-ylamino)propan-2-ol    (M+H⁺: 447);-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(5,6,7,8-tetrahydronaphthalen-1-ylamino)propan-2-ol    (M+H⁺: 470);-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(2-methoxyphenylamino)propan-2-ol    (M+H⁺: 446);-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(3-methoxyphenylamino)propan-2-ol    (M+H⁺: 446);-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(4-methoxyphenylamino)propan-2-ol    (M+H⁺: 446);-   3-(3-Chlorophenylamino)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H⁺: 450);-   3-(5-Chloro-2-methylphenylamino)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H⁺: 464);-   3-(2,6-Dimethylphenylamino)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H⁺: 444);-   1,1,1-Trifluoro-3-(4-fluorophenylamino)-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H⁺: 434);-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(4-methylsulfanylphenylamino)propan-2-ol    (M+H⁺: 462);-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(naphthalen-2-ylamino)propan-2-ol    (M+H⁺: 466);-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(2-methylquinolin-8-ylamino)propan-2-ol    (M+H⁺: 481);-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(methylphenylamino)propan-2-ol    (M+H⁺: 430);-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-[(4-methoxyphenyl)methylamino]propan-2-ol    (M+Hf: 460);-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(naphthalen-1-ylamino)propan-2-ol    (M+H⁺: 466);-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(4-morpholin-4-ylphenylamino)propan-2-ol    (M+H⁺: 501);-   3-(2,3-Dihydro-1,4-benzodioxin-6-ylamino)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H⁺: 474);-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(2,4,6-trifluorophenylamino)propan-2-ol    (M+H⁺: 470);-   3-(Biphenyl-2-ylamino)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H⁺: 492);-   3-(2,4-Dimethylphenylamino)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H⁺: 444);-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(2,4,6-trimethylphenylamino)propan-2-ol    (M+H⁺: 444);-   3-(2,6-Dimethylphenylamino)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H⁺: 444);-   3-(2-Ethyl-6-methylphenylamino)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H⁺: 458);-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(3-methylsulfanylphenylamino)propan-2-ol    (M+H⁺: 462);-   3-(3,5-Dimethylphenylamino)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H⁺: 444);-   3-(4-Chlorophenylamino)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H⁺: 450);-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(4-phenoxyphenylamino)propan-2-ol    (M+H⁺: 508);-   3-(2,4-Dimethoxyphenylamino)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H⁺: 476);-   3-(3,5-Dimethoxyphenylamino)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H: 476);-   3-(4,5-Dimethoxy-2-methylphenylamino)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H⁺: 490);-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(3-trifluoromethoxyphenylamino)propan-2-ol    (M+H⁺: 500);-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(2-methoxy-5-trifluoromethylphenylamino)propan-2-ol    (M+H⁺: 514);-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(4-methoxy-3-trifluoromethylphenylamino)propan-2-ol    (M+H⁺: 514);-   3-(Biphenyl-3-ylamino)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H⁺: 492);-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(4-piperidin-1-ylphenylamino)propan-2-ol    (M+H⁺: 499);-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(3-oxazol-5-ylphenylamino)propan-2-ol    (M+H⁺: 483);-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(4-pyridin-4-ylmethylphenylamino)propan-2-ol    (M+H⁺: 507);-   3-(4-Chloro-2,6-dimethylphenylamino)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H⁺: 478);-   1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(2-methylnaphthalen-1-ylamino)propan-2-ol    (M+H⁺: 480);-   3-(Biphenyl-4-ylamino)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol    (M+H⁺: 492); and-   5-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropylamino}-1,3-dihydrobenzimidazol-2-one    (M+H⁺: 472).

Example 231-(1-Allyl-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol

Step (a): In a 100 mL flask was placed 3.0 g (25.7 mmol, 1 equiv.) ofindole in 15 mL of DMF. This was cooled to 0° C. where 1.5 g (38.4 mmol,1.5 equiv.) of a 65% suspension of sodium hydride in mineral oil wasadded in portions. After gas evolution (30 minutes), allyl bromide (2.4mL, 28.2 mmol, 1.1 equiv.) was added and the reaction allowed to warm toroom temperature. After 30 minutes, the reaction was poured into 300 mLof water and extracted with diethyl ether (Et₂O). The combined diethylether extracts were dried, filtered, and evaporated in vacuo and used inthe next step without further purification.

Step (b): In a 100 mL flask was placed 4 g of crude 1-allylindole in 30mL of DMF. This was cooled to 0° C. where trifluoroacetic anhydride (5.7mL, 40.7 mmol) was added and the reaction allowed to stir at roomtemperature. After 30 minutes, the reaction was poured into a separatoryfunnel and diluted with diethyl ether. The organic was separated andrinsed with two portions of brine and saturated sodium bicarbonatesolution. The organic was dried, filtered, and evaporated in vacuo. Theresidue was purified by flash chromatography (0-5% EtOAc-hexanes) toprovide 5.54 g of the desired product as a yellow oil (86%, M+H⁺: 254).

Step (c): In a 50 mL flask under argon was placed1-(1-allyl-1H-indol-3-yl)-2,2,2-trifluoroethanone (747 mg, 2.6 mmol, 1.3equiv.) in 10 mL of THF. This was cooled to −78° C. In a separate vialwas placed 1-allyl-3-trifluoromethylcarbonyl indole (500 mg, 2.0 mmol, 1equiv.) in 5 mL of THF and was cooled to −78° C. At this point, n-BuLi(0.87 mL, 2.2 mmol, 1.1 equiv., 2.5 M in hexanes) was added quickly anddropwise to the flask containing bromoindazole (prepared according to aprocedure reported by Bamborough et al. (WO 2005/073189, which is herebyincorporated by reference). After addition, the solution containingindole was added in one portion. After 5 minutes, the reaction wasquenched with 5 mL of water and brought to room temperature. This wasdiluted with EtOAc and rinsed with water/brine. The organic was dried,filtered, and evaporated in vacuo. The residue was purified by flashchromatography (0-20% EtOAc/hexanes) to provide 813 mg of the desiredproduct as a pale yellow foam (88%, M+H⁺: 466).

The following examples were synthesized following the procedureillustrated for Example 23 step (c), using the correspondingbromoindazoles and suitably functionalized(indol-3-yl)-2,2,2-trifluoroethanone. The % yield and M+H⁺ are indicatedin parentheses.

-   1-(7-Bromo-1-methyl-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol    (44%, M+H⁺: 519);-   1-Methyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylic    acid methyl ester (48%; M+H⁺: 498);-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1-methyl-7-nitro-1H-indol-3-yl)ethanol    (23%, M+H⁺: 485);-   1-(1-Allyl-1H-indol-3-yl)-2,2,2-trifluoro-1-(1-p-tolyl-1H-indazol-5-yl)ethanol    (60%, M+H⁺: 462);-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1-methyl-1H-indol-3-yl)ethanol    (11%, M+H⁺: 440);-   1-(6-Bromo-1-methyl-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol    (15%, M+H⁺: 519);-   1-Methyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-6-carbonitrile    (7%, M+H⁺: 465);-   1-Benzyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylic    acid methyl ester (53%, M+H⁺: 574); and-   1-[6-Bromo-1-(4-methoxybenzyl)-1H-indol-3-yl]-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol    (31%, M+H⁺: 625).

Example 242-(3-{2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}indol-1-yl)acetamide

Step (a): In a 50 mL flask was placed1-(1-allyl-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol(250 mg, 0.54 mmol, 1 equiv.) in 10 mL of acetone/water (3:1). This wascooled to 0° C. where potassium permanganate (KMnO₄; 94 mg, 0.59 mmol,1.1 equiv.) was added as a solution in 10 mL of acetone/water (3:1)dropwise. The ice bath was then removed and the reaction allowed to stirat room temperature for 2 hours. The reaction was filtered and thevolatiles were removed. The residue was then partitioned between waterand EtOAc. The organics were dried, filtered, and evaporated in vacuo.The residue dissolved in minimal DMF and purified by HPLC (5-100%CH₃CN/water/0.1% TFA) to provide 218 mg of the desired product3-(3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}indol-1-yl)propane-1,2-diolas a white solid (80%, M+H⁺: 500).

Step (b): In a 50 mL flask was placed the diol (350 mg, 0.70 mmol, 1equiv.) in 6 mL of acetone and 2 mL of water. To this was added sodiumperiodate (172 mg, 0.77 mmol, 1.1 equiv.) and the reaction allowed tostir at room temperature for 72 hours. The solids were filtered andrinsed with acetone. The volatiles were then removed and the mixture wasthen transferred to a separatory funnel, basified with saturated aqueoussodium bicarbonate solution and extracted with EtOAc. The combinedorganics were dried, filtered, and evaporated in vacuo to provide 319 mgof the desired product as white foam (97%, M+H⁺: 468).

Step (c): In a 100 mL flask was placed the aldehyde (269 mg, 0.58 mmol,1 equiv.) in 9 mL of 3:1 acetone:water. Potassium permanganate (100 mg,0.63 mmol, 1.1 equiv.) was added and the reaction allowed to stir atroom temperature for 2 hours. The solids were filtered and rinsed withacetone. The volatiles were removed and the aqueous transferred to aseparatory funnel. The aqueous was extracted with EtOAc. The combinedorganics were dried, filtered, and evaporated in vacuo to provide 261 mgof the desired acid as a tan solid (94%, M+H⁺: 484).

Step (d): In a 7 mL vial was placed the carboxylic acid (40 mg, 0.083mmol, 1 equiv.) in 1 mL of DMF. To this was added triethylamine (63 μL,0.5 mmol, 6 equiv.) followed bybenzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate(PyBOP; (56 mg, 0.11 mmol, 1.3 equiv.). After 5 minutes, ammoniumchloride (44 mg, 0.83 mmol, 10 equiv.) was added, the reaction wascapped, and the reaction allowed stirring at room temperature for 18hours. The mixture was filtered into a vial and purified by HPLC (5-90%CH₃CN/water/0.1% TFA). The desired fractions were combined and the CH₃CNwas removed. The organic was then extracted with EtOAc. The combinedorganics were dried, filtered, and evaporated in vacuo to provide 20 mgof the desired product as a white solid (50%, M+H⁺: 483).

The following examples were synthesized following the procedureillustrated for Example 24 using the corresponding amines and suitablyfunctionalized (indol-1-yl)acetic acid. The % yield and M+H⁺ areindicated in parentheses.

-   N-Methyl-2-(3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}indol-1-yl)acetamide    (46%, M+H⁺: 497);-   N-Cyanomethyl-2-(3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}indol-1-yl)acetamide    (49%, M+H⁺: 522);-   N-Carbamoylmethyl-2-(3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}indol-1-yl)acetamide    (50%, M+H⁺: 540);-   1-Morpholin-4-yl-2-(3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}indol-1-yl)ethanone    (44%, M+H⁺: 553);-   N-Carbamoylmethyl-N-methyl-2-{3-[2,2,2-trifluoro-1-hydroxy-1-(1-p-tolyl-1H-indazol-5-yl)ethyl]indol-1-yl}acetamide    (44%, M+H⁺: 550);-   N-Carbamoylmethyl-2-{3-[2,2,2-trifluoro-1-hydroxy-1-(1-p-tolyl-1H-indazol-5-yl)ethyl]indol-1-yl}acetamide    (40%, M+H⁺: 536);-   N-(2-Methoxyethyl)-N-methyl-2-{3-[2,2,2-trifluoro-1-hydroxy-1-(1-p-tolyl-1H-indazol-5-yl)ethyl]indol-1-yl}acetamide    (50%, M+H⁺: 551);-   N-(2-Methoxyethyl)-2-{3-[2,2,2-trifluoro-1-hydroxy-1-(1-p-tolyl-1H-indazol-5-yl)ethyl]indol-1-yl}acetamide    (49%, M+H⁺: 537);-   N-Cyanomethyl-2-{3-[2,2,2-trifluoro-1-hydroxy-1-(1-p-tolyl-1H-indazol-5-yl)ethyl]indol-1-yl}acetamide    (37%, M+H⁺: 518);-   N-Methyl-2-{3-[2,2,2-trifluoro-1-hydroxy-1-(1-p-tolyl-1H-indazol-5-yl)ethyl]indol-1-yl}acetamide    (39%, M+H⁺: 493); and-   2-{3-[2,2,2-Trifluoro-1-hydroxy-1-(1-p-tolyl-1H-indazol-5-yl)ethyl]indol-1-yl}acetamide    (35%, M+H⁺: 479).

Example 252,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1H-indol-3-yl)ethanol

To a stirred solution of indole (0.037 g, 0.320 mmol) in 4 mL oftert-butyl methyl ether at room temperature was added a solution ofethyl magnesium bromide (3M in diethyl ether, 0.200 mL, 0.600 mmol). Theresulting dark grey solution was stirred at room temperature for 45minutes, then copper iodide (0.032 g, 0.170 mmol) was added. Thereaction mixture was stirred at room temperature for 45 minutes. Asolution of the ketone in tert-butyl methyl ether (0.100 g, 0.324 mmolin 2.0 mL of tert-butyl methyl ether) was added to the reaction mixtureat room temperature, and the reaction was allowed to be stirred at for 2hours at room temperature. 2.0 mL of ice-cold water was added to thereaction, and the reaction was stirred at room temperature for 10minutes. The reaction mixture was added to 10 mL of dichloromethane andthe resulting dark precipitate was filtered through a pad of CELITE®filter aid. The dichloromethane phase was washed with a 5 mL portion ofbrine, dried over sodium sulfate, filtered, and the solvent wasevaporated in vacuo. The crude material was purified by flash columnchromatography with silica gel (eluted with 80% hexanes/EtOAc). Thedesired product was obtained as a light yellow solid (37% yield, M+H⁺:426).

The following examples were synthesized following the procedureillustrated for Example 25 using the corresponding ketones and suitablyfunctionalized indoles. The % yield and M+H⁺ are indicated inparentheses.

-   2,2,2-Trifluoro-1-(5-fluoro-1H-indol-3-yl)-1-(1-p-tolyl-1H-indazol-5-yl)ethanol    (48%, M+H⁺: 440);-   2,2,2-Trifluoro-1-(5-fluoro-1H-indol-3-yl)-1-[1-(2-fluorophenyl)-1H-indazol-5-yl]ethanol    (47%, M+H⁺: 444);-   2,2,2-Trifluoro-1-(5-fluoro-1H-indol-3-yl)-1-[1-(4-methoxyphenyl)-1H-indazol-5-yl]ethanol    (46%, M+H⁺: 456);-   2,2,2-Trifluoro-1-(5-fluoro-1H-indol-3-yl)-1-(1-pyridin-2-yl-1H-indazol-5-yl)ethanol    (35%, M+H⁺: 427);-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(5-methoxy-4-methyl-1H-indol-3-yl)ethanol    (14%, M+H⁺: 470);-   1-(4-Chloro-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol    (7%, M+H⁺: 460);-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(6-methoxy-1H-indol-3-yl)ethanol    (20%, M+H⁺: 456);-   1-(2,5-Dimethyl-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol    (20%, M+H⁺: 454);-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(7-methoxy-1H-indol-3-yl)ethanol    (34%, M+H⁺: 456);-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1H-indol-3-yl)ethanol    (36%, M+H⁺: 426);-   1-(6-Bromo-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol    (12%; M+H⁺: 505);-   1-(7-Bromo-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol    (48%; M+H⁺: 505);-   1-(5-Bromo-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol    (39%, M+H⁺: 505);-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(5-methyl-1H-indol-3-yl)ethanol    (32%, M+H⁺: 440);-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(2-methyl-1H-indol-3-yl)ethanol    (34%, M+H⁺: 440);-   1-(6-Chloro-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol    (21%, M+H⁺: 460);-   1-(5-Chloro-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol    (17%, M+H⁺: 460);-   1-(4-Bromo-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol    (4%, M+H⁺: 505);-   2,2,2-Trifluoro-1-(5-fluoro-1H-indol-3-yl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol    (24%, M+H⁺: 444);-   2,2,2-Trifluoro-1-(4-fluoro-1H-indol-3-yl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol    (17%, M+H⁺: 444);-   2,2,2-Trifluoro-1-(6-fluoro-1H-indol-3-yl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol    (26%, M+H⁺: 444);-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(5-methoxy-1H-indol-3-yl)ethanol    (29%, M+H⁺: 456);-   2,2,2-Trifluoro-1-(7-fluoro-1H-indol-3-yl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol    (7%, M+H⁺: 444);-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(6-methyl-1H-indol-3-yl)ethanol    (33%, M+H⁺: 440);-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(7-methyl-1H-indol-3-yl)ethanol    (45%, M+H⁺: 440); and-   3-{2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-5-carbonitrile    (11%, M+H⁺: 451).

Example 262,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1-methyl-6-pyridin-3-yl-1H-indol-3-yl)ethanol

To a solution of the bromoindole (0.100 g, 0.193 mmol) in 5 mL of DMF atroom temperature in a microwave tube was added 3-pyridineboronic acid(0.049 g, 0.40 mmol), tetrakis(triphenylphosphine)palladium(0) (0.023 g,0.020 mmol) in aqueous sodium carbonate solution (2 M, 0.064 g, 0.60mmol). The resulting reaction mixture was degassed with nitrogen for 10minutes. The reaction was allowed to heat at 120° C. in the SmithPersonal Synthesizer for 2.5 hours. The reaction was cooled to roomtemperature and 3 mL of saturated ammonium chloride solution was addedto quench the reaction. 10 mL of ethyl acetate was added and the organiclayer was washed with brine, dried over sodium sulfate, and filtered.The solvent was evaporated in vacuo, and the crude material was purifiedby flash column chromatography to obtain the desired product (60%; M+H⁺:517).

The following examples were synthesized following the procedureillustrated for Example 26 using the corresponding boronic acid andsuitably functionalized bromoindoles. The % yield and M+H⁺ are indicatedin parentheses.

-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1-methyl-6-pyridin-4-yl-1H-indol-3-yl)ethanol    (60%, M+H⁺: 517);-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(6-furan-2-yl-1-methyl-1H-indol-3-yl)ethanol    (22%, M+H⁺: 506); and-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1-methyl-6-pyrimidin-5-yl-1H-indol-3-yl)ethanol    (25%, M+H⁺: 518).

Example 272,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-{6-[(2-methoxyethyl)methylamino]-1-methyl-1H-indol-3-yl}ethanol

To a stirred degassed solution of the bromoindole (0.050 g, 0.096 mmol)in dioxane at room temperature was added theN-(2-methoxyethyl)methylamine (0.023 g, 0.26 mmol), palladium(II)acetate di-tert-butylbiphenylphosphine catalyst (0.005 mg, catalyticamount), and sodium tert-butoxide (0.019 g, 0.200 mmol). The resultingreaction solution was allowed to heat at 90° C. for 2 hours under anitrogen atmosphere. The reaction mixture was cooled to roomtemperature, and filtered through a CELITE® filter aid pad. The solventwas evaporated in vacuo. The crude material was purified by flash columnchromatography to obtain the desired product (57%, M+H⁺: 527).

The following examples were synthesized following the procedureillustrated for Example 27 using the corresponding amines and suitablyfunctionalized bromoindoles. The % yield and M+H⁺ are indicated inparentheses.

-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-[6-(2-methoxyethylamino)-1-methyl-1H-indol-3-yl]ethanol    (47%, M+H⁺: 513);-   1-{6-[(2-Dimethylaminoethyl)methylamino]-1-methyl-1H-indol-3-yl}-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol    (19%, M+H⁺: 540);-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1-methyl-5-morpholin-4-yl-1H-indol-3-yl)ethanol    (55%, M+H⁺: 525);-   1-[6-(2-Dimethylaminoethylamino)-1-methyl-1H-indol-3-yl]-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol    (43%, M+H⁺: 526);-   1-[5-(2-Dimethylaminoethylamino)-1-methyl-1H-indol-3-yl]-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol    (33%, M+H⁺: 526);-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1-methyl-6-pyrrolidin-1-yl-1H-indol-3-yl)ethanol    (41%, M+H⁺: 509); and-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1-methyl-5-pyrrolidin-1-yl-1H-indol-3-yl)ethanol    (34%, M+H⁺: 509).

Example 28N-(1-Methyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indol-7-yl)methanesulfonamide

Step (a): In a 50 mL flask was placed2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1-methyl-7-nitro-1H-indol-3-yl)ethanol(180 mg, 0.37 mmol) in 3 mL of DMF. To this was added a catalytic amountof 10% Pd/C. The atmosphere was evacuated and hydrogen gas added. Thiswas repeated three times and the reaction allowed to stir under hydrogengas atmosphere at room temperature for 48 hours. The reaction was thenfiltered under argon and the filtrate extracted with EtOAc. The combinedorganics were dried, filtered, and evaporated in vacuo. The residue wasthen dissolved in minimal DMF and purified by HPLC (5-95%CH₃CN/water/0.1% TFA). The desired peaks were combined and the CH₃CN wasremoved. The aqueous was then basified with saturated sodium bicarbonatesolution and extracted with EtOAc. The organics were combined, dried,and evaporated in vacuo to provide 96 mg of the desired product1-(7-amino-1-methyl-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanolas a white solid (57%, M+H⁺: 455).

Step (b): In a 7 mL vial was placed1-(7-amino-1-methyl-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol(35 mg, 0.08 mmol, 1 equiv.) in 1 mL of THF. To this was addedtriethylamine (20 μL, 0.16 mmol, 2 equiv.) followed by methanesulfonylchloride (12 μL, 0.16 mmol, 2 equiv.). This was allowed to stir at roomtemperature for 2 hours. The reaction was then filtered into an HPLCvial and purified by HPLC (5-95% CH₃CN/water/0.1% TFA). The desiredfractions were combined and the CH₃CN was removed. The aqueous wasbasified with saturated aqueous sodium bicarbonate solution andextracted with EtOAc. The combined organics were dried, filtered, andevaporated in vacuo to provide 12 mg of the desired product as a tanfoam (29%, M+H⁺: 533).

Example 29N-(1-Methyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indol-7-yl)methanesulfonamide

Step (a): In a 50 mL flask was placed1-methyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylicacid methyl ester (357 mg, 0.72 mmol) in 2 mL of THF and 20 mL of 1MNaOH. This was allowed to stir at room temperature. After 2 hours,another 10 mL of THF was added and the reaction heated at 50° C. for 18hours. At this point, 3 pellets of solid NaOH were added and the heatingcontinued. After another 2 hours, another 3 pellets of NaOH were addedand the reaction allowed stirring at 50° C. for 72 hours. The reactionwas cooled and transferred to a separatory funnel where it was acidifedto pH 7 with saturated aqueous ammonium chloride solution. This wasextracted with EtOAc and the combined organics were dried, filtered, andevaporated in vacuo to provide 280 mg of the desired product as a tansolid (81%, M+H⁺: 484).

Step (b): In a 7 mL vial was placed1-methyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylicacid, (50 mg, 0.1 mmol, 1 equiv.) in 1 mL of DMF. To this was addedtriethylamine (79 μL, 0.6 mol, 6 equiv.) followed by PyBOP (80 mg, 0.15mmol, 1.5 equiv.). After 5 minutes, ammonium chloride (55 mg, 1 mmol, 10equiv.) was added, the reaction was capped, and the reaction allowed tostir at room temperature for 18 hours. The mixture was filtered into avial and purified by HPLC (5-90% CH₃CN/water/0.1% TFA). The desiredfractions were combined and the CH₃CN was removed. The aqueous portionwas basified with saturated aqueous sodium bicarbonate solution andextracted with EtOAc. The combined organics were dried, filtered, andevaporated in vacuo to provide 36 mg of the desired product as a whitesolid (72%, M+H⁺: 483).

The following examples were synthesized following the procedureillustrated for Example 29, step (b) using the corresponding amines andsuitably functionalized indole-carboxylic acids. The % yield and M+H⁺are indicated in parentheses.

-   1-Methyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylic    acid methylamide (70% M+H⁺: 497);-   1-Methyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylic    acid (2-cyanoethyl)amide (63%, M+H⁺: 536);-   1-Methyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylic    acid (2-methoxyethyl)amide (79%, M+H⁺: 541);-   1-Methyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylic    acid (2-methoxyethyl)methylamide (77%<M+H⁺: 555);-   1-Methyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylic    acid carbamoylmethylamide (74%, M+H⁺: 540);-   1-Methyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylic    acid cyanomethylamide (80%, M+H⁺: 522); and-   1-Allyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylic    acid amide (66%, M+H⁺: 509).

Example 30 2,2,2-Trifluoro-1-phenyl-1-(1-phenyl-1H-indol-5-yl)ethanol

Step (a): To a solution of 1-phenyl-1H-indole-5-carbonitrile (2.51 g,11.47 mmol) in 60 mL of CH₂Cl₂ at 0° C. was added DIBAL-H (1M in THF, 16mL, 16 mmol). The resulting yellow suspension was stirred for 2 hoursand then poured into 30 mL of cold 1N HCl solution. The biphasic systemwas cooled to 0° C. and then basified to pH 8 by the addition ofsaturated aqueous sodium bicarbonate solution. The aqueous layer wasextracted with three 20 mL portions of CH₂Cl₂. The combined organicphase was dried over sodium sulfate, filtered, and then concentrated invacuo. The crude material was purified by flash column chromatographywith silica gel (eluted with 100%-80% hexanes/EtOAc). The desiredproduct 1-phenyl-1H-indole-5-carbaldehyde was obtained as a light yellowsolid (1.77 g, 70% yield; M+H⁺: 222).

Step (b): To a solution of 1-phenyl-1H-indole-5-carbaldehyde (1.2 g, 5.4mmol) in 10 mL of THF at 0° C. was added a solution of TMSCF₃ in THF(0.9 g, 6.4 mmol). The resulting light yellow solution was stirred at 0°C. for 15 minutes, then tetrabutylammonium fluoride (TBAF) (1M in THF,1.6 mL, 1.6 mmol) was added. The reaction mixture was allowed to warm upto room temperature and then stirred for an additional 14 hours. The THFwas evaporated in vacuo and the resulting residue was dissolved in 20 mLof EtOAc, washed with three 25 mL portions of water, and a 25 mL portionof brine, dried over sodium sulfate, filtered, and the solvent wasevaporated in vacuo. The crude material was purified by flash columnchromatography with silica gel (eluted with 80% hexanes/EtOAc). Thedesired product 2,2,2-trifluoro-1-(1-phenyl-1H-indol-5-yl)ethanol wasobtained as a light yellow solid (1.4 g, 87.0% yield; M+H⁺: 292).

Step (c): A suspension of Dess-Martin periodinane (2.4 g, 5.6 mmol) and2,2,2-trifluoro-1-(1-phenyl-1H-indol-5-yl)ethanol (1.4 g, 4.8 mmol) in20 mL of CH₂Cl₂ was allowed to stir for 12 hours at room temperature.The reaction mixture was added to 150 mL of hexane and the resultingwhite precipitate was filtered through a pad of CELITE® filter aid. Thecombined organic solution was washed with three 25 mL portions of sodiumbicarbonate and a 25 mL portion of brine, dried over sodium sulfate,filtered, and the solvent was evaporated in vacuo. The crude materialwas purified by flash column chromatography with silica gel (eluted with85% hexanes/EtOAc) The desired product2,2,2-trifluoro-1-(1-phenyl-1H-indol-5-yl)ethanone was obtained as awhite solid (1.3 g, 91.0% yield; M+H⁺: 290).

Step (d): To a solution of2,2,2-trifluoro-1-(1-phenyl-1H-indol-5-yl)ethanone (50.0 mg, 0.2 mmol)in 0.5 mL of THF was added phenylmagnesium bromide (1.0 M, 1.0 mL, 1.0mmol) at room temperature. The solution was stirred at this temperaturefor 12.0 hours. The reaction was quenched with 2 mL of saturated aqueousammonium chloride solution and 3.0 mL of water. The aqueous layer wasextracted with three 5 mL portions of EtOAc and the combined organiclayers were dried over sodium sulfate, filtered, and the solvent wasevaporated in vacuo. The crude material was purified by flash columnchromatography with silica gel (eluted with 100%-85% hexanes/EtOAc). Thedesired product2,2,2-Trifluoro-1-phenyl-1-(1-phenyl-1H-indol-5-yl)ethanol was obtainedas a white solid (49.0 mg, 80% yield; M+H⁺: 368).

The following examples were synthesized following the procedureillustrated for Example 30, step (d), using the corresponding Grignardor equivalent organometallic reagent. The percent yield of the reactionand the M+H⁺ are indicated in parentheses.

-   2,2,2-Trifluoro-1-(4-fluoronaphthalen-1-yl)-1-(1-phenyl-1H-indol-5-yl)ethanol    (66%, M+H⁺: 436); and-   2,2,2-Trifluoro-1-naphthalen-1-yl-1-(1-phenyl-1H-indol-5-yl)ethanol    (78%, M+H⁺: 418).

Example 31N-{3-[2,2,2-Trifluoro-1-hydroxy-1-(1-phenyl-1H-indazol-5-yl)ethyl]phenyl}acetamide

Step (a): In a 100 mL flask was placed1-[3-(2,5-dimethylpyrrol-1-yl)phenyl]-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol(112 mg, 0.24 mmol, 1 equiv.) in 7 mL of EtOH and 3 mL of water. To thiswas added hydroxylamine hydrochloride (168 mg, 2.4 mmol, 10 equiv.) andthe reaction refluxed for 18 hours. The EtOH was then removed and thereaction diluted with EtOAc. This was then basified with saturatedaqueous sodium bicarbonate solution, transferred to a separatory funnel,and extracted with EtOAc. The combined organics were dried, filtered,and evaporated in vacuo. The residue was purified by flashchromatography to provide 25 mg of1-(3-aminophenyl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol asa pale orange solid (70%, M+H⁺: 462).

Step (b): In a 10 mL flask was placed1-(3-aminophenyl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol(20 mg, 0.05 mmol, 1 equiv.) in 1 mL of pyridine. To this was added 1drop of acetyl chloride. After 2 hours, the pyridine was removed and theresidue was purified by flash chromatography to provide 16.4 mg of thedesired product as a white solid (74%, M+H⁺: 426).

Example 321-(1-Allyl-1H-indol-3-yl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-methylpropan-1-ol

Step (a): In a 250 mL flask was placed5-bromo-1-(4-fluorophenyl)-1H-indazole (3.5 g 11.5 mmol, 1.1 equiv.) in50 mL of dry THF. This was cooled to −78° C. In a separate vial wasplaced 1-allyl-1H-indole-3-carbaldehyde (2.0 g 10.8 mmol, 1 equiv.) in 5mL of THF and this was cooled to −78° C. n-BuLi (2.5 M in hexanes, 4.7mL, 11.5 mmol, 1.1 equiv) was added to the5-bromo-1-(4-fluorophenyl)-1H-indazole by syringe quickly at whichpoint, the solution of 1-allyl-1H-indole-3-carbaldehyde was added in oneportion. The reaction was allowed to stir at −78° C. for 30 minutes atwhich point it was quenched with water and allowed to come to roomtemperature. The reaction was then diluted with brine and extracted withEtOAc. The combined organics were dried, filtered, and evaporated invacuo. The residue was purified by flash chromatography (0-30%EtOAc/hexanes) to provide 1.5 g of(1-allyl-1H-indol-3-yl)-[1-(4-fluorophenyl)-1H-indazol-5-yl]methanol asa tan solid (35%, M+H⁺: 398).

Step (b): In a 100 mL flask was placed(1-allyl-1H-indol-3-yl)-[1-(4-fluorophenyl)-1H-indazol-5-yl]methanol(1.3 g, 3.2 mmol, 1 equiv.) in 50 mL of CH₂Cl₂. This was cooled to 0° C.where pyridinium chlorochromate (PCC; 764 mg, 3.5 mmol, 1.1 equiv.) wasadded. After 5 minutes, the ice bath was removed and the reactionallowed to stir at room temperature for 18 hours. The reaction wastransferred to a separatory funnel and diluted with CH₂Cl₂ and washedwith saturated aqueous sodium bicarbonate solution. The organic wasremoved, dried, filtered, and evaporated in vacuo. The residue waspurified by flash chromatography (0-30% EtOAc-hexanes) to provide 820 mgof (1-allyl-1H-indol-3-yl)-[1-(4-fluorophenyl)-1H-indazol-5-yl]methanoneas a tan solid which was used without further purification (65%, M+H⁺:396).

Step (c): In a 25 mL flask was placed(1-allyl-1H-indol-3-yl)-[1-(4-fluorophenyl)-1H-indazol-5-yl]methanone(100 mg, 0.3 mmol, 1 equiv.) in 5 mL of THF. This was cooled to −78° C.where isopropyl lithium (0.7 M in pentane, 0.43 mL, 1.2 equiv.) wasadded dropwise. The reaction was then allowed to stir for 30 minutes.The reaction was then diluted with water and allowed to come to roomtemperature. The mixture was transferred to a separatory funnel andextracted with EtOAc. The combined organics were dried, filtered, andevaporated in vacuo. The residue was purified by flash chromatography(0-20% EtOAc/hexanes) to provide 21 mg of the desired compound as awhite solid (19%, M+H⁺: 440).

The following examples were synthesized following the procedureillustrated for Example 32, step (c), reacting the correspondingGrignard or equivalent organometallic reagent with the desiredbiarylketones. The percent yield of the reaction and the M+H⁺ areindicated in parentheses.

-   1-(1-Phenyl-1H-indazol-5-yl)-1-quinolin-4-ylethanol (65%, M+H⁺:    366);-   1-(1-Phenyl-1H-indazol-5-yl)-1-quinolin-4-ylpropan-1-ol (30%, M+H⁺:    380);-   1-(4-Fluoronaphthalen-1-yl)-1-(1-phenyl-1H-indazol-5-yl)propan-1-ol    (81%, M+H⁺: 397); and-   1-(1-Allyl-1H-indol-3-yl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-1-ol    (18%, M+H⁺: 426).

Example 332,2,2-Trifluoro-1-(4-fluoro-3-hydroxymethylphenyl)-1-(1-phenyl-1H-indazol-5-yl)ethanol

Step (a): To a solution of2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanone (0.150 g, 0.517mmol) in TIF at room temperature was added the3-(1,3-dioxan-2-yl)-4-fluorophenyl magnesium bromide (0.25 M in THF, 6.0mL, 1.5 mmol). The resulting solution was allowed to stir overnight atroom temperature. The reaction was quenched with a saturated solution ofammonium chloride. Ethyl acetate was added and the organic layer waswashed with brine, dried over sodium sulfate, and filtered. The solventwas evaporated in vacuo, and the crude material was purified by flashcolumn chromatography to obtain the desired product1-(3-1,3-dioxinan-2-yl-4-fluorophenyl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol(82%, M+H⁺: 473).

Step (b): To a solution of1-(3-1,3-dioxinan-2-yl-4-fluorophenyl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol(0.2 g, 0.423 mmol) in THF at room temperature was added a solution ofHCl (2 M, 5 mL). The resulting solution was allowed to stir overnight atroom temperature. The reaction mixture was neutralized by saturatedaqueous sodium carbonate solution to pH 7. Ethyl acetate was added andthe organic layers were washed with brine, dried over sodium sulfate andfiltered. The solvent was evaporated in vacuo, and the crude materialwas purified by flash column chromatography to obtain the desiredproduct2-fluoro-5-[2,2,2-trifluoro-1-hydroxy-1-(1-phenyl-1H-indazol-5-yl)ethyl]benzaldehyde(48%, M+H⁺: 415).

Step (c): To a stirred solution of2-fluoro-5-[2,2,2-trifluoro-1-hydroxy-1-(1-phenyl-1H-indazol-5-yl)ethyl]benzaldehyde(0.04 g, 0.097 mmol) in dichloromethane at room temperature was addedsodium triacetoxyborohydride (0.032 g, 0.15 mmol). The reaction mixturewas allowed to be stirred at room temperature overnight, then dilutedwith 3 mL of dichloromethane and 4 mL of saturated aqueous sodiumbicarbonate solution. 10 mL of ethyl acetate was added and the organiclayer was washed with brine, dried over sodium sulfate, and filtered.The solvents were evaporated in vacuo, and the crude material waspurified by flash column chromatography to obtain the desired product2,2,2-trifluoro-1-(4-fluoro-3-hydroxymethylphenyl)-1-(1-phenyl-1H-indazol-5-yl)ethanol(80%, M+H⁺: 417).

To a solution of2,2,2-trifluoro-1-(3-methoxyphenyl)-1-(1-phenyl-1H-indazol-5-yl)ethanol(0.054 g, 0.136 mmol) in CH₂Cl₂ at 0° C. was added the BBr₃ (1M inCH₂Cl₂, 1.36 mL, 1.36 mmol) dropwise. The resulting solution was stirredfor 2 days at 5° C. The reaction was allowed to warmed up to roomtemperature, then quenched with 2 mL of MeOH. Ethyl acetate was added tothe reaction and the organic layer was washed with brine, dried oversodium sulfate, and filtered. The solvent was evaporated in vacuo, andthe crude material was purified by flash column chromatography to obtainthe desired compound3-[2,2,2-trifluoro-1-hydroxy-1-(1-phenyl-1H-indazol-5-yl)ethyl]phenol(38%, M+H⁺: 389).

Assessment of Biological Properties

Compounds of the invention were evaluated for binding to the steroidreceptor by a fluorescence polarization competitive binding assay.Detailed descriptions for preparation of recombinant glucocorticoidreceptor (GR) complex used in the assay is described in U.S. PatentApplication Publication No. US 2003/0017503, filed May 20, 2002, andincorporated herein by reference in its entirety. Preparation of thetetramethylrhodamine (TAMRA)-labeled dexamethasone probe wasaccomplished using a standard literature procedure (M. Pons et al., J.Steroid Biochem., 1985, 22, pp. 267-273).

A. Glucocorticoid Receptor Competitive Binding Assay

Step 1. Characterization of the Fluorescent Probe

The wavelengths for maximum excitation and emission of the fluorescentprobe should first be measured. An example of such a probe is rhodamine(TAMRA)-labeled dexamethasone.

The affinity of the probe for the steroid receptor was then determinedin a titration experiment. The fluorescence polarization value of theprobe in assay buffer was measured on an SLM-8100 fluorometer using theexcitation and emission maximum values described above. Aliquots ofexpression vector lysate were added and fluorescence polarization wasmeasured after each addition until no further change in polarizationvalue was observed. Non-linear least squares regression analysis wasused to calculate the dissociation constant of the probe from thepolarization values obtained for lysate binding to the probe.

Step 2. Screening for Inhibitors of Probe Binding

This assay uses fluorescence polarization (FP) to quantitate the abilityof test compounds to compete with tetramethylrhodamine (TA RA)-labeleddexamethasone for binding to a human glucocorticoid receptor (GR)complex prepared from an insect expression system. The assay buffer was:10 mM TES, 50 mM KCl, 20 mM Na₂MoO₄.2H₂O, 1.5 mM EDTA, 0.04% w/v CHAPS,10% v/v glycerol, 1 mM dithiothreitol, pH 7.4. Test compounds weredissolved to 1 mM in neat DMSO and then further diluted to 10× assayconcentration in assay buffer supplemented with 10% v/v DMSO. Testcompounds were serially diluted at 10× assay concentrations in 10%DMSO-containing buffer in 96-well polypropylene plates. Binding reactionmixtures were prepared in 96-well black Dynex microtiter plates bysequential addition of the following assay components to each well: 15μL of 10× test compound solution, 85 μL of GR-containing baculoviruslysate diluted 1:170 in assay buffer, and 50 μL of 15 nM TAMRA-labeleddexamethasone. Positive controls were reaction mixtures containing notest compound; negative controls (blanks) were reaction mixturescontaining 0.7 μM to 2 μM dexamethasone. The binding reactions wereincubated for 1 hour at room temperature and then read for fluorescencepolarization in the LJL Analyst set to 550 nm excitation and 580 nmemission, with the Rhodamine 561 dichroic mirror installed. IC₅₀ valueswere determined by iterative non-linear curve fitting of the FP signaldata to a 4-parameter logistic equation.

Compounds found to bind to the glucocorticoid receptor may be evaluatedfor binding to the progesterone receptor (PR), estrogen receptor (ER),and mineralocorticoid receptors to evaluate the compound's selectivityfor GR. The protocols for PR and MR are identical to the above GRmethod, with the following exceptions: PR insect cell lysate is diluted1:7.1 and MR lysate diluted 1:9.4. PR probe is TAMRA-labeledmifepristone, used at a final concentration of 5 nM in the assay, andthe negative controls (blanks) were reactions containing mifepristone at0.7 μM to 2 μM.

The ER protocol is similar to the above protocols, but uses PanVera kitreceptor, fluorescein-labeled probe. The assay components are made inthe same volumes as above, to produce final assay concentrations for ERof 15 nM and ES2 probe of 1 nM. In addition, the component order ofaddition is modified from the above assays: probe is added to the platefirst, followed by receptor and test compound. The plates are read inthe LJL Analyst set to 485 nm excitation and 530 nm emission, with theFluorescein 505 dichroic mirror installed.

Compounds found to bind to the glucocorticoid receptor may be evaluatedfor dissociation of transactivation and transrepression by assays citedin the Background of the Invention (C. M. Bamberger and H. M. Schulte,Eur. J. Clin. Invest., 2000, 30 (suppl. 3) 6-9) or by the assaysdescribed below.

B. Glucocorticoid Receptor Cell Assays

1. Induction of Aromatase in Fibroblasts (Cell Assay forTransactivation)

Dexamethasone, a synthetic ligand to the glucocorticoid receptor (GR),induces expression of aromatase in human foreskin fibroblast cells. Theactivity of aromatase is measured by the conversion of testosterone toestradiol in culture media. Compounds that exhibit binding to GR areevaluated for their ability to induce aromatase activity in humanforeskin fibroblasts.

Human foreskin fibroblast cells (ATCC Cat. No. CRL-2429, designationCCD112SK) are plated on 96 well plates at 50,000 cells per well 5 daysbefore use, in Iscove's Modified Dulbecco's Media (GibcoBRL LifeTechnologies Cat No. 12440-053) supplemented with 10% charcoal filteredFBS (Clonetech Cat No. SH30068) and Gentamycin (GibcoBRL LifeTechnologies Cat. No. 15710-064). On the day of the experiment, themedia in the wells is replaced with fresh media. Cells are treated withtest compounds to final concentrations of 10⁻⁵ M to 10⁻⁸ M, andtestosterone to a final concentration of 300 ng/mL. Each well has atotal volume of 100 μL. Samples are made in duplicates. Control wellsinclude: (a) wells that receive testosterone only, and (b) wells thatreceive testosterone plus 2 μM of dexamethasone to provide maximuminduction of aromatase. Plates are incubated at 37° C. overnight (15 to18 hours), and supernatants are harvested at the end of incubation.Estradiol in the supernatant is measured using ELISA kits for estradiol(made by ALPCO, obtained from American Laboratory Products Cat. No.020-DR-2693) according to the manufacture's instruction. The amount ofestradiol is inversely proportional to the ELISA signals in each well.The extent of aromatase induction by test compounds is expressed as arelative percentage to dexamethasone. EC₅₀ values of test compounds arederived by non-linear curve fitting.

2. Inhibition of IL-6 Production in Fibroblasts (Cell Assay forTransrepression)

Human foreskin fibroblast cells produce IL-6 in response to stimulationby proinflammatory cytokine IL-1. This inflammatory response, asmeasured by the production of IL-6, can be effectively inhibited bydexamethasone, a synthetic ligand to the glucocorticoid receptor (GR).Compounds that exhibit binding to GR are evaluated for their ability toinhibit IL-6 production in human foreskin fibroblasts.

Human foreskin fibroblast cells (ATCC Cat. No. CRL-2429) are plated on96 well plates at 5,000 cells per well the day before use, in Iscove'sModified Dulbecco's Media (GibcoBRL Life Technologies Cat. No.12440-053) supplemented with 10% charcoal filtered FBS (Clonetech Cat.No. SH30068) and Gentamycin (GibcoBRL Life Technologies Cat. No.15710-064). On the next day, media in the wells is replaced with freshmedia. Cells are treated with IL-1 (rhIL-1α, R&D Systems Cat. No.200-LA) to a final concentration of 1 ng/mL, and with test compounds tofinal concentrations of 10⁻⁵ M to 10⁻⁸ M, in a total volume of 200 μLper well. Samples are done in duplicates. Background control wells donot receive test compounds or IL-1. Positive control wells receive IL-1only and represent maximum (or 100%) amount of IL-6 production. Platesare incubated at 37° C. overnight (15 to 18 hours), and supernatants areharvested at the end of incubation. IL-6 levels in the supernatants aredetermined by the ELISA kits for IL-6 (MedSystems Diagnostics GmbH,Vienna, Austria, Cat. No. BMS213TEN) according to manufacture'sinstructions. The extent of inhibition of IL-6 by test compounds isexpressed in percentage relative to positive controls. IC₅₀ values oftest compounds are derived by non-linear curve fitting.

Evaluation of agonist or antagonist activity of compounds binding to theglucocorticoid receptor may be determined by any of the assays.

3. Modulation of Tyrosine Aminotransferase (TAT) Induction in RatHepatoma Cells

Testing of compounds for agonist or antagonist activity in induction oftyrosine aminotransferase (TAT) in rat hepatoma cells.

H4-II-E-C3 cells were incubated overnight in 96 well plates (20,000cells/100 μL/well) in MEM medium containing 10% heat inactivated FBS and1% nonessential amino acids. On the next day, cells were stimulated withthe indicated concentrations of dexamethasone or test compound(dissolved in DMSO, final DMSO concentration 0.2%) for 18 hours. Controlcells were treated with 0.2% DMSO. After 18 hours, the cells were lysedin a buffer containing 0.1% Triton X-100 and the TAT activity wasmeasured in a photometric assay using tyrosine and alpha-ketoglutarateas substrates.

For measuring antagonist activity, the hepatoma cells werepre-stimulated by addition of dexamethasone (concentration ranges from3×10⁻⁹ M to 3×10⁻⁸ M) shortly before the test compound was applied tothe cells. The steroidal non-selective GR/PR antagonist mifepristone wasused as control.

4. Modulation of MMTV-Luc Induction in HeLa Cells

Testing of compounds for agonist or antagonist activity in stimulationof MMTV-(mouse mammary tumor virus) promoter in HeLa cells.

HeLa cells were stably co-transfected with the pHHLuc-plasmid containinga fragment of the MMTV-LTR (−200 to +100 relative to the transcriptionstart site) cloned in front of the luciferase gene (Norden, 1988) andthe pcDNA3.1 plasmid (Invitrogen) constitutively expressing theresistance for the selective antibiotic GENETICIN®. Clones with bestinduction of the MMTV-promoter were selected and used for furtherexperiments.

Cells were cultured overnight in DMEM medium without phenol red,supplemented with 3% CCS (charcoal treated calf serum) and thentransferred to 96 well plates (15,000 cells/100 μL/well). On the nextday, activation of the MMTV-promoter was stimulated by addition of testcompound or dexamethasone dissolved in DMSO (final concentration 0.2%).Control cells were treated with DMSO only. After 18 hours, the cellswere lysed with cell lysis reagent (Promega, Cat. No. E1531), luciferaseassay reagent (Promega, Cat. No. E1501) was added and the glowluminescence was measured using a luminometer (BMG, Offenburg).

For measuring antagonist activity, the MMTV-promoter was pre-stimulatedby adding dexamethasone (3×10⁻⁹ M to 3×10⁻⁸ M) shortly before the testcompound was applied to the cells. The steroidal non-selective GR/PRantagonist mifepristone was used as control.

5. Modulation of IL-8 Production in U937 Cells

Testing of compounds for agonist or antagonist activity in GR-mediatedinhibition of LPS-induced IL-8 secretion in U-937 cells.

U-937 cells were incubated for 2 to 4 days in RPMI1640 medium containing10% CCS (charcoal treated calf serum). The cells were transferred to 96well plates (40,000 cells/100 μL/well) and stimulated with 1 μg/mL LPS(dissolved in PBS) in the presence or absence of dexamethasone or testcompound (dissolved in DMSO, final concentration 0.2%). Control cellswere treated with 0.2% DMSO. After 18 hours, the IL-8 concentration inthe cell supernatant was measured by ELISA, using the “OptEIA human IL-8set” (Pharmingen, Cat. No. 2654KI).

For measuring antagonist activity, the LPS-induced IL-8 secretion wasinhibited by adding dexamethasone (3×10⁻⁹ M to 3×10⁻⁸ M) shortly beforethe test compound was applied to the cells. The steroidal non-selectiveGR/PR antagonist mifepristone was used as control.

6 Modulation of ICAM-Luc Expression in HeLa Cells

Testing of compounds for agonist or antagonist activity in inhibition ofTNF-alpha-induced activation of the ICAM-promoter in HeLa cells.

HeLa cells were stably co-transfected with a plasmid containing a 1.3 kbfragment of the human ICAM-promoter (−1353 to −9 relative to thetranscription start site, Ledebur and Parks, 1995) cloned in front ofthe luciferase gene and the pcDNA3.1 plasmid (Invitrogen) whichconstitutively expresses the resistance for the antibiotic GENETICIN®.Clones with best induction of the ICAM-promoter were selected and usedfor further experiments. Cells were transferred to 96 well plates(15,000 cells/100 μL/well) in DMBM medium supplemented with 3% CCS. Onthe following day the activation of the ICAM-promoter was induced byaddition of 10 ng/mL recombinant TNF-alpha (R&D System, Cat. No.210-TA). Simultaneously the cells were treated with the test compound ordexamethasone (dissolved in DMSO, final concentration 0.2%). Controlcells were treated with DMSO only. After 18 hours, the cells were lysedwith cell lysis reagent (Promega, Cat. No. E1531), luciferase assayreagent (Promega, Cat. No. E1501) was added and glow luminescence wasmeasured using a luminometer (BMG, Offenburg).

For measuring antagonist activity, the TNF-alpha-induced activation ofthe ICAM-promoter was inhibited by adding dexamethasone (3×10⁻⁹ M to3×10⁻⁸ M) shortly before the test compound was applied to the cells. Thesteroidal non-selective GR/PR antagonist mifepristone was used ascontrol.

In general, the preferred potency range in the above assays is between0.1 nM and 10 μM, the more preferred potency range is 0.1 nM to 1 μM,and the most preferred potency range is 0.1 nM to 100 nM.

Representative compounds of the invention have been tested and haveshown activity as modulators of the glucocorticoid receptor function inone or more of the above assays. For example, the followingrepresentative compounds of the invention have demonstrated potentactivity (between 0.1 nM and 100 nM) in the GR binding assay:

-   1-Biphenyl-3-yl-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   1-(3,4-Difluorophenyl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   1-(3,5-Difluorophenyl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   1-(3-Chloro-5-fluorophenyl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   1-(4-Chloro-3-methylphenyl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   1-(3-Chlorophenyl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   1-(3-Chloro-4-fluorophenyl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   1-(4-Chloro-3-fluorophenyl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   2,2,2-Trifluoro-1-naphthalen-1-yl-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   2,2,2-Trifluoro-1-(3-fluorophenyl)-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   2,2,2-Trifluoro-1-(4-methylnaphthalen-1-yl)-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   1-(2,3-Dihydrobenzo[1,4]dioxin-6-yl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   1-(3,4-Dichlorophenyl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   2,2,2-Trifluoro-1-(4-fluorophenyl)-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   2,2,2-Trifluoro-1-(3-fluoro-4-methylphenyl)-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   1-Benzo[1,3]dioxol-5-yl-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   1-(4-Chlorophenyl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   2,2,2-Trifluoro-1-(3-methoxyphenyl)-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   2,2,2-Trifluoro-1-(3-fluoro-4-methylphenyl)-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   1-(2,2-Difluoro-1,3-benzodioxol-4-yl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   2,2,2-Trifluoro-1-(4-fluoronaphthalen-1-yl)-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   1-(4-Dimethylaminonaphthalen-1-yl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   2,2,2-Trifluoro-1-(2-methoxynaphthalen-1-yl)-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   2,2,2-Trifluoro-1-(1-phenyl-1H-indazol-5-yl)-1-quinolin-4-ylethanol;-   2,2,2-Trifluoro-1-(1H-indol-4-yl)-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   1,1,1-Trifluoro-3-(3-fluorophenyl)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1,1,1-Trifluoro-3-phenyl-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   3-(3,5-Difluorophenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol;-   1-Benzo[b]thiophen-3-yl-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;-   1-Benzo[b]thiophen-3-yl-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   2,2,2-Trifluoro-1-(1-phenyl-1H-indazol-5-yl)-1-quinolin-4-ylethanol;-   1-Benzo[b]thiophen-3-yl-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-phenylethanol;-   1-(3-Chloro-4-fluorophenyl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-naphthalen-1-ylethanol;-   2,2,2-Trifluoro-1-(4-fluoronaphthalen-1-yl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(4-methylnaphthalen-1-yl)ethanol;-   1-Benzo[b]thiophen-3-yl-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;-   1-1,3-Benzodioxol-4-yl-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;    and-   1-(2,2-Difluoro-1,3-benzodioxol-4-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol.

The following compounds of the invention have demonstrated agonisticactivity by inhibiting IL-6 production in Fibroblasts (Cell Assay forTransrepression):

-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(4-methylnaphthalen-1-yl)ethanol;-   2,2,2-Trifluoro-1-(4-fluoronaphthalen-1-yl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;-   2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-naphthalen-1-ylethanol;-   1-(3-Chloro-4-fluorophenyl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;-   1-Benzo[b]thiophen-3-yl-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;-   1-Benzo[b]thiophen-3-yl-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   2,2,2-Trifluoro-1-(1-phenyl-1H-indazol-5-yl)-1-quinolin-4-ylethanol;-   2,2,2-Trifluoro-1-(4-fluoronaphthalen-1-yl)-1-(1-phenyl-1H-indazol-5-yl)ethanol;-   2,2,2-Trifluoro-1-naphthalen-1-yl-1-(1-phenyl-1H-indazol-5-yl)ethanol;    and-   1-(3-Chloro-4-fluorophenyl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol.    Methods of Therapeutic Use

As pointed out above, the compounds of the invention are useful inmodulating the glucocorticoid receptor function. In doing so, thesecompounds have therapeutic use in treating disease-states and conditionsmediated by the glucocorticoid receptor function or that would benefitfrom modulation of the glucocorticoid receptor function.

As the compounds of the invention modulate the glucocorticoid receptorfunction, they have very useful anti-inflammatory and antiallergic,immune-suppressive, and anti-proliferative activity and they can be usedin patients as drugs, particularly in the form of pharmaceuticalcompositions as set forth below, for the treatment of disease-states andconditions.

The agonist compounds according to the invention can be used in patientsas drugs for the treatment of the following disease-states orindications that are accompanied by inflammatory, allergic, and/orproliferative processes:

-   (i) Lung diseases: chronic, obstructive lung diseases of any    genesis, particularly bronchial asthma and chronic obstructive    pulmonary disease (COPD); adult respiratory distress syndrome    (ARDS); bronchiectasis; bronchitis of various genesis; all forms of    restrictive lung diseases, particularly allergic alveolitis; all    forms of lung edema, particularly toxic lung edema; all forms of    interstitial lung diseases of any genesis, e.g., radiation    pneumonitis; and sarcoidosis and granulomatoses, particularly Boeck    disease;-   (ii) Rheumatic diseases or autoimmune diseases or joint diseases:    all forms of rheumatic diseases, especially rheumatoid arthritis,    acute rheumatic fever, and polymyalgia rheumatica; reactive    arthritis; rheumatic soft tissue diseases; inflammatory soft tissue    diseases of other genesis; arthritic symptoms in degenerative joint    diseases (arthroses); traumatic arthritis; collagenoses of any    genesis, e.g., systemic lupus erythematosus, scleroderma,    polymyositis, dermatomyositis, Sjögren syndrome, Still disease, and    Felty syndrome;-   (iii) Allergic diseases: all forms of allergic reactions, e.g.,    angioneurotic edema, hay fever, insect bites, allergic reactions to    drugs, blood derivatives, contrast agents, etc., anaphylactic shock    (anaphylaxis), urticaria, angioneurotic edema, and contact    dermatitis;-   (iv) Vasculitis diseases: panarteritis nodosa, polyarteritis nodosa,    arteritis temporalis, Wegner granulomatosis, giant cell arthritis,    and erythema nodosum;-   (v) Dermatological diseases: atopic dermatitis, particularly in    children; psoriasis; pityriasis rubra pilaris; erythematous diseases    triggered by various noxa, e.g., rays, chemicals, burns, etc.;    bullous dermatoses; diseases of the lichenoid complex; pruritus    (e.g., of allergic genesis); seborrheic dermatitis; rosacea;    pemphigus vulgaris; erythema multiforme exudativum; balanitis;    vulvitis; hair loss, such as occurs in alopecia greata; and    cutaneous T cell lymphomas;-   (vi) Renal diseases: nephrotic syndrome; and all types of nephritis,    e.g., glomerulonephritis;-   (vii) Hepatic diseases: acute liver cell disintegration; acute    hepatitis of various genesis, e.g., viral, toxic, drug-induced; and    chronically aggressive and/or chronically intermittent hepatitis;-   (viii) Gastrointestinal diseases: inflammatory bowel diseases, e.g.,    regional enteritis (Crohn disease), colitis ulcerosa; gastritis;    peptic esophagitis (refluxoesophagitis); and gastroenteritis of    other genesis, e.g., nontropical sprue;-   (ix) Proctological diseases: anal eczema; fissures; hemorrhoids; and    idiopathic proctitis;-   (x) Eye diseases: allergic keratitis, uveitis, or iritis;    conjunctivitis; blepharitis; neuritis nervi optici; choroiditis; and    sympathetic ophthalmia;-   (xi) Diseases of the ear, nose, and throat (ENT) area: allergic    rhinitis or hay fever; otitis externa, e.g., caused by contact    eczema, infection, etc.; and otitis media;-   (xii) Neurological diseases: brain edema, particularly tumor-related    brain edema; multiple sclerosis; acute encephalomyelitis;    meningitis; acute spinal cord injury; stroke; and various forms of    seizures, e.g., nodding spasms;-   (xiii) Blood diseases: acquired hemolytic anemia; and idiopathic    thrombocytopenia;-   (xiv) Tumor diseases: acute lymphatic leukemia; malignant lymphoma;    lymphogranulomatoses; lymphosarcoma; extensive metastases,    particularly in mammary, bronchial, and prostatic carcinoma;-   (xv) Endocrine diseases: endocrine ophthalmopathy; endocrine    orbitopathia; thyrotoxic crisis; Thyroiditis de Quervain; Hashimoto    thyroiditis; Morbus Basedow; granulomatous thyroiditis; struma    lymphomatosa; and Grave disease;-   (xvi) Organ and tissue transplantations and graft-versus-host    diseases; (xvii) Severe states of shock, e.g., septic shock,    anaphylactic shock, and systemic inflammatory response syndrome    (SIRS);-   (xviii) Substitution therapy in: congenital primary adrenal    insufficiency, e.g., adrenogenital syndrome; acquired primary    adrenal insufficiency, e.g., Addison disease, autoimmune    adrenalitis, post-infection, tumors, metastases, etc.; congenital    secondary adrenal insufficiency, e.g., congenital hypopituitarism;    and acquired secondary adrenal insufficiency, e.g., post-infection,    tumors, metastases, etc.;-   (xix) Pain of inflammatory genesis, e.g., lumbago; and-   (xx) various other disease-states or conditions including type I    diabetes (insulin-dependent diabetes), osteoarthritis,    Guillain-Barre syndrome, restenosis following percutaneous    transluminal coronary angioplasty, Alzheimer disease, acute and    chronic pain, atherosclerosis, reperfusion injury, bone resorption    diseases, congestive heart failure, myocardial infarction, thermal    injury, multiple organ injury secondary to trauma, acute purulent    meningitis, necrotizing enterocolitis and syndromes associated with    hemodialysis, leukopheresis, and granulocyte transfusion.

In addition, the compounds according to the invention can be used forthe treatment of any other disease-states or conditions not mentionedabove which have been treated, are treated, or will be treated withsynthetic glucocorticoids (see, e.g., H. J. Hatz, Glucocorticoide:Immunologische Grundlagen, Pharmakologie und Therapierichtlinien[Glucocorticoids: Immunological Fundamentals, Pharmacology, andTherapeutic Guidelines], Stuttgart: Verlagsgesellschaft mbH, 1998, whichis hereby incorporated by reference in its entirety). Most or all of theindications (i) through (xx) mentioned above are described in detail inH. J. Hatz, Glucocorticoide: Immunologische Grundlagen, Pharmakologieund Therapierichtlinien. Furthermore, the compounds of the invention canalso be used to treat disorders other than those listed above ormentioned or discussed herein, including in the Background of theInvention.

The antagonist compounds according to the invention, whether fullantagonists or partial antagonists, can be used in patients as drugs forthe treatment of the following disease-states or indications, withoutlimitation: type II diabetes (non-insulin-dependent diabetes); obesity;cardiovascular diseases; hypertension; arteriosclerosis; neurologicaldiseases, such as psychosis and depression; adrenal and pituitarytumors; glaucoma; and Cushing syndrome based on an ACTH-secreting tumorlike pituitary adenoma. In particular, the compounds of the inventionare useful for treating obesity and all disease-states and indicationsrelated to a deregulated fatty acids metabolism such as hypertension,atherosclerosis, and other cardiovascular diseases. Using the compoundsof the invention that are GR antagonists, it should be possible toantagonize both the carbohydrate metabolism and fatty acids metabolism.Thus, the antagonist compounds of the invention are useful in treatingall disease-states and conditions that involve increased carbohydrate,protein, and lipid metabolism and would include disease-states andconditions leading to catabolism like muscle frailty (as an example ofprotein metabolism).

Methods of Diagnostic Use

The compounds of the invention may also be used in diagnosticapplications and for commercial and other purposes as standards incompetitive binding assays. In such uses, the compounds of the inventionmay be used in the form of the compounds themselves or they may bemodified by attaching a radioisotope, luminescence, fluorescent label orthe like in order to obtain a radioisotope, luminescence, or fluorescentprobe, as would be known by one of skill in the art and as outlined inHandbook of Fluorescent Probes and Research Chemicals, 6th Edition, R.P. Haugland (ed.), Eugene: Molecular Probes, 1996; Fluorescence andLuminescence Probes for Biological Activity, W. T. Mason (ed.), SanDiego: Academic Press, 1993; Receptor-Ligand Interaction, A PracticalApproach, E. C. Hulme (ed.), Oxford: IRL Press, 1992, each of which ishereby incorporated by reference in their entireties.

General Administration and Pharmaceutical Compositions

When used as pharmaceuticals, the compounds of the invention aretypically administered in the form of a pharmaceutical composition. Suchcompositions can be prepared using procedures well known in thepharmaceutical art and comprise at least one compound of the invention.The compounds of the invention may also be administered alone or incombination with adjuvants that enhance stability of the compounds ofthe invention, facilitate administration of pharmaceutical compositionscontaining them in certain embodiments, provide increased dissolution ordispersion, increased inhibitory activity, provide adjunct therapy, andthe like. The compounds according to the invention may be used on theirown or in conjunction with other active substances according to theinvention, optionally also in conjunction with other pharmacologicallyactive substances. In general, the compounds of this invention areadministered in a therapeutically or pharmaceutically effective amount,but may be administered in lower amounts for diagnostic or otherpurposes.

In particular, the compounds of the invention are useful in combinationwith glucocorticoids or corticosteroids. As pointed out above, standardtherapy for a variety of immune and inflammatory disorders includesadministration of corticosteroids, which have the ability to suppressimmunologic and inflammatory responses. (A. P. Truhan et al., Annals ofAllergy, 1989, 62, pp. 375-391; J. D. Baxter, Hospital Practice, 1992,27, pp. 111-134; R. P. Kimberly, Curr. Opin. Rheumatol., 1992, 4, pp.325-331; M. H. Weisman, Curr. Opin. Rheumatol., 1995, 7, pp. 183-190; W.Sterry, Arch. Dermatol. Res., 1992, 284 (Suppl.), pp. S27-S29). Whiletherapeutically beneficial, however, the use of corticosteroids isassociated with a number of side effects, ranging from mild to possiblylife threatening, especially with prolonged and/or high dose steroidusage. Accordingly, methods and compositions that enable the use of alower effective dosage of corticosteroids (referred to as the “steroidsparing effect”) would be highly desirable to avoid unwanted sideeffects. The compounds of the invention provide such a steroid sparingeffect by achieving the desired therapeutic effect while allowing theuse of lower doses and less frequent administration of glucocorticoidsor corticosteroids.

Administration of the compounds of the invention, in pure form or in anappropriate pharmaceutical composition, can be carried out using any ofthe accepted modes of administration of pharmaceutical compositions.Thus, administration can be, for example, orally, buccally (e.g.,sublingually), nasally, parenterally, topically, transdermally,vaginally, or rectally, in the form of solid, semi-solid, lyophilizedpowder, or liquid dosage forms, such as, for example, tablets,suppositories, pills, soft elastic and hard gelatin capsules, powders,solutions, suspensions, or aerosols, or the like, preferably in unitdosage forms suitable for simple administration of precise dosages. Thepharmaceutical compositions will generally include a conventionalpharmaceutical carrier or excipient and a compound of the invention asthe/an active agent, and, in addition, may include other medicinalagents, pharmaceutical agents, carriers, adjuvants, diluents, vehicles,or combinations thereof. Such pharmaceutically acceptable excipients,carriers, or additives as well as methods of making pharmaceuticalcompositions for various modes or administration are well-known to thoseof skill in the art. The state of the art is evidenced, e.g., byRemington: The Science and Practice of Pharmacy, 20th Edition, A.Gennaro (ed.), Lippincott Williams & Wilkins, 2000; Handbook ofPharmaceutical Additives, Michael & Irene Ash (eds.), Gower, 1995;Handbook of Pharmaceutical Excipients, A. H. Kibbe (ed.), AmericanPharmaceutical Ass'n, 2000; H. C. Ansel and N. G. Popovish,Pharmaceutical Dosage Forms and Drug Delivery Systems, 5th ed., Lea andFebiger, 1990; each of which is incorporated herein by reference intheir entireties to better describe the state of the art.

As one of skill in the art would expect, the forms of the compounds ofthe invention utilized in a particular pharmaceutical formulation willbe selected (e.g., salts) that possess suitable physical characteristics(e.g., water solubility) that is required for the formulation to beefficacious.

Pharmaceutical compositions suitable for buccal (sub-lingual)administration include lozenges comprising a compound of the presentinvention in a flavored base, usually sucrose, and acacia or tragacanth,and pastilles comprising the compound in an inert base such as gelatinand glycerin or sucrose and acacia.

Pharmaceutical compositions suitable for parenteral administrationcomprise sterile aqueous preparations of a compound of the presentinvention. These preparations are preferably administered intravenously,although administration can also be effected by means of subcutaneous,intramuscular, or intradermal injection. Injectable pharmaceuticalformulations are commonly based upon injectable sterile saline,phosphate-buffered saline, oleaginous suspensions, or other injectablecarriers known in the art and are generally rendered sterile andisotonic with the blood. The injectable pharmaceutical formulations maytherefore be provided as a sterile injectable solution or suspension ina nontoxic parenterally acceptable diluent or solvent, including1,3-butanediol, water, Ringer's solution, isotonic sodium chloridesolution, fixed oils such as synthetic mono- or diglycerides, fattyacids such as oleic acid, and the like. Such injectable pharmaceuticalformulations are formulated according to the known art using suitabledispersing or setting agents and suspending agents. Injectablecompositions will generally contain from 0.1 to 5% w/w of a compound ofthe invention.

Solid dosage forms for oral administration of the compounds includecapsules, tablets, pills, powders, and granules. For such oraladministration, a pharmaceutically acceptable composition containing acompound(s) of the invention is formed by the incorporation of any ofthe normally employed excipients, such as, for example, pharmaceuticalgrades of mannitol, lactose, starch, pregelatinized starch, magnesiumstearate, sodium saccharine, talcum, cellulose ether derivatives,glucose, gelatin, sucrose, citrate, propyl gallate, and the like. Suchsolid pharmaceutical formulations may include formulations, as are wellknown in the art, to provide prolonged or sustained delivery of the drugto the gastrointestinal tract by any number of mechanisms, whichinclude, but are not limited to, pH sensitive release from the dosageform based on the changing pH of the small intestine, slow erosion of atablet or capsule, retention in the stomach based on the physicalproperties of the formulation, bioadhesion of the dosage form to themucosal lining of the intestinal tract, or enzymatic release of theactive drug from the dosage form.

Liquid dosage forms for oral administration of the compounds includeemulsions, microemulsions, solutions, suspensions, syrups, and elixirs,optionally containing pharmaceutical adjuvants in a carrier, such as,for example, water, saline, aqueous dextrose, glycerol, ethanol and thelike. These compositions can also contain additional adjuvants such aswetting, emulsifying, suspending, sweetening, flavoring, and perfumingagents.

Topical dosage forms of the compounds include ointments, pastes, creams,lotions, gels, powders, solutions, sprays, inhalants, eye ointments, eyeor ear drops, impregnated dressings and aerosols, and may containappropriate conventional additives such as preservatives, solvents toassist drug penetration and emollients in ointments and creams. Topicalapplication may be once or more than once per day depending upon theusual medical considerations. Furthermore, preferred compounds for thepresent invention can be administered in intranasal form by topical useof suitable intranasal vehicles. The formulations may also containcompatible conventional carriers, such as cream or ointment bases andethanol or oleyl alcohol for lotions. Such carriers may be present asfrom about 1% up to about 98% of the formulation, more usually they willform up to about 80% of the formulation.

Transdermal administration is also possible. Pharmaceutical compositionssuitable for transdermal administration can be presented as discretepatches adapted to remain in intimate contact with the epidermis of therecipient for a prolonged period of time. To be administered in the formof a transdermal delivery system, the dosage administration will, ofcourse, be continuous rather than intermittent throughout the dosageregimen. Such patches suitably contain a compound of the invention in anoptionally buffered, aqueous solution, dissolved and/or dispersed in anadhesive, or dispersed in a polymer. A suitable concentration of theactive compound is about 1% to 35%, preferably about 3% to 15%.

For administration by inhalation, the compounds of the invention areconveniently delivered in the form of an aerosol spray from a pump spraydevice not requiring a propellant gas or from a pressurized pack or anebulizer with the use of a suitable propellant, e.g.,dichlorodifluoromethane, trichlorofluoromethane,dichlorotetrafluoroethane, tetrafluoroethane, heptafluoropropane, carbondioxide, or other suitable gas. In any case, the aerosol spray dosageunit may be determined by providing a valve to deliver a metered amountso that the resulting metered dose inhaler (MDI) is used to administerthe compounds of the invention in a reproducible and controlled way.Such inhaler, nebulizer, or atomizer devices are known in the art, forexample, in PCT International Publication Nos. WO 97/12687 (particularlyFIG. 6 thereof, which is the basis for the commercial RESPIMAT®nebulizer); WO 94/07607; WO 97/12683; and WO 97/20590, to whichreference is hereby made and each of which is incorporated herein byreference in their entireties.

Rectal administration can be effected utilizing unit dose suppositoriesin which the compound is admixed with low-melting water-soluble orinsoluble solids such as fats, cocoa butter, glycerinated gelatin,hydrogenated vegetable oils, mixtures of polyethylene glycols of variousmolecular weights, or fatty acid esters of polyethylene glycols, or thelike. The active compound is usually a minor component, often from about0.05 to 10% by weight, with the remainder being the base component.

In all of the above pharmaceutical compositions, the compounds of theinvention are formulated with an acceptable carrier or excipient. Thecarriers or excipients used must, of course, be acceptable in the senseof being compatible with the other ingredients of the composition andmust not be deleterious to the patient. The carrier or excipient can bea solid or a liquid, or both, and is preferably formulated with thecompound of the invention as a unit-dose composition, for example, atablet, which can contain from 0.05% to 95% by weight of the activecompound. Such carriers or excipients include inert fillers or diluents,binders, lubricants, disintegrating agents, solution retardants,resorption accelerators, absorption agents, and coloring agents.Suitable binders include starch, gelatin, natural sugars such as glucoseor β-lactose, corn sweeteners, natural and synthetic gums such asacacia, tragacanth or sodium alginate, carboxymethylcellulose,polyethylene glycol, waxes, and the like. Lubricants include sodiumoleate, sodium stearate, magnesium stearate, sodium benzoate, sodiumacetate, sodium chloride, and the like. Disintegrators include starch,methyl cellulose, agar, bentonite, xanthan gum, and the like.

Generally, a therapeutically effective daily dose is from about 0.001 mgto about 15 mg/kg of body weight per day of a compound of the invention;preferably, from about 0.1 mg to about 10 mg/kg of body weight per day;and most preferably, from about 0.1 mg to about 1.5 mg/kg of body weightper day. For example, for administration to a 70 kg person, the dosagerange would be from about 0.07 mg to about 1050 mg per day of a compoundof the invention, preferably from about 7.0 mg to about 700 mg per day,and most preferably from about 7.0 mg to about 105 mg per day. Somedegree of routine dose optimization may be required to determine anoptimal dosing level and pattern. Pharmaceutically acceptable carriersand excipients encompass all the foregoing additives and the like.

Examples of Pharmaceutical Formulations

A. TABLETS Component Amount per tablet (mg) active substance 100 lactose140 corn starch 240 polyvinylpyrrolidone 15 magnesium stearate 5 TOTAL500

The finely ground active substance, lactose, and some of the corn starchare mixed together. The mixture is screened, then moistened with asolution of polyvinylpyrrolidone in water, kneaded, wet-granulated anddried. The granules, the remaining corn starch and the magnesiumstearate are screened and mixed together. The mixture is compressed toproduce tablets of suitable shape and size.

B. TABLETS Component Amount per tablet (mg) active substance 80 lactose55 corn starch 190 polyvinylpyrrolidone 15 magnesium stearate 2microcrystalline cellulose 35 sodium-carboxymethyl starch 23 TOTAL 400

The finely ground active substance, some of the corn starch, lactose,microcrystalline cellulose, and polyvinylpyrrolidone are mixed together,the mixture is screened and worked with the remaining corn starch andwater to form a granulate which is dried and screened. Thesodium-carboxymethyl starch and the magnesium stearate are added andmixed in and the mixture is compressed to form tablets of a suitablesize.

C. COATED TABLETS Component Amount per tablet (mg) active substance 5lactose 30 corn starch 41.5 polyvinylpyrrolidone 3 magnesium stearate0.5 TOTAL 90

The active substance, corn starch, lactose, and polyvinylpyrrolidone arethoroughly mixed and moistened with water. The moist mass is pushedthrough a screen with a 1 mm mesh size, dried at about 45° C. and thegranules are then passed through the same screen. After the magnesiumstearate has been mixed in, convex tablet cores with a diameter of 6 mmare compressed in a tablet-making machine. The tablet cores thusproduced are coated in known manner with a covering consistingessentially of sugar and talc. The finished coated tablets are polishedwith wax.

D. CAPSULES Component Amount per capsule (mg) active substance 50 cornstarch 268.5 magnesium stearate 1.5 TOTAL 320

The substance and corn starch are mixed and moistened with water. Themoist mass is screened and dried. The dry granules are screened andmixed with magnesium stearate. The finished mixture is packed into size1 hard gelatine capsules.

E. AMPOULE SOLUTION Component Amount per ampoule active substance 50 mgsodium chloride 50 mg water for inj. 5 mL

The active substance is dissolved in water at its own pH or optionallyat pH 5.5 to 6.5 and sodium chloride is added to make it isotonic. Thesolution obtained is filtered free from pyrogens and the filtrate istransferred under aseptic conditions into ampoules which are thensterilized and sealed by fusion. The ampoules contain 5 mg, 25 mg, and50 mg of active substance.

F. SUPPOSITORIES Component Amount per suppository (mg) active substance50 solid fat 1650 TOTAL 1700

The hard fat is melted. At 40° C., the ground active substance ishomogeneously dispersed therein. The mixture is cooled to 38° C. andpoured into slightly chilled suppository molds.

G. METERING AEROSOL Component Amount active substance 0.005 sorbitantrioleate 0.1 monofluorotrichloromethane and to 100difluorodichloromethane (2:3)

The suspension is transferred into a conventional aerosol container witha metering valve. Preferably, 50 μL of suspension are delivered perspray. The active substance may also be metered in higher doses ifdesired (e.g., 0.02% by weight).

H. POWDER FOR INHALATION Component Amount active substance 1.0 mglactose monohydrate to 25 mg

I. POWDER FOR INHALATION Component Amount active substance 2.0 mglactose monohydrate to 25 mg

J. POWDER FOR INHALATION Component Amount active substance 1.0 mglactose monohydrate to 5 mg

K. POWDER FOR INHALATION Component Amount active substance 2.0 mglactose monohydrate to 5 mg

In Examples H, I, J, and K, the powder for inhalation is produced in theusual way by mixing the individual ingredients together.

A B IA 1-Biphenyl-3-yl-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol

1-(3,4-Difluorophenyl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol

1-(3,5-Difluorophenyl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol

1-(3-Chloro-5-fluorophenyl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol

1-(4-Chloro-3-methylphenyl)-2,2,2- trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol

1-(3-Chlorophenyl)-2,2,2-trifluoro-1-(1- phenyl-1H-indazol-5-yl)ethanol

1-(3-Chloro-4-fluorophenyl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol

1-(4-Chloro-3-fluorophenyl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol

1-(3,5-Dichlorophenyl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol

2,2,2-Trifluoro-1-(3-fluorophenyl)-1-(1- phenyl-1H-indazol-5-yl)ethanol

1-(2,3-Dihydrobenzo[1,4]dioxin-6-yl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5- yl)ethanol

1-Benzo[1,3]dioxol-5-yl-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol

1-1,3-Benzodioxol-4-yl-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol

1-(2,2-Difluoro-1,3-benzodioxol-4-yl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5- yl)ethanol

1-(3,4-Dichlorophenyl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol

2,2,2-Trifluoro-1-(4-fluorophenyl)-1-(1- phenyl-1H-indazol-5-yl)ethanol

2,2,2-Trifluoro-1-(3-fluoro-4- methylphenyl)-1-(1-phenyl-1H-indazol-5-yl)ethanol

1-(4-Chlorophenyl)-2,2,2-trifluoro-1-(1- phenyl-1H-indazol-5-yl)ethanol

2,2,2-Trifluoro-1-phenyl-1-(1-phenyl-1H- indazol-5-yl)ethanol

2,2,2-Trifluoro-1-(1-phenyl-1H-indazol-5-yl)-1-(2,4,5-trimethylphenyl)ethanol

2,2,2-Trifluoro-1-(1-phenyl-1H-indazol-5-yl)-1-(2,4,6-trimethylphenyl)ethanol

1-(4-tert-Butyl-2,6-dimethylphenyl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5- yl)ethanol

2,2,2-Trifluoro-1-(3-methoxyphenyl)-1-(1- phenyl-1H-indazol-5-yl)ethanol

1-(3,5-Dimethylphenyl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol

2,2,2-Trifluoro-1-(4-methoxy-3,5-dimethylphenyl)-1-(1-phenyl-1H-indazol-5- yl)ethanol

2,2,2-Trifluoro-1-(4-methoxyphenyl)-1-(1- phenyl-1H-indazol-5-yl)ethanol

1-(3,4-Dimethylphenyl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol

2,2,2-Trifluoro-1-(3-fluoro-4- methoxyphenyl)-1-(1-phenyl-1H-indazol-5-yl)ethanol

2,2,2-Trifluoro-1-(5-fluoro-2- methoxyphenyl)-1-(1-phenyl-1H-indazol-5-yl)ethanol

1-(2,5-Dimethoxyphenyl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol

2,2,2-Trifluoro-1-(2-morpholin-4-ylmethylphenyl)-1-(1-phenyl-1H-indazol-5- yl)ethanol

2,2,2-Trifluoro-1-(1-phenyl-1H-indazol-5-yl)-1-(2-piperidin-1-ylmethylphenyl)ethanol

2,2,2-Trifluoro-1-(1-phenyl-1H-indazol-5-yl)-1-(3-piperidin-1-ylmethylphenyl)ethanol

1-Biphenyl-2-yl-2,2,2-trifluoro-1-(1-phenyl- 1H-indazol-5-yl)ethanol

1-Biphenyl-4-yl-2,2,2-trifluoro-1-(1-phenyl- 1H-indazol-5-yl)ethanol

1-(4-Chloro-2-methylphenyl)-2,2,2- trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol

1-(2,4-Dimethoxyphenyl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol

1-(3,4-Dimethoxyphenyl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol

2,2,2-Trifluoro-1-(2-methoxy-5- methylphenyl)-1-(1-phenyl-1H-indazol-5-yl)ethanol

2,2,2-Trifluoro-1-(4-methoxy-2- methylphenyl)-1-(1-phenyl-1H-indazol-5-yl)ethanol

2,2,2-Trifluoro-1-(2-methoxyphenyl)-1-(1- phenyl-1H-indazol-5-yl)ethanol

2,2,2-Trifluoro-1-(4-methoxy-3- methylphenyl)-1-(1-phenyl-1H-indazol-5-yl)ethanol

2,2,2-Trifluoro-1-(4-phenoxyphenyl)-1-(1- phenyl-1H-indazol-5-yl)ethanol

2,2,2-Trifluoro-1-(4-isopropylphenyl)-1-(1-phenyl-1H-indazol-5-yl)ethanol

2,2,2-Trifluoro-1-(2-methylsulfanylphenyl)-1-(1-phenyl-1H-indazol-5-yl)ethanol

2,2,2-Trifluoro-1-(4-methylsulfanylphenyl)-1-(1-phenyl-1H-indazol-5-yl)ethanol

1-(2,3-Dimethylphenyl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol

1-(2,4-Dimethylphenyl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol

1-(2,5-Dimethylphenyl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol

1-(2,6-Dimethylphenyl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol

1-(4-Ethylphenyl)-2,2,2-trifluoro-1-(1- phenyl-1H-indazol-5-yl)ethanol

1-(2-Ethylphenyl)-2,2,2-trifluoro-1-(1- phenyl-1H-indazol-5-yl)ethanol

2,2,2-Trifluoro-1-(2-fluorobiphenyl-4-yl)-1-(1-phenyl-1H-indazol-5-yl)ethanol

2,2,2-Trifluoro-1-(4-fluoro-2- methoxyphenyl)-1-(1-phenyl-1H-indazol-5-yl)ethanol

2,2,2-Trifluoro-1-(3-fluoro-4- methylphenyl)-1-(1-phenyl-1H-indazol-5-yl)ethanol

2,2,2-Trifluoro-1-(4-fluoro-2- methylphenyl)-1-(1-phenyl-1H-indazol-5-yl)ethanol

2,2,2-Trifluoro-1-(5-fluoro-2- methylphenyl)-1-(1-phenyl-1H-indazol-5-yl)ethanol

2,2,2-Trifluoro-1-(3-fluoro-2- methylphenyl)-1-(1-phenyl-1H-indazol-5-yl)ethanol

2,2,2-Trifluoro-1-naphthalen-1-yl-1-(1- phenyl-1H-indazol-5-yl)ethanol

2,2,2-Trifluoro-1-(4-methylnaphthalen-1-yl)-1-(1-phenyl-1H-indazol-5-yl)ethanol

2,2,2-Trifluoro-1-(4-fluoronaphthalen-1-yl)-1-(1-phenyl-1H-indazol-5-yl)ethanol

2,2,2-Trifluoro-1-(4-nitronaphthalen-1-yl)-1-(1-phenyl-1H-indazol-5-yl)ethanol

1-(4-Aminonaphthalen-1-yl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol

2,2,2-Trifluoro-1-(4- methylaminonaphthalen-1-yl)-1-(1-phenyl-1H-indazol-5-yl)ethanol

1-(4-Dimethylaminonaphthalen-1-yl)-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5- yl)ethanol

4-[2,2,2-Trifluoro-1-hydroxy-1-(1-phenyl-1H-indazol-5-yl)ethyl]naphthalene-1- sulfonic acid amide

4-[2,2,2-Trifluoro-1-hydroxy-1-(1-phenyl-1H-indazol-5-yl)ethyl]naphthalene-1- sulfonic acid methylamide

4-[2,2,2-Trifluoro-1-hydroxy-1-(1-phenyl-1H-indazol-5-yl)ethyl]naphthalene-1- sulfonic acid dimethylamide

4-[2,2,2-Trifluoro-1-hydroxy-1-(1-phenyl-1H-indazol-5-yl)ethyl]naphthalene-1- carbonitrile

4-[2,2,2-Trifluoro-1-hydroxy-1-(1-phenyl-1H-indazol-5-yl)ethyl]naphthalene-1- carboxylic acid amide

4-[2,2,2-Trifluoro-1-hydroxy-1-(1-phenyl-1H-indazol-5-yl)ethyl]naphthalene-1- carboxylic acid methylamide

4-[2,2,2-Trifluoro-1-hydroxy-1-(1-phenyl-1H-indazol-5-yl)ethyl]naphthalene-1- carboxylic acid dimethylamide

2,2,2-Trifluoro-1-(2-methylnaphthalen-1-yl)-1-(1-phenyl-1H-indazol-5-yl)ethanol

2,2,2-Trifluoro-1-(2-methoxynaphthalen-1-yl)-1-(1-phenyl-1H-indazol-5-yl)ethanol

2,2,2-Trifluoro-1-(6-methoxynaphthalen-2-yl)-1-(1-phenyl-1H-indazol-5-yl)ethanol

2,2,2-Trifluoro-1-naphthalen-2-yl-1-(1- phenyl-1H-indazol-5-yl)ethanol

4-[2,2,2-Trifluoro-1-hydroxy-1-(1-phenyl-1H-indazol-5-yl)ethyl]quinoline-3- carboxylic acid dimethylamide

4-[2,2,2-Trifluoro-1-hydroxy-1-(1-phenyl-1H-indazol-5-yl)ethyl]quinoline-3- carboxylic acid methylamide

4-[2,2,2-Trifluoro-1-hydroxy-1-(1-phenyl-1H-indazol-5-yl)ethyl]quinoline-3- carboxylic acid amide

4-[2,2,2-Trifluoro-1-hydroxy-1-(1-phenyl-1H-indazol-5-yl)ethyl]quinoline-3- carboxylic acid ethyl ester

2,2,2-Trifluoro-1-(1-phenyl-1H-indazol-5- yl)-1-quinolin-4-ylethanol

2,2,2-Trifluoro-1-(2-methylquinolin-4-yl)-1-(1-phenyl-1H-indazol-5-yl)ethanol

2,2,2-Trifluoro-1-isoquinolin-1-yl-1-(1- phenyl-1H-indazol-5-yl)ethanol

2,2,2-Trifluoro-1-isoquinolin-4-yl-1-(1- phenyl-1H-indazol-5-yl)ethanol

2,2,2-Trifluoro-1-(3-methylpyridin-2-yl)-1-(1-phenyl-1H-indazol-5-yl)ethanol

2,2,2-Trifluoro-1-(4-methylpyridin-2-yl)-1-(1-phenyl-1H-indazol-5-yl)ethanol

2,2,2-Trifluoro-1-(5-methylpyridin-2-yl)-1-(1-phenyl-1H-indazol-5-yl)ethanol

2,2,2-Trifluoro-1-(6-methylpyridin-2-yl)-1-(1-phenyl-1H-indazol-5-yl)ethanol

2,2,2-Trifluoro-1-(1-phenyl-1H-indazol-5- yl)-1-pyridin-2-ylethanol

1-Benzo[b]thiophen-3-yl-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol

2,2,2-Trifluoro-1-(1H-indol-4-yl)-1-(1- phenyl-1H-indazol-5-yl)ethanol

2,2,2-Trifluoro-1-(1H-indol-3-yl)-1-(1- phenyl-1H-indazol-5-yl)ethanol

1,1,1-Trifluoro-3-(1H-indol-2-yl)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol

1,1,1-Trifluoro-3-indol-1-yl-2-(1-phenyl- 1H-indazol-5-yl)propan-2-ol

1-[3,3,3-Trifluoro-2-hydroxy-2-(1-phenyl-1H-indazol-5-yl)propyl]-1H-indole-3- carbonitrile

1,1,1-Trifluoro-3-morpholin-4-yl-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol

1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-piperidin-1-ylpropan-2-ol

1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-piperazin-1-ylpropan-2-ol

3-(2,3-Dihydrobenzo[1,4]oxazin-4-yl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5- yl)propan-2-ol

3-(3,4-Dihydro-1H-isoquinolin-2-yl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5- yl)propan-2-ol

3-(3,4-Dihydro-2H-quinoxalin-1-yl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5- yl)propan-2-ol

3-(3,4-Dihydro-2H-quinolin-1-yl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5- yl)propan-2-ol

1,1,1-Trifluoro-3-(3-fluorophenyl)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol

1,1,1-Trifluoro-3-phenyl-2-(1-phenyl-1H- indazol-5-yl)propan-2-ol

1,1,1-Trifluoro-2-phenyl-3-(1-phenyl-1H- indazol-5-yl)propan-2-ol

2-Benzyl-1,1,1-trifluoro-3-(1-phenyl-1H- indazol-5-yl)propan-2-ol

1,1,1-Trifluoro-4-phenyl-2-(1-phenyl-1H- indazol-5-yl)butan-2-ol

3-(2,3-Dichlorophenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5- yl)propan-2-ol

1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5- yl)-3-(4-trifluoromethylphenylsulfanyl)propan-2-ol

1,1,1-Trifluoro-3-(naphthalen-1-ylsulfanyl)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol

1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(4-thiophen-2-ylpyrimidin-2- ylsulfanyl)propan-2-ol

1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5- yl)-3-(4-phenylpyrimidin-2-ylsulfanyl)propan-2-ol

3-[4-(4-Chlorophenyl)pyrimidin-2-ylsulfanyl]-1,1,1-trifluoro-2-(1-phenyl-1H- indazol-5-yl)propan-2-ol

6-Methyl-2-[3,3,3-trifluoro-2-hydroxy-2-(1-phenyl-1H-indazol-5-yl)propylsulfanyl]-4- trifluoromethylnicotinonitrile

1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(5-trifluoromethylpyridin-2- ylsulfanyl)propan-2-ol

3-(2-Chloro-4-fluorophenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5- yl)propan-2-ol

1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5- yl)-3-(4-trifluoromethoxyphenylsulfanyl)propan-2-ol

3-(4-Bromo-2- trifluoromethoxyphenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5- yl)propan-2-ol

1,1,1-Trifluoro-3-(4- methoxyphenylsulfanyl)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol

1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(quinolin-2-ylsulfanyl)propan-2-ol

3-(4-Chlorophenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol

1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(pyrimidin-2-ylsulfanyl)propan-2-ol

3-(4,6-Dimethylpyrimidin-2-ylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5- yl)propan-2-ol

3-(3,4-Dichlorophenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5- yl)propan-2-ol

3-(2,5-Dichlorophenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5- yl)propan-2-ol

1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(pyridin-4-ylsulfanyl)propan-2-ol

1,1,1-Trifluoro-3-(3- methoxyphenylsulfanyl)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol

1,1,1-Trifluoro-3-(2- methoxyphenylsulfanyl)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol

3-(3-Chlorophenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol

3-(2,6-Dichlorophenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5- yl)propan-2-ol

3-(2,6-Dichlorophenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5- yl)propan-2-ol

3-(3-Bromophenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol

3-(3,4-Dimethylphenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5- yl)propan-2-ol

1,1,1-Trifluoro-3-(naphthalen-2-ylsulfanyl)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol

1,1,1-Trifluoro-3-(2-fluorophenylsulfanyl)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol

1,1,1-Trifluoro-3-(3-fluorophenylsulfanyl)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol

3-(2,5-Dimethoxyphenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5- yl)propan-2-ol

3-(2,4-Dimethylphenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5- yl)propan-2-ol

3-(2,5-Dimethylphenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5- yl)propan-2-ol

3-(2,6-Dimethylphenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5- yl)propan-2-ol

3-(2-Ethylphenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol

2-[3,3,3-Trifluoro-2-hydroxy-2-(1-phenyl-1H-indazol-5-yl)propylsulfanyl]benzoic acid methyl ester

1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(4-trifluoromethylpyrimidin-2- ylsulfanyl)propan-2-ol

3-(3,5-Dimethylphenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5- yl)propan-2-ol

3-(3,5-Bis-trifluoromethylphenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5- yl)propan-2-ol

3-(2,4-Dilluorophenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5- yl)propan-2-ol

1,1,1-Trifluoro-3-(4- isopropylphenylsulfanyl)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol

3-(2,4-Dichlorophenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5- yl)propan-2-ol

3-(3,5-Dichlorophenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5- yl)propan-2-ol

1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5- yl)-3-(2-trifluoromethylphenylsulfanyl)propan-2-ol

3-(3,4-Difluorophenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5- yl)propan-2-ol

3-(3-Ethoxyphenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol

3-(4-tert-Butylphenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5- yl)propan-2-ol

N-{4-[3,3,3-Trifluoro-2-hydroxy-2-(1- phenyl-1H-indazol-5-yl)propylsulfanyl]phenyl }acetamide

3-(4-Bromophenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol

1,1,1-Trifluoro-3-(4-fluorophenylsulfanyl)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol

1,1,1-Trifluoro-3-(2- isopropylphenylsulfanyl)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol

1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(pyridin-2-ylsulfanyl)propan-2-ol

1,1,1-Trifluoro-3-(4-nitrophenylsulfanyl)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol

1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-o-tolylsulfanylpropan-2-ol

1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-m-tolylsulfanylpropan-2-ol

1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-p-tolylsulfanylpropan-2-ol

3-(3-Chloro-4-fluorophenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5- yl)propan-2-ol

3-(3,4-Dimethoxyphenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5- yl)propan-2-ol

3-(5-tert-Butyl-2-methylphenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5- yl)propan-2-ol

1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5- yl)-3-(2,4,6-trimethylphenylsulfanyl)propan-2-ol

1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5- yl)-3-(3-trifluoromethylphenylsulfanyl)propan-2-ol

1,1,1-Trifluoro-3-(4- methylsulfanylphenylsulfanyl)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol

3-(2-Chloro-6-methylphenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5- yl)propan-2-ol

3-(2-tert-Butylphenylsu1fanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5- yl)propan-2-ol

1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(3-trifluoromethylpyridin-2- ylsulfanyl)propan-2-ol

1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5- yl)-3-(3-trifluoromethoxyphenylsulfanyl)propan-2-ol

3-(3,5-Dimethylphenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol

1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(2,3,6-trifluorophenoxy)propan-2-ol

1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(2,3,5-trifluorophenoxy)propan-2-ol

1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(quinolin-7-yloxy)propan-2-ol

5-Chloro-2-[3,3,3-trifluoro-2-hydroxy-2-(1- phenyl-1H-indazol-5-yl)propoxy]benzonitrile

1,1,1-Trifluoro-3-(3-morpholin-4- ylphenoxy)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol

3-(3-Bromophenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol

3-(2,4-Dichlorophenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol

1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(quinolin-5-yloxy)propan-2-ol

3-(2-Bromophenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol

2-[3,3,3-Trifluoro-2-hydroxy-2-(1-phenyl-1H-indazol-5-yl)propoxy]benzonitrile

1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(3-trifluoromethylphenoxy)propan-2- ol

3-(2-Chloro-5-methylphenoxy)-1,1,1- trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol

1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(4-trifluoromethylphenoxy)propan-2- ol

1,1,1-Trifluoro-3-(naphthalen-2-yloxy)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol

3-(2-Chlorophenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol

3-(4-Chlorophenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol

3-(3,5-Difluorophenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol

1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(2-trifluoromethylphenoxy)propan-2- ol

3-(2,4-Difluorophenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol

1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(quinolin-8-yloxy)propan-2-ol

3-(2-Chloro-4-methylphenoxy)-1,1,1- trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol

3-(2,5-Difluorophenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol

3-(4-Chloro-2-fluorophenoxy)-1,1,1- trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol

1,1,1-Trifluoro-3-(4-fluoro-2- methylphenoxy)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol

1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(2,3,4-trifluorophenoxy)propan-2-ol

1,1,1-Trifluoro-3-(2-fluoro-6- methoxyphenoxy)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol

1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(2,3,6-trifluorophenoxy)propan-2-ol

1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(2,4,6-trifluorophenoxy)propan-2-ol

2-Chloro-4-[3,3,3-trifluoro-2-hydroxy-2-(1- phenyl-1H-indazol-5-yl)propoxy]benzonitrile

3-(2-Chloro-3,5-difluorophenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5- yl)propan-2-ol

1,1,1-Trifluoro-3-(7-methoxynaphthalen-2-yloxy)-2-(1-phenyl-1H-indazol-5-yl)propan- 2-ol

3-(2-Bromo-5-fluorophenoxy)-1,1,1- trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol

5-Acetyl-2-[3,3,3-trifluoro-2-hydroxy-2-(1-phenyl-1H-indazol-5-yl)propoxy]benzoic acid methyl ester

2-Fluoro-4-[3,3,3-trifluoro-2-hydroxy-2-(1- phenyl-1H-indazol-5-yl)propoxy]benzonitrile

1,1,1-Trifluoro-3-(2-fluoro-5- trifluoromethylphenoxy)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol

3-(4-Bromo-3-methylphenoxy)-1,1,1- trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol

1,1,1-Trifluoro-3-(2-fluoro-5- methylphenoxy)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol

N-{4-[3,3,3-Trifluoro-2-hydroxy-2-(1- phenyl-1H-indazol-5-yl)propoxy]phenyl}butyramide

3-(5-Chloro-2-methylphenoxy)-1,1,1- trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol

1,1,1-Trifluoro-3-(4- methylsulfanylphenoxy)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol

3-(4-Bromophenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol

3-(3-Chlorophenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol

1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5- yl)-3-o-tolyloxypropan-2-ol

1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5- yl)-3-m-tolyloxypropan-2-ol

1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5- yl)-3-p-tolyloxypropan-2-ol

3-[3,3,3-Trifluoro-2-hydroxy-2-(1-phenyl-1H-indazol-5-yl)propoxy]benzonitrile

4-[3,3,3-Trifluoro-2-hydroxy-2-(1-phenyl-1H-indazol-5-yl)propoxy]benzonitrile

3-(2,4-Dimethylphenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol

3-(2,6-Dimethylphenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol

3-(2,6-Dichlorophenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol

3-(3,5-Dichlorophenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol

1,1,1-Trifluoro-3-(3-fluorophenoxy)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol

1,1,1-Trifluoro-3-(4-fluorophenoxy)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol

1,1,1-Trifluoro-3-(isoquinolin-5-yloxy)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol

1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(2,4,6-trichlorophenoxy)propan-2-ol

1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(2,4,6-trimethylphenoxy)propan-2-ol

1,1,1-Trilluoro-3-(6-methoxynaphthalen-2-yloxy)-2-(1-phenyl-1H-indazol-5-yl)propan- 2-ol

1,1,1-Trifluoro-3-(naphthalen-1-yloxy)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol

1-{3,5-Difluoro-4-[3,3,3-trifluoro-2- hydroxy-2-(1-phenyl-1H-indazol-5-yl)propoxy]phenyl}ethanone

1,1,1-Trifluoro-3-(isoquinolin-7-yloxy)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol

1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(2-trifluoromethoxyphenoxy)propan- 2-ol

1,1,1-Trifluoro-3-(4-phenylaminophenoxy)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol

3-(3-Chloro-4-methylphenoxy)-1,1,1- trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol

1,1,1-Trifluoro-3-(3-fluoro-5- trifluoromethylphenoxy)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol

1,1,1-Trifluoro-3-(2- methylsulfanylphenoxy)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol

3-(4-Dimethylaminomethylphenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5- yl)propan-2-ol

5-Bromo-2-[3,3,3-trifluoro-2-hydroxy-2-(1- phenyl-1H-indazol-5-yl)propoxy]benzonitrile

3-(4-Chloro-3-trifluoromethylphenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5- yl)propan-2-ol

3-(2,4-Dichloro-6-methylphenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5- yl)propan-2-ol

3-(2-Dimethylaminomethylphenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5- yl)propan-2-ol

3-(2,6-Dichloro-4-methylphenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5- yl)propan-2-ol

3-Methoxy-4-[3,3,3-trifluoro-2-hydroxy-2-(1-phenyl-1H-indazol-5-yl)propoxy]benzoic acid ethyl ester

4-[3,3,3-Trifluoro-2-hydroxy-2-(1-phenyl-1H-indazol-5-yl)propoxy]benzoic acid methyl ester

1,1,1-Trifluoro-3-(4-imidazol-1-ylphenoxy)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol

N-{4-[3,3,3-Trifluoro-2-hydroxy-2-(1- phenyl-1H-indazol-5-yl)propoxy]phenyl}acetamide

3-(3-Dimethylaminophenoxy)-1,1,1- trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol

1-(4-{4-[3,3,3-Trifluoro-2-hydroxy-2-(1- phenyl-1H-indazol-5-yl)propoxy]phenyl}piperazin-1-yl)ethanone

1,1,1-Trifluoro-3-(2-methyl-3H-1□⁴-benzothiazol-5-yloxy)-2-(1-phenyl-1H- indazol-5-yl)propan-2-ol

3-(3-Chloro-5-trifluoromethylpyridin-2-yloxy)-1,1,1-trifluoro-2-(1-phenyl-1H- indazol-5-yl)propan-2-ol

1,1,1-Trifluoro-3-(3-methoxy-5- trifluoromethylphenylamino)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol

1,1,1-Trifluoro-3-(naphthalen-1-ylamino)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol

4-[3,3,3-Trifluoro-2-hydroxy-2-(1-phenyl-1H-indazol-5-yl)propylamino]naphthalene- 1-carbonitrile

3-(4-Chloronaphthalen-1-ylamino)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5- yl)propan-2-ol

1,1,1-Trifluoro-3-(naphthalen-2-ylamino)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol

1-Biphenyl-3-yl-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol

2,2,2-Trifluoro-1-(4-fluoro-3-oxazol-5-ylphenyl)-1-[1-(4-fluorophenyl)-1H- indazol-5-yl]ethanol

4-{2,2,2-Trifluoro-1-[1-(4-fluorophenyl)- 1H-indazol-5-yl]-1-hydroxyethyl}benzonitrile

4-{2,2,2-Trifluoro-1-[1-(4-fluorophenyl)- 1H-indazol-5-yl]-1-hydroxyethyl}benzamide

N,N-Dimethyl-4-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1- hydroxyethyl}benzamide

1-(3,4-Difluorophenyl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol

1-(3,5-Difluorophenyl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol

1-(3-Chloro-5-fluorophenyl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5- yl]ethanol

1-(4-Chloro-3-methylphenyl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol- 5-yl]ethanol

1-(3-Chlorophenyl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol

1-(3-Chloro-4-fluorophenyl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5- yl]ethanol

1-(4-Chloro-3-fluorophenyl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5- yl]ethanol

1-(3,5-Dichlorophenyl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol

1-(3,4-Dichlorophenyl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol

2,2,2-Trifluoro-1-(4-fluorophenyl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol

2,2,2-Trifluoro-1-(3-fluoro-4- methylphenyl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol

2,2,2-Trifluoro-1-(3-fluorophenyl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol

1-(4-Chlorophenyl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol

2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-naphthalen-1-ylethanol

2,2,2-Trifluoro-1-(4-fluoronaphthalen-1-yl)-1-[1-(4-fluorophenyl)-1H-indazol-5- yl]ethanol

2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(4-methylnaphthalen-1- yl)ethanol

2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(4-nitronaphthalen-1- yl)ethanol

1-(4-Aminonaphthalen-1-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5- yl]ethanol

2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(4-methylaminonaphthalen- 1-yl)ethanol

1-(4-Dimethylaminonaphthalen-1-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol- 5-yl]ethanol

4-{2,2,2-Trifluoro-1-[1-(4-fluorophenyl)- 1H-indazol-5-yl]-1-hydroxyethyl}naphthalene-1-sulfonic acid amide

4-{2,2,2-Trifluoro-1-[1-(4-fluorophenyl)- 1H-indazol-5-yl]-1-hydroxyethyl}naphthalene-1-sulfonic acid methylamide

4-{2,2,2-Trifluoro-1-[1-(4-fluorophenyl)- 1H-indazol-5-yl]-1-hydroxyethyl}naphthalene-1-sulfonic acid dimethylamide

4-{2,2,2-Trifluoro-1-[1-(4-fluorophenyl)- 1H-indazol-5-yl]-1-hydroxyethyl}naphthalene-1-carbonitrile

4-{2,2,2-Trifluoro-1-[1-(4-fluorophenyl)- 1H-indazol-5-yl]-1-hydroxyethyl}naphthalene-1-carboxylic acid amide

4-{2,2,2-Trifluoro-1-[1-(4-fluorophenyl)- 1H-indazol-5-yl]-1-hydroxyethyl}naphthalene-1-carboxylic acid methylamide

4-{2,2,2-Trifluoro-1-[1-(4-fluorophenyl)- 1H-indazol-5-yl]-1-hydroxyethyl}naphthalene-1-carboxylic acid dimethylamide

2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(2-methylnaphthalen-1- yl)ethanol

2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(2-methoxynaphthalen-1- yl)ethanol

2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(6-methoxynaphthalen-2- yl)ethanol

2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-naphthalen-2-ylethanol

4-{2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}quinoline- 3-carboxylic aciddimethylamide

4-{2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}quinoline- 3-carboxylic acid methylamide

4-{2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}quinoline- 3-carboxylic acid amide

4-{2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}quinoline- 3-carboxylic acid ethyl ester

2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-quinolin-4-ylethanol

2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(2-methylquinolin-4- yl)ethanol

2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-isoquinolin-1-ylethanol

2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-isoquinolin-4-ylethanol

1-(2,3-Dihydrobenzo[1,4]dioxin-6-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol- 5-yl]ethanol

1-Benzo[1,3]dioxol-5-yl-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol

1-Benzofuran-5-yl-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol

1-Benzofuran-2-yl-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol

2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1H-indol-4-yl)ethanol

2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1-methyl-1H-indol-4- yl)ethanol

1-Benzo[b]thiophen-3-yl-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol

1,1,1-Trifluoro-3-(3-fluorophenyl)-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-phenylpropan-2-ol

1,1,1-Trifluoro-3-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-phenylpropan-2-ol

2-Benzyl-1,1,1-trifluoro-3-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H- indazol-5-yl]-3-(3-methoxy-5-trifluoromethylphenylamino)propan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H- indazol-5-yl]-3-(naphthalen-1-ylamino)propan-2-ol

4-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)- 1H-indazol-5-yl]-2-hydroxypropylamino}naphthalene-1- carbonitrile

3-(4-Chloronaphthalen-1-ylamino)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol- 5-yl]propan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H- indazol-5-yl]-3-(naphthalen-2-ylamino)propan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(4-morpholin-4- ylphenylamino)propan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H- indazol-5-yl]-3-(quinolin-5-ylamino)propan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H- indazol-5-yl]-3-(quinolin-6-ylamino)propan-2-ol

3-(2,3-Dihydro-1,4-benzodioxin-6- ylamino)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(isoquinolin-5- ylamino)propan-2-ol

2-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)- 1H-indazol-5-yl]-2-hydroxypropylamino}benzonitrile

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H- indazol-5-yl]-3-(2,4,6-trifluorophenylarnino)propan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H- indazol-5-yl]-3-(2-fluoro-5-trifluoromethylphenylamino)propan-2-ol

3-(2,6-Difluorophenylamino)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol- 5-yl]propan-2-ol

3-(2-Chlorophenylamino)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5- yl]propan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H- indazol-5-yl]-3-(2,4,6-trichlorophenylamino)propan-2-ol

3-(2,5-Dichlorophenylamino)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol- 5-yl]propan-2-ol

3-(2,6-Dichlorophenylamino)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol- 5-yl]propan-2-ol

3-(Biphenyl-2-ylamino)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5- yl]propan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-o-tolylaminopropan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H- indazol-5-yl]-3-(4-methoxy-2-methylphenylamino)propan-2-ol

3-(2,4-Dimethylphenylamino)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol- 5-yl]propan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H- indazol-5-yl]-3-(2,4,6-trimethylphenylamino)propan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H- indazol-5-yl]-3-(2,4,6-trimethylphenylamino)propan-2-ol

3-(2,6-Dimethylphenylamino)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol- 5-yl]propan-2-ol

3-(2-Ethyl-6-methylphenylamino)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol- 5-yl]propan-2-ol

3-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)- 1H-indazol-5-yl]-2-hydroxypropylamino}benzonitrile

3-(3-Bromophenylamino)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5- yl]propan-2-ol

3-(3-Chlorophenylamino)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5- yl]propan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H- indazol-5-yl]-3-(3-methylsulfanylphenylamino)propan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H- indazol-5-yl]-3-(3-trifluoromethylphenylamino)propan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-m-tolylaminopropan-2-ol

3-(3,5-Dimethylphenylamino)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol- 5-yl]propan-2-ol

4-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)- 1H-indazol-5-yl]-2-hydroxypropylamino}benzonitrile

3-(4-Chlorophenylamino)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5- yl]propan-2-ol

3-(4-Dimethylaminophenylamino)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol- 5-yl]propan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H- indazol-5-yl]-3-(4-phenoxyphenylamino)propan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H- indazol-5-yl]-3-(4-methylsulfanylphenylamino)propan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H- indazol-5-yl]-3-(4-isopropylphenylamino)propan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-p-tolylaminopropan-2-ol

4-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)- 1H-indazol-5-yl]-2-hydroxypropylamino}benzenesulfonamide

3-(2,4-Dimethoxyphenylamino)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol- 5-yl]propan-2-ol

3-(3,5-Dimethoxyphenylamino)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol- 5-yl]propan-2-ol

3-(4,5-Dimethoxy-2-methylphenylamino)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H- indazol-5-yl]propan-2-ol

3-(Benzothiazol-6-ylamino)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5- yl]propan-2-ol

2-Chloro-6-{3,3,3-trifluoro-2-[1-(4- fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropylamino}benzonitrile

3-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)- 1H-indazol-5-yl]-2-hydroxypropylamino}benzoic acid methyl ester

5-Chloro-2-{3,3,3-trifluoro-2-[1-(4- fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropylamino}benzonitrile

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(2-methylquinolin-8- ylamino)propan-2-ol

N,N-Dimethyl-4-{3,3,3-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2- hydroxypropylamino}benzenesulfonamide

2-Chloro-4-{3,3,3-trifluoro-2-[1-(4- fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropylamino}benzonitrile

4-Chloro-2-{3,3,3-trifluoro-2-[1-(4- fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropylamino}benzonitrile

1,1,1-Trifluoro-3-(2-fluoro-4- methylphenylamino)-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H- indazol-5-yl]-3-(4-trifluoromethoxyphenylamino)propan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H- indazol-5-yl]-3-(3-trifluoromethoxyphenylamino)propan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H- indazol-5-yl]-3-(2-methoxy-5-trifluoromethylphenylamino)propan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H- indazol-5-yl]-3-(4-methoxy-3-trifluoromethylphenylamino)propan-2-ol

3-(2,4-Dichloro-6-methylphenylamino)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H- indazol-5-yl]propan-2-ol

3-(Biphenyl-3-ylamino)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5- yl]propan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(4-piperidin-1- ylphenylamino)propan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H- indazol-5-yl]-3-(3-oxazol-5-ylphenylamino)propan-2-ol

3-Chloro-4-{3,3,3-trifluoro-2-[1-(4- fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropylamino}benzonitrile

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H- indazol-5-yl]-3-(4-pyridin-4-ylmethylphenylamino)propan-2-ol

2-Methyl-6-{3,3,3-trifluoro-2-[1-(4- fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropylamino}benzonitrile

3-(4-Chloro-2,6-dimethylphenylamino)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H- indazol-5-yl]propan-2-ol

3-(Benzoxazol-6-ylamino)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5- yl]propan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(2-methylnaphthalen-1- ylamino)propan-2-ol

3-(Biphenyl-4-ylamino)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5- yl]propan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H- indazol-5-yl]-3-(3-phenoxyphenylamino)propan-2-ol

3-(3-Chloro-2-methylphenylamino)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol- 5-yl]propan-2-ol

3-(2-Chloro-5- trifluoromethylphenylamino)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol- 5-yl]propan-2-ol

2-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)- 1H-indazol-5-yl]-2-hydroxypropylamino}benzoic acid methyl ester

N-(4-{3,3,3-Trifluoro-2-[1-(4- fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropylamino}phenyl)acetamide

5-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropylamino}- 1,3-dihydrobenzimidazol-2-one

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-indol-1-ylpropan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-pyrrolo[2,3-b]pyridin-1- ylpropan-2-ol

1-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H- indole-2-carboxylic acid ethylester

3-(2,3-Dimethylindol-l-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5- yl]propan-2-ol

3-(5-Chloro-2-methylindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol- 5-yl]propan-2-ol

1-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H- indole-3-carbonitrile

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(5-methoxy-2-methylindol- 1-yl)propan-2-ol

3-(2,5-Dimethylindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5- yl]propan-2-ol

1-(1-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H- indol-3-yl)ethanone

3-(3-Dimethylaminomethylindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H- indazol-5-yl]propan-2-ol

3-(3-Dimethylaminomethyl-5- methoxyindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol

(1-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H- indol-3-yl)acetic acid ethyl ester

2-(1-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H- indol-3-yl)acetamide

3-(4-Chloroindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2- ol

3-(5-Bromoindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2- ol

1,1,1-Trifluoro-3-(5-fluoroindol-1-yl)-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2- ol

3-(5-Chloroindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2- ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(5-nitroindol-1-yl)propan-2- ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(5-methoxyindol-1- yl)propan-2-ol

3-(5,6-Dimethoxyindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5- yl]propan-2-ol

3-(6-Chloroindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2- ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(7-nitroindol-1-yl)propan-2- ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(4-methoxyindol-1- yl)propan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(4-nitroindol-1-yl)propan-2- ol

1-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H- indole-6-carbonitrile

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(6-methoxyindol-1- yl)propan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(2,3,7-trimethylindol-1- yl)propan-2-ol

1,1,1-Trifluoro-3-(4-fluoroindol-1-yl)-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2- ol

1,1,1-Trifluoro-3-(5-fluoroindol-1-yl)-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2- ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(2-methyl-5-nitroindol-1- yl)propan-2-ol

4-Methoxy-1-{3,3,3-trifluoro-2-[1-(4- fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H-indole-2-carboxylic acid methyl ester

6-Methoxy-1-{3,3,3-trifluoro-2-[1-(4- fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H-indole-2-carboxylic acid methyl ester

3-(7-Ethylindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2- ol

1-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H- indole-5-carboxylic acid methylester

1-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H- indole-3-carboxylic acid methylester

1-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H- indole-4-carboxylic acid methylester

1-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H- indole-6-carboxylic acid methylester

3-(6-Bromoindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2- ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(6-trifluoromethylindol- yl)propan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(3-methoxymethylindol-1- yl)propan-2-ol

1-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H- indole-2-carboxylic acid methylester

3-(4-Bromoindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2- ol

3-(7-Bromoindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2- ol

1,1,1-Trifluoro-3-(7-fluoroindol-1-yl)-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2- ol

3-(3-Dimethylaminomethyl-6- methoxyindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol

3-(7-Chloroindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2- ol

3-(7-Bromo-2-methylindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol- 5-yl]propan-2-ol

(5-Methoxy-1-{3,3,3-trifluoro-2-[1-(4- fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H-indol-3-yl)acetonitrile

5-Chloro-1-{3,3,3-trifluoro-2-[1-(4- fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H-indole-2-carboxylic acid ethyl ester

5-Methyl-1-{3,3,3-trifluoro-2-[1-(4- fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H-indole-2-carboxylic acid ethyl ester

5-Methyl-1-{3,3,3-trifluoro-2-[1-(4- fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H-indole-2-carboxylic acid ethyl ester

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-morpholin-4-ylpropan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-piperidin-1-ylpropan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-piperazin-1-ylpropan-2-ol

3-(2,3-Dihydro-1,4-benzoxazin-4-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol- 5-yl]propan-2-ol

3-(3,4-Dihydro-1H-isoquinolin-2-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol- 5-yl]propan-2-ol

3-(3,4-Dihydro-2H-quinoxalin-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol- 5-yl]propan-2-ol

3-(3,4-Dihydro-2H-quinolin-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol- 5-yl]propan-2-ol

2,2,2-Trifluoro-1-phenyl-1-(1-phenyl-1H- benzotriazol-5-yl)ethanol

1-(3-Chloro-4-fluorophenyl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-benzotriazol-5- yl]ethanol

2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-benzotriazol-5-yl]-1-naphthalen-1-ylethanol

2,2,2-Trifluoro-1-(4-fluoronaphthalen-1-yl)-1-[1-(4-fluorophenyl)-1H-benzotriazol-5- yl]ethanol

2,2,2-Trifluoro-1-phenyl-1-(1-phenyl-1H- benzimidazol-5-yl)ethanol

1-(3-Chloro-4-fluorophenyl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-benzimidazol-5- yl]ethanol

2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-benzimidazol-5-yl]-1-naphthalen-1- ylethanol

2,2,2-Trifluoro-1-(4-fluoronaphthalen-1-yl)-1-[1-(4-fluorophenyl)-1H-benzimidazol-5- yl]ethanol

2,2,2-Trifluoro-1-phenyl-1-(1-phenyl-1H- indol-5-yl)ethanol

1-(3-Chloro-4-fluorophenyl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indol-5-yl]ethanol

2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indol-5-yl]-1-naphthalen-1-ylethanol

2,2,2-Trifluoro-1-(4-fluoronaphthalen-1-yl)-1-[1-(4-fluorophenyl)-1H-indol-5-yl]ethanol

1-(3-Chloro-4-fluorophenyl)-1-[1-(4-dimethylaminophenyl)-1H-indazol-5-yl]- 2,2,2-trifluoroethanol

1-[1-(4-Dimethylaminophenyl)-1H-indazol-5-yl]-2,2,2-trifluoro-1-naphthalen-1- ylethanol

1-[1-(4-Dimethylaminophenyl)-1H-indazol-5-yl]-2,2,2-trifluoro-1-(4-fluoronaphthalen- 1-yl)ethanol

4-{5-[1-(3-Chloro-4-fluorophenyl)-2,2,2-trifluoro-1-hydroxyethyl]indazol-1- yl}phenol

4-[5-(2,2,2-Trifluoro-1-hydroxy-1-naphthalen-1-ylethyl)indazol-1-yl]phenol

4-{5-[2,2,2-Trifluoro-1-(4- fluoronaphthalen-1-yl)-1-hydroxyethyl]indazol-1-yl}phenol

1-(3-Chloro-4-fluorophenyl)-2,2,2-trifluoro-1-[1-(4-methoxyphenyl)-1H-indazol-5- yl]ethanol

2,2,2-Trifluoro-1-[1-(4-methoxyphenyl)-1H-indazol-5-yl]-1-naphthalen-1-ylethanol

2,2,2-Trifluoro-1-(4-fluoronaphthalen-1-yl)-1-[1-(4-methoxyphenyl)-1H-indazol-5- yl]ethanol

1-(3-Chloro-4-fluorophenyl)-2,2,2-trifluoro-1-[1-(3-fluorophenyl)-1H-indazol-5- yl]ethanol

2,2,2-Trifluoro-1-[1-(3-fluorophenyl)-1H-indazol-5-yl]-1-naphthalen-1-ylethanol

2,2,2-Trifluoro-1-(4-fluoronaphthalen-1-yl)-1-[1-(3-fluorophenyl)-1H-indazol-5- yl]ethanol

1-(3-Chloro-4-fluorophenyl)-2,2,2-trifluoro-1-(1-p-tolyl-1H-indazol-5-yl)ethanol

2,2,2-Trifluoro-1-naphthalen-1-yl-1-(1-p- tolyl-1H-indazol-5-yl)ethanol

2,2,2-Trifluoro-1-(4-fluoronaphthalen-1-yl)-1-(1-p-tolyl-1H-indazol-5-yl)ethanol

1-(3-Chloro-4-fluorophenyl)-1-[1-(4-chlorophenyl)-1H-indazol-5-yl]-2,2,2- trifluoroethanol

1-[1-(4-Chlorophenyl)-1H-indazol-5-yl]-2,2,2-trifluoro-1-naphthalen-1-ylethanol

1-[1-(4-Chlorophenyl)-1H-indazo1-5-yl]-2,2,2-trifluoro-1-(4-fluoronaphthalen-1- yl)ethanol

1-(3-Chloro-4-fluorophenyl)-2,2,2-trifluoro-1-(1-pyridin-2-yl-1H-indazol-5-yl)ethanol

2,2,2-Trifluoro-1-naphthalen-1-yl-1-(1-pyridin-2-yl-1H-indazol-5-yl)ethanol

2,2,2-Trifluoro-1-(4-fluoronaphthalen-1-yl)-1-(1-pyridin-2-yl-1H-indazol-5-yl)ethanol

1-(3-Chloro-4-fluorophenyl)-2,2,2-trifluoro-1-(1-pyridin-4-yl-1H-indazol-5-yl)ethanol

2,2,2-Trifluoro-1-naphthalen-1-yl-1-(1-pyridin-4-yl-1H-indazol-5-yl)ethanol

2,2,2-Trifluoro-1-(4-fluoronaphthalen-1-yl)-1-(1-pyridin-4-yl-1H-indazol-5-yl)ethanol

1-(3-Chloro-4-fluorophenyl)-1-(1- cyclohexyl-1H-indazol-5-yl)-2,2,2-trifluoroethanol

1-(1-Cyclohexyl-1H-indazol-5-yl)-2,2,2-trifluoro-1-naphthalen-1-ylethanol

1-(1-Cyclohexyl-1H-indazol-5-yl)-2,2,2-trifluoro-1-(4-fluoronaphthalen-1-yl)ethanol

2,2,2-Trifluoro-1-(6-fluoropyridin-2-yl)-1-(1-phenyl-1H-indazol-5-yl)ethanol

3-(3-Chloro-2-fluorophenyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol

3-(4-Chloro-3-fluorophenyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol

3-(4-Chloro-2-fluorophenyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol

1-(2,2-Difluoro-1,3-benzodioxol-4-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H- indazol-5-yl]ethanol

1-1,3-Benzodioxol-4-yl-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol

2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1H-indol-7-yl)ethanol

2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1-methyl-1H-indol-7- yl)ethanol

2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1-methyl-1H-indol-5- yl)ethanol

2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1-methyl-1H-indol-6- yl)ethanol

4-{2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl)indole-1- carboxylic acid tert-butylester

1-(3-Aminophenyl)-2,2,2-trifluoro-1-(1- phenyl-1H-indazol-5-yl)ethanol

N-{3-[2,2,2-Trifluoro-1-hydroxy-1-(1- phenyl-1H-indazol-5-yl)ethyl]phenyl}acetamide

1-Methyl-4-{2,2,2-trifluoro-1-[1-(4- fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-quinolin-2-one

1-(1-Allyl-1H-indol-4-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol

3-(4-{2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}indol-1- yl)propane-1,2-diol

3-Hydroxy-4-(4-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1- hydroxyethyl}indol-1-yl)butyronitrile

2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-[1-(2-hydroxyethyl)-1H- indol-4-yl]ethanol

2-(4-{2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}indol-1- yl)acetamide

N-Methyl-2-(4-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1- hydroxyethyl}indol-1-yl)acetamide

1-[1-(2-Cyclopropyl-2-hydroxyethyl)-1H-indol-4-yl]-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol

1-(7-Bromo-1-methyl-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol- 5-yl]ethanol

1-Methyl-3-{2,2,2-trifluoro-1-[1-(4- fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylic acid methyl ester

1-Methyl-3-{2,2,2-trifluoro-1-[1-(4- fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylic acid

1-Methyl-3-{2,2,2-trifluoro-1-[1-(4- fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylic acid amide

1-Methyl-3-{2,2,2-trifluoro-1-[1-(4- fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylic acid methylamide

1-Methyl-3-{2,2,2-trifluoro-1-[1-(4- fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylic acid (2-cyanoethyl)amide

1-Methyl-3-{2,2,2-trifluoro-1-[1-(4- fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylic acid (2-methoxyethyl)amide

1-Methyl-3-{2,2,2-trifluoro-1-[1-(4- fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylic acid (2-methoxyethyl)methylamide

2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1-methyl-7-nitro-1H-indol- 3-yl)ethanol

1-(7-Amino-1-methyl-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol- 5-yl]ethanol

1-Methyl-3-{2,2,2-trifluoro-1-[1-(4- fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylic acid carbamoylmethylamide

1-Methyl-3-{2,2,2-trifluoro-1-[1-(4- fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylic acid cyanomethylamide

1-(1-Allyl-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol

N-(1-Methyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1- hydroxyethyl}-1H-indol-7-yl)methanesulfonamide

3-(3-{2,2,2-Trifluoro-1-[-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}indol-1- yl)propane-1,2-diol

1-Benzyl-3-{2,2,2-trifluoro-1-[1-(4- fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylic acid methyl ester

2-(3-{2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}indol-1- yl)acetamide

2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-[1-(2-hydroxyethyl)-1H- indol-3-yl]ethanol

N-Methyl-2-(3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1- hydroxyethyl}indol-1-yl)acetamide

N-Cyanomethyl-2-(3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1- hydroxyethyl}indol-1-yl)acetamide

N-Carbamoylmethyl-2-(3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}indol-1-yl)acetamide

1-Morpholin-4-yl-2-(3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1- hydroxyethyl}indol-1-yl)ethanone

1-Allyl-3-{2,2,2-trifluoro-1-[1-(4- fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylic acid methyl ester

1-(1-Allyl-1H-imidazol-4-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol- 5-yl]ethanol

3-(4-{2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}imidazol- 1-yl)propane-1,2-diol

1-Allyl-3-{2,2,2-trifluoro-1-[1-(4- fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylic acid amide

1-(2,3-Dihydroxypropyl)-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylic acid amide

1-(1-Allyl-1H-indol-3-yl)-2,2,2-trifluoro-1-(1-p-tolyl-1H-indazol-5-yl)ethanol

3-{3-[2,2,2-Trifluoro-1-hydroxy-1-(1-p-tolyl-1H-indazol-5-yl)ethyl]indol-1- yl}propane-1,2-diol

2,2,2-Trifluoro-1-(4-fluoronaphthalen-1-yl)-1-(1-phenyl-1H-indol-5-yl)ethanol

2,2,2-Trifluoro-1-naphthalen-1-yl-1-(1- phenyl-1H-indol-5-yl)ethanol

1-(3,4-Dichlorophenyl)-2,2,2-trifluoro-1-(1-pyridin-2-yl-1H-indazol-5-yl)ethanol

1-(3-Chlorophenyl)-2,2,2-trifluoro-1-(1-pyridin-2-yl-1H-indazol-5-yl)ethanol

1-(3,4-Difluorophenyl)-2,2,2-trifluoro-1-(1-pyridin-2-yl-1H-indazol-5-yl)ethanol

2,2,2-Trifluoro-1-phenyl-1-(1-pyridin-2-yl- 1H-indazol-5-yl)ethanol

2,2,2-Trifluoro-1-[1-(2-fluorophenyl)-1H- indazol-5-yl]-1-phenylethanol

2,2,2-Trifluoro-1-[1-(2-fluorophenyl)-1H-indazol-5-yl]-1-naphthalen-1-ylethanol

2,2,2-Trifluoro-1-(4-fluoronaphthalen-1-yl)-1-[1-(2-fluorophenyl)-1H-indazol-5- yl]ethanol

2,2,2-Trifluoro-1-phenyl-1-(1-p-tolyl-1H- indazol-5-yl)ethanol

2,2,2-Trifluoro-1-[1-(4-methoxyphenyl)- 1H-indazol-5-yl]-1-phenylethanol

2,2,2-Trifluoro-1-phenyl-1-(1-o-tolyl-1H- indazol-5-yl)ethanol

2,2,2-Trifluoro-1-naphthalen-1-yl-1-(1-c- tolyl-1H-indazol-5-yl)ethanol

2,2,2-Trifluoro-1-(4-fluoronaphthalen-1-yl)-1-(1-o-tolyl-1H-indazol-5-yl)ethanol

2,2,2-Trifluoro-1-(5-fluoro-1H-indol-3-yl)-1-(1-p-tolyl-1H-indazol-5-yl)ethanol

2,2,2-Trifluoro-1-(5-fluoro-1H-indol-3-yl)-1-[1-(2-fluorophenyl)-1H-indazol-5- yl]ethanol

2,2,2-Trifluoro-1-(5-fluoro-1H-indol-3-yl)-1-[1-(4-methoxyphenyl)-1H-indazol-5- yl]ethanol

2,2,2-Trifluoro-1-(5-fluoro-1H-indol-3-yl)-1-(1-pyridin-2-yl-1H-indazol-5-yl)ethanol

3-[2,2,2-Trifluoro-1-hydroxy-1-(1-phenyl- 1H-indazol-5-yl)ethyl]phenol

2,2,2-Trifluoro-1-(4-fluoro-3- hydroxymethylphenyl)-1-(1-phenyl-1H-indazol-5-yl)ethanol

4-[2,2,2-Trifluoro-1-hydroxy-1-(1-phenyl- 1H-indazol-5-yl)ethyl]phenol

2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(5-methoxy-4-methyl-1H- indol-3-yl)ethanol

1-(4-Chloro-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5- yl]ethanol

2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(6-methoxy-1H-indol-3- yl)ethanol

1-(2,5-Dimethyl-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol- 5-yl]ethanol

2,2,2-Trifluoro-1-[-(4-fluorophenyl)-1H-indazol-5-yl]-1-(7-methoxy-1H-indol-3- yl)ethanol

2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1H-indol-3-yl)ethanol

1-(6-Bromo-1H-indol-3-yl)-2,2,2-trifluoro-1-[-(4-fluorophenyl)-1H-indazol-5- yl]ethanol

1-(7-Bromo-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5- yl]ethanol

1-(5-Bromo-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5- yl]ethanol

2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(5-methyl-1H-indol-3- yl)ethanol

2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(2-methyl-1H-indol-3- yl)ethanol

1-(6-Chloro-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5- yl]ethanol

1-(5-Chloro-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5- yl]ethanol

1-(4-Bromo-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5- yl]ethanol

2,2,2-Trifluoro-1-(5-fluoro-1H-indol-3-yl)-1-[1-(4-fluorophenyl)-1H-indazol-5- yl]ethanol

2,2,2-Trifluoro-1-(4-fluoro-1H-indol-3-yl)-1-[1-(4-fluorophenyl)-1H-indazol-5- yl]ethanol

2,2,2-Trifluoro-1-(6-fluoro-1H-indol-3-yl)-1-[1-(4-fluorophenyl)-1H-indazol-5- yl]ethanol

2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(5-methoxy-1H-indol-3- yl)ethanol

2,2,2-Trifluoro-1-(7-fluoro-1H-indol-3-yl)-1-[1-(4-fluorophenyl)-1H-indazol-5- yl]ethanol

2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(6-methyl-1H-indol-3- yl)ethanol

2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(7-methyl-1H-indol-3- yl)ethanol

3-{2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H- indole-5-carbonitrile

2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1-methyl-1H-indol-3- yl)ethanol

1-(6-Bromo-1-methyl-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol- 5-yl]ethanol

1-Methyl-3-{2,2,2-trifluoro-1-[1-(4- fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-6-carbonitrile

2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1-methyl-6-pyridin-3-yl- 1H-indol-3-yl)ethanol

2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1-methyl-6-pyridin-4-yl- 1H-indol-3-yl)ethanol

2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1-methyl-6-morpholin-4- yl-1H-indol-3-yl)ethanol

1-Methyl-3-{2,2,2-trifluoro-1-[1-(4- fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-6-carboxylic acid methyl ester

2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(6-furan-2-yl-1-methyl-1H- indol-3-yl)ethanol

2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1-methyl-6-pyrimidin-5-yl- 1H-indol-3-yl)ethanol

2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H- indazol-5-yl]-1-{6-[(2-methoxyethyl)methylamino]-1-methyl-1H- indol-3-yl}ethanol

2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-[6-(2-methoxyethylamino)- 1-methyl-1H-indol-3-yl]ethanol

1-{6-[(2- Dimethylaminoethyl)methylamino]-1-methyl-1H-indol-3-yl}-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol

2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1-methyl-5-morpholin-4- yl-1H-indol-3-yl)ethanol

1-[6-(2-Dimethylaminoethylamino)-1-methyl-1H-indol-3-yl]-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol

1-[5-(2-Dimethylaminoethylamino)-1-methyl-1H-indol-3-yl]-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol

2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1-methyl-6-pyrrolidin-1-yl- 1H-indol-3-yl)ethanol

2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1-methyl-5-pyrrolidin-1-yl- 1H-indol-3-yl)ethanol

1-[6-Bromo-1-(4-methoxybenzyl)-1H-indol-3-yl]-2,2,2-trifluoro-1-[1-(4-fluorophenyl)- 1H-indazol-5-yl]ethanol

N-Carbamoylmethyl-N-methyl-2-{3-[2,2,2-trifluoro-1-hydroxy-1-(1-p-tolyl-1H-indazol-5-yl)ethyl]indol-1-yl}acetamide

N-Carbamoylmethyl-2-{3-[2,2,2-trifluoro-1-hydroxy-1-(1-p-tolyl-1H-indazol-5- yl)ethyl]indol-1-yl}acetamide

N-(2-Methoxyethyl)-N-methyl-2-{3-[2,2,2-trifluoro-1-hydroxy-1-(1-p-tolyl-1H-indazol-5-yt)ethyl]indol-1-yl}acetamide

N-(2-Methoxyethyl)-2-{3-[2,2,2-trifluoro-1-hydroxy-1-(1-p-tolyl-1H-indazol-5- yl)ethyl]indol-1-yl}acetamide

N-Cyanomethyl-2-{3-[2,2,2-trifluoro-1-hydroxy-1-(1-p-tolyl-1H-indazol-5- yl)ethyl]indol-1-yl}acetamide

N-Methyl-2-{3-[2,2,2-trifluoro-1-hydroxy-1-(1-p-tolyl-1H-indazol-5-yl)ethyl]indol-1- yl}acetamide

2-{3-[2,2,2-Trifluoro-1-hydroxy-1-(1-p-tolyl-1H-indazol-5-yl)ethyl]indol-1- yl}acetamide

2,2,2-Trifluoro-1-[1-(2-hydroxyethyl)-1H-indol-3-yl]-1-(1-p-tolyl-1H-indazol-5- yl)ethanol

3-{3-[2,2,2-Trifluoro-1-hydroxy-1-(1-p-tolyl-1H-indazol-5-yl)ethyl]indol-1- yl}propane-1,2-diol

1,1,1-Trifluoro-3-(2- isopropylphenylsulfanyl)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol

1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(pyridin-2-ylsulfanyl)propan-2-ol

3-(4-Ethylphenylsulfanyl)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol

4-Methyl-7-[3,3,3-trifluoro-2-hydroxy-2-(1-phenyl-1H-indazol-5-yl)propylsulfanyl]-1- benzopyran-2-one

1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5- yl)-3-(3-trifluoromethylphenylsulfanyl)propan-2-ol

1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5- yl)-3-(2-trifluoromethoxyphenylsulfanyl)propan-2-ol

1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(2-trifluoromethylphenoxy)propan-2- ol

3-(2-Chloro-3,5-difluorophenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5- yl)propan-2-ol

3-(5-Chloro-2-methylphenoxy)-1,1,1- trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol

3-(4-Bromophenoxy)-1,1,1-trifluoro-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol

1,1,1-Trifluoro-3-(indan-5-yloxy)-2-(1-phenyl-1H-indazol-5-yl)propan-2-ol

1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(2,4,6-trichlorophenoxy)propan-2-ol

1,1,1-Trifluoro-2-(1-phenyl-1H-indazol-5-yl)-3-(2,4,6-trimethylphenoxy)propan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H- indazol-5-yl]-3-(5,6,7,8-tetrahydronaphthalen-1-yloxy)propan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H- indazol-5-yl]-3-(5,6,7,8-tetrahydronaphthalen-2-yloxy)propan-2-ol

2-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)- 1H-indazol-5-yl]-2-hydroxypropoxy}benzonitrile

3-(2-Bromophenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2- ol

3-(2-Chlorophenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2- ol

3-(2,4-Dichlorophenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5- yl]propan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H- indazol-5-yl]-3-(2,4,6-trichlorophenoxy)propan-2-ol

3-(2-Chloro-5-methylphenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol- 5-yl]propan-2-ol

3-(2,6-Dichlorophenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5- yl]propan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H- indazol-5-yl]-3-(2-trifluoromethylphenoxy)propan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-o-tolyloxypropan-2-ol

3-(2,4-Dimethylphenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5- yl]propan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H- indazol-5-yl]-3-(2,4,6-trimethylphenoxy)propan-2-ol

3-(2,6-Dimethylphenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5- yl]propan-2-ol

3-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)- 1H-indazol-5-yl]-2-hydroxypropoxy}benzonitrile

3-(3-Bromophenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2- ol

1,1,1-Trifluoro-3-(3-fluorophenoxy)-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2- ol

3-(3,5-Difluorophenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5- yl]propan-2-ol

3-(3-Chlorophenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2- ol

3-(3,5-Dichlorophenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5- yl]propan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-m-tolyloxypropan-2-ol

3-(3,5-Dimethylphenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5- yl]propan-2-ol

4-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)- 1H-indazol-5-yl]-2-hydroxypropoxy}benzonitrile

3-(4-Bromophenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2- ol

1,1,1-Trifluoro-3-(4-fluorophenoxy)-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2- ol

3-(4-Chlorophenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2- ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H- indazol-5-yl]-3-(4-trifluoromethylphenoxy)propan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-p-tolyloxypropan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(indan-5-yloxy)propan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H- indazol-5-yl]-3-(naphthalen-1-yloxy)propan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H- indazol-5-yl]-3-(naphthalen-2-yloxy)propan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(quinolin-5-yloxy)propan-2- ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(quinolin-8-yloxy)propan-2- ol

3-(2,4-Difluorophenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5- yl]propan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(quinolin-7-yloxy)propan-2- ol

3-Methoxy-4-{3,3,3-trifluoro-2-[1-(4- fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropoxy}benzoic acid ethyl ester

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H- indazol-5-yl]-3-(4-phenylaminophenoxy)propan-2-ol

N-(4-{3,3,3-Trifluoro-2-[1-(4- fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropoxy}phenyl)butyramide

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H- indazol-5-yl]-3-(4-trifluoromethylsulfanylphenoxy)propan-2-ol

5-Acetyl-2-{3,3,3-trifluoro-2-[1-(4- fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropoxy}benzoic acid methyl ester

3-(2-Bromo-5-fluorophenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol- 5-yl]propan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H- indazol-5-yl]-3-(2,3,4-trifluorophenoxy)propan-2-ol

3-(2,5-Difluorophenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5- yl]propan-2-ol

3-(4-Chloro-3-trifluoromethylphenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H- indazol-5-yl]propan-2-ol

3-(Acridin-4-yloxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(3-morpholin-4- ylphenoxy)propan-2-ol

2-Chloro-4-{3,3,3-trifluoro-2-[1-(4- fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropoxy}benzonitrile

3-(4-Bromo-2-methylphenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol- 5-yl]propan-2-ol

3-(3-Chloro-4-methylphenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol- 5-yl]propan-2-ol

3-(5-Chloro-2-methylphenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol- 5-yl]propan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H- indazol-5-yl]-3-(2,3,6-trifluorophenoxy)propan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H- indazol-5-yl]-3-(2,4,5-trifluorophenoxy)propan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H- indazol-5-yl]-3-(2,4,6-trifluorophenoxy)propan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H- indazol-5-yl]-3-(2-fluoro-5-trifluoromethylphenoxy)propan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H- indazol-5-yl]-3-(3-fluoro-5-trifluoromethylphenoxy)propan-2-ol

3-(2-Chloro-4-methylphenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol- 5-yl]propan-2-ol

3-(4-Chloro-2-fluorophenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol- 5-yl]propan-2-ol

1,1,1-Trifluoro-3-(4-fluoro-2- methylphenoxy)-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol

1,1,1-Trifluoro-3-(2-fluoro-6- methoxyphenoxy)-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol

3-(2-Chloro-3,5-difluorophenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol- 5-yl]propan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)- indazol-5-yl]-3-(2,3,5-trifluorophenoxy)propan-2-ol

4-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)- 1H-indazol-5-yl]-2-hydroxypropoxy}benzonitrile

3-(4-Bromo-3-methylphenoxy)-1,1,1-trilluoro-2-[1-(4-fluorophenyl)-1H-indazol- 5-yl]propan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(6-methoxynaphthalen-2- yloxy)propan-2-ol

3-(2,6-Dichloro-4-methylphenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol- 5-yl]propan-2-ol

4-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropoxy}indan- 1-one

5-Bromo-2-{3,3,3-trifluoro-2-[1-(4- fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropoxy}benzonitrile

1,1,1-Trifluoro-3-(2-fluoro-5- methylphenoxy)-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol

5-Chloro-2-{3,3,3-trifluoro-2-[1-(4- fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropoxy}benzonitrile

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H- indazol-5-yl]-3-(2-trifluoromethoxyphenoxy)propan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(isoquinolin-7- yloxy)propan-2-ol

3-(3,4-Dimethoxyphenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5- yl]propan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H- indazol-5-yl]-3-(3-trifluoromethoxyphenoxy)propan-2-ol

3-(2,4-Dichloro-6-methylphenoxy)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol- 5-yl]propan-2-ol

6-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropylamino}- 3H-isobenzofuran-1-one

N-(4-{3,3,3-Trifluoro-2-[1-(4- fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropylamino}phenyl)acetamide

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(indan-5-ylamino)propan-2- ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(indan-4-ylamino)propan-2- ol

3-(3-Bromophenylamino)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5- yl]propan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-o-tolylaminopropan-2-ol

3-(4-Chlorophenylamino)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5- yl]propan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-m-tolylaminopropan-2-ol

3-(4-Chloronaphthalen-1-ylamino)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol- 5-yl]propan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(6-methoxypyridin-3- ylamino)propan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H- indazol-5-yl]-3-(5,6,7,8-tetrahydronaphthalen-1-ylamino)propan-2- ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H- indazol-5-yl]-3-(2-methoxyphenylamino)propan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H- indazol-5-yl]-3-(3-methoxyphenylamino)propan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H- indazol-5-yl]-3-(4-methoxyphenylamino)propan-2-ol

3-(3-Chlorophenylamino)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5- yl]propan-2-ol

3-(5-Chloro-2-methylphenylamino)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol- 5-yl]propan-2-ol

3-(2,6-Dimethylphenylamino)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol- 5-yl]propan-2-ol

1,1,1-Trifluoro-3-(4-fluorophenylamino)-2-[1-(4-fluorophenyl)-1H-indazol-5- yl]propan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H- indazol-5-yl]-3-(4-methylsulfanylphenylamino)propan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H- indazol-5-yl]-3-(naphthalen-2-ylamino)propan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(2-methylquinolin-8- ylamino)propan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H- indazol-5-yl]-3-(methylphenylamino)propan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H- indazol-5-yl]-3-[(4-methoxyphenyl)methylamino]propan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(4-methylindol-1-yl)propan- 2-ol

3-[2-(4-Chlorophenyl)indol-1-yl]-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol- 5-yl]propan-2-ol

(1-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H- indol-3-yl)acetonitrile

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(6-methoxyindol-1- yl)propan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(5-methylindol-1-yl)propan- 2-ol

3-(4-Benzyloxyindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5- yl]propan-2-ol

3-(4-Chloroindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2- ol

3-(6-Chloroindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2- ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(6-methylindol-1-yl)propan- 2-ol

1-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H- indole-4-carboxylic acid methylester

1,1,1-Trifluoro-3-(6-fluoroindol-1-yl)-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2- ol

1-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H- indole-3-carboxylic acid methylester

2,2,2-Trifluoro-1-(1-{3,3,3-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H-indol-3-yl)ethanone

1,1,1-Trifluoro-3-(4-fluoroindol-1-yl)-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2- ol

N-[2-(5-Methoxy-1-{3,3,3-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2- hydroxypropyl}-1H-indol-3-yl)ethyl]acetamide

3-(7-Bromoindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2- ol

3-(7-Chloroindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2- ol

(2-Methyl-1-{3,3,3-trifluoro-2-[1-(4- fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H-indol-3-yl)acetic acid ethyl ester

1-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H- indole-5-carboxylic acid methylester

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(2-methyl-5-nitroindol-1- yl)propan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-[2-(4-fluorophenyl)indol-1- yl]propan-2-ol

3-(4-Bromoindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2- ol

3-(6-Bromoindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2- ol

3-(3-Dimethylaminomethyl-6- methoxyindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol

(5-Methoxy-1-{3,3,3-trifluoro-2-[1-(4- fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H-indol-3-yl)acetonitrile

(5-Benzyloxy-1-{3,3,3-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H-indol-3-yl)acetonitrile

1-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H- indole-6-carboxylic acid methylester

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(7-nitroindol-1-yl)propan-2- ol

1-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H- indole-4-carbonitrile

3-(5-Benzyloxyindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5- yl]propan-2-ol

1-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H- indole-5-carbonitrile

3-(3-Dimethylaminomethyl-5- methoxyindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(5-methoxy-2-methylindol- 1-yl)propan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(2-methylindol-1-yl)propan- 2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(3-methylindol-1-yl)propan- 2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(7-methylindol-1-yl)propan- 2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(5-nitroindol-1-yl)propan-2- ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(2-phenylindol-1-yl)propan- 2-ol

(2-Phenyl-1-{3,3,3-trifluoro-2-[1-(4- fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H-indol-3-yl)acetonitrile

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-pyrrolo[2,3-c]pyridin-1- ylpropan-2-ol

3-(7-Ethylindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2- ol

3-(2,3-Dimethyt-5-nitroindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol- 5-yl]propan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-(6-trifluoromethylindol-1- yl)propan-2-ol

1,1,1-Trifluoro-3-(7-fluoroindol-1-yl)-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-2- ol

1-{3,3,3-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxypropyl}-1H- indole-6-carbonitrile

3-(2,5-Dimethylindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5- yl]propan-2-ol

3-(6-Benzyloxyindol-1-yl)-1,1,1-trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5- yl]propan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-pyrrolo[3,2-b]pyridin-1- ylpropan-2-ol

1,1,1-Trifluoro-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-pyrrolo[3,2-c]pyridin-1- ylpropan-2-ol

or a tautomer, prodrug, solvate, or salt thereof. IBCyclopropylphenyl-(1-phenyl-1H-indazol- 5-yl)methanol

Cyclopropyl-(3,5-dichlorophenyl)-(1- phenyl-1H-indazol-5-yl)methanol

(3-Chloro-4-fluorophenyl)cyclopropyl-(1- phenyl-1H-indazol-5-yl)methanol

Cyclopropylnaphthalen-1-yl-(1-phenyl-1H- indazol-5-yl)methanol

Cyclopropyl-(4-fluoronaphthalen-1-yl)-(1-phenyl-1H-indazol-5-yl)methanol

Cyclopropyl-[1-(4-fluorophenyl)-1H- indazol-5-yl]naphthalen-1-ylmethanol

Cyclopropyl-(4-fluoronaphthalen-1-yl)-[1-(4-fluorophenyl)-1H-indazol-5-yl]methanol

Cyclopropyl-[1-(4-fluorophenyl)-1H- indazol-5-yl]quinolin-4-ylmethanol

Cyclopropyl-[1-(4-fluorophenyl)-1H-indazol-5-yl]isoquinolin-1-ylmethanol

1-Cyclopropyl-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-phenylsulfanylethanol

1-Cyclopropyl-1-[1-(4-fluorophenyl)-1H- indazol-5-yl]-2-(4-fluorophenylsulfanyl)ethanol

1-Cyclopropyl-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-(naphthalen-1-yloxy)ethanol

1-Cyclopropyl-2-(3,5-difluorophenoxy)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol

1-Cyclopropyl-2-(3-fluorophenylamino)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol

1-Cyclopropyl-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-phenylaminoethanol

1-Cyclopropyl-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-p-tolylaminoethanol

2-(4-Chlorophenylamino)-1-cyclopropyl-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol

1-{2-Cyclopropyl-2-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-hydroxyethyl}-1H- indole-3-carbonitrile

1-Cyclopropyl-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-2-indol-1-ylethanol

1-{2-[1-(4-Fluorophenyl)-1H-indazol-5-yl]-2-hydroxy-3,3-dimethylbutyl}-1H-indole-3- carbonitrile

2-[1-(4-Fluorophenyl)-1H-indazol-5-yl]-1-indol-1-yl-3,3-dimethylbutan-2-ol

1-(4-Fluoronaphthalen-1-yl)-1-[1-(4- fluorophenyl)-1H-indazol-5-yl]-2,2-dimethylpropan-1-ol

1-[1-(4-Fluorophenyl)-1H-indazol-5-yl]-2,2-dimethyl-1-quinolin-4-ylpropan-1-ol

1-[1-(4-Fluorophenyl)-1H-indazol-5-yl]-1-isoquinolin-1-yl-2,2-dimethylpropan-1-ol

Cyclopentylphenyl-(1-p-tolyl-1H-indazol-5- yl)methanol

Cyclopentyl-(3,5-dichlorophenyl)-(1-p- tolyl-1H-indazol-5-yl)methanol

(3-Chloro-4-fluorophenyl)cyclopentyl-(1-p-tolyl-1H-indazol-5-yl)methanol

Cyclohexylphenyl-(1-p-tolyl-1H-indazol-5- yl)methanol

Cyclohexyl-(3,5-dichlorophenyl)-(1-p-tolyl- 1H-indazol-5-yl)methanol

(3-Chloro-4-fluorophenyl)cyclohexyl-(1-p- tolyl-1H-indazol-5-yl)methanol

2-Cyclohexyl-1-phenyl-1-(1-pyridin-2-yl- 1H-indazol-5-yl)ethanol

2-Cyclohexyl-1-(3,5-dichiorophenyl)-1-(1-pyridin-2-yl-1H-indazol-5-yl)ethanol

1-(3-Chloro-4-fluorophenyl)-2-cyclohexyl-1-(1-pyridin-2-yl-1H-indazol-5-yl)ethanol

1-(4-Fluoronaphthalen-1-yl)-1-[1-(4-methoxyphenyl)-1H-indazol-5-yl]propan-1- ol

1-[1-(4-Methoxyphenyl)-1H-indazol-5-yl]- 1-quinolin-4-ylpropan-1-ol

1-Isoquinolin-1-yl-1-[1-(4-methoxyphenyl)- 1H-indazol-5-yl]propan-1-ol

1-Benzo[b]thiophen-3-yl-1-[1-(3- fluorophenyl)-1H-indazol-5-yl]ethanol

1-[1-(3-Fluorophenyl)-1H-indazol-5-yl]-1- (1H-indol-4-yl)ethanol

1-[1-(3-Fluorophenyl)-1H-indazol-5-yl]-1- (1H-indol-7-yl)ethanol

1-(2,3-Dihydro-1,4-benzoxazin-4-yl)-2-[1-(3-fluorophenyl)-1H-indazol-5-yl]propan-2- ol

1-(3,4-Dihydro-2H-quinolin-1-yl)-2-[1-(3-fluorophenyl)-1H-indazol-5-yl]propan-2-ol

1-(3,4-Dihydro-2H-quinoxalin-1-yl)-2-[1-(3-fluorophenyl)-1H-indazol-5-yl]propan-2- ol

1-(1-Cyclohexyl-1H-indazol-5-yl)-2- methyl-1-naphthalen-1-ylpropan-1-ol

1-(1-Cyclohexyl-1H-indazol-5-yl)-1-(4-fluoronaphthalen-1-yl)-2-methylpropan-1-ol

1-(1-Cyclohexyl-1H-indazol-5-yl)-2- methyl-1-quinolin-4-ylpropan-1-ol

(1-Cyclohexyl-1H-indazol-5-yl)isoquinolin- 1-ylphenylmethanol

1-Cyclopropyl-2-phenyl-1-(1-phenyl-1H- indazol-5-yl)ethanol

1-Cyclopropyl-2-(3,5-dichlorophenyl)-1-(1-phenyl-1H-indazol-5-yl)ethanol

1-Cyclopropyl-1-(1-phenyl-1H-indazol-5- yl)-2-m-tolylethanol

1-Cyclopropyl-1-(1-phenyl-1H-indazol-5- yl)-2-p-tolylethanol

1-Cyclopropyl-2-(3-fluorophenyl)-1-(1- phenyl-1H-indazol-5-yl)ethanol

1-Cyclopropyl-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-3-phenylpropan-1-ol

1-[1-(4-Fluorophenyl)-1H-indazol-5-yl]-2- m-tolylpropan-2-ol

2-Phenyl-1-(1-phenyl-1H-indazol-5- yl)propan-2-ol

1-[1-(4-Fluorophenyl)-1H-indazol-5-yl]-2- methyl-3-phenylpropan-2-ol

Cyclopropyl-(4-fluoronaphthalen-1-yl)-[1-(4-fluorophenyl)-1H-benzotriazol-5- yl]methanol

Cyclopropyl-[1-(4-fluorophenyl)-1H-benzotriazol-5-yl]quinolin-4-ylmethanol

Cyclopropyl-[1-(4-fluorophenyl)-1H-benzotriazol-5-yl]isoquinolin-1-ylmethanol

Cyclopropylphenyl-(1-phenyl-1H- benzotriazol-5-yl)methanol

Cyclopropyl-(4-fluoronaphthalen-1-yl)-[1-(4-fluorophenyl)-1H-benzimidazol-5- yl]methanol

Cyclopropyl-[1-(4-fluorophenyl)-1H-benzimidazol-5-yl]quinolin-4-ylmethanol

Cyclopropyl-[1-(4-fluorophenyl)-1H-benzimidazol-5-yl]isoquinolin-1-ylmethanol

Cyclopropylphenyl-(1-phenyl-1H-indol-5- yl)methanol

Cyclopropyl-(4-fluoronaphthalen-1-yl)-[1-(4-fluorophenyl)-1H-indol-5-yl]methanol

Cyclopropyl-[1-(4-fluorophenyl)-1H-indol- 5-yl]quinolin-4-ylmethanol

Cyclopropyl-[1-(4-fluorophenyl)-1H-indol- 5-yl]isoquinolin-1-ylmethanol

1-(1-Phenyl-1H-indazol-5-yl)-1-quinolin-4- ylethanol

1-(1-Phenyl-1H-indazol-5-yl)-1-quinolin-4- ylpropan-1-ol

1-(4-Fluoronaphthalen-1-yl)-1-(1-phenyl- 1H-indazol-5-yl)propan-1-ol

1-(1-Allyl-1H-indol-3-yl)-1-[1-(4- fluorophenyl)-1H-indazol-5-yl]-2-methylpropan-1-ol

1-(1-Allyl-1H-indol-3-yl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]propan-1-ol

or a tautomer, prodrug, solvate, or salt thereof.

1. A compound of Formula (IA)

wherein: R¹ is aryl or C₃-C₇ cycloalkyl, each optionally independentlysubstituted with one to three substituent groups selected from C₁-C₃alkyl, hydroxy, halogen, oxo, methoxy, amino wherein the nitrogen atomis optionally independently mono- or disubstituted with a methyl group,or thiomethyl wherein the sulfur atom is optionally oxidized to asulfoxide or sulfone; R² is hydrogen or a halogen; A is N; B is CH; Cand E are each a bond; D is —CR⁴R⁵—, where R⁴ is —CF₃ and R⁵ is —OH; andR³ is heteroaryl independently substituted with one to three substituentgroups, wherein each substituent group of R³ is independently aryl,C₁-C₅ alkyl, C₁-C₅ alkenyl, cycloalkyl, cycloalkenyl, acyl,alkoxycarbonyl, C₁-C₅ alkanoyloxy, C₁-C₅ alkanoyl, aroyl, C₁-C₅alkanoylamino, alkylaminocarbonyl, dialkylaminocarbonyl,aminocarbonyloxy, C₁-C₅ alkylaminocarbonyloxy, C₁-C₅dialkylaminocarbonyloxy, C₁-C₅ alkanoylamino, C₁-C₅ alkoxycarbonylamino,C₁-C₅ alkylsulfonylamino, aminosulfonyl, C₁-C₅ alkylaminosulfonyl, C₁-C₅dialkylaminosulfonyl, C₁-C₅ alkyloxy, aryloxy, halogen, hydroxy, oxo,cyano, trifluoromethyl, nitro, carboxyl, aminocarbonyl, amino whereinthe nitrogen atom is optionally independently mono- or disubstitutedwith a C₁-C₅ alkyl, or C₁-C₅ alkylthio wherein the sulfur atom isoptionally oxidized to a sulfoxide or sulfone, wherein each substituentgroup of R³ is optionally independently substituted with one to threesubstituents selected from aryl, acyl, C₁-C₅ alkyl, C₁-C₅ alkanoyloxy,C₁-C₅ alkanoyl, C₁-C₅ alkanoylamino, alkylaminocarbonyl,dialkylaminocarbonyl, C₁-C₅ alkylsulfonylamino, aminosulfonyl, C₁-C₅alkylaminosulfonyl, C₁-C₅ dialkylaminosulfonyl, C₁-C₅ alkyloxy, C₁-C₅cycloalkyl, aryloxy, halogen, hydroxy, oxo, cyano, trifluoromethyl,nitro, aminocarbonyl, amino wherein the nitrogen atom is optionallyindependently mono- or disubstituted with a C₁-C₅ alkyl, or alkylthiowherein the sulfur atom is optionally oxidized to a sulfoxide orsulfone, or a tautomer ester, amide or salt thereof.
 2. The compound ofFormula (IA) according to claim 1, wherein: R¹ is aryl optionallyindependently substituted with one to three substituent groups selectedfrom hydroxy, halogen, or oxo; and R² is hydrogen, or a tautomer ester,amide or salt thereof.
 3. The compound of Formula (IA) according toclaim 1, wherein: R¹ is a phenyl optionally substituted with one tothree halogen groups; and R³ is a pyridyl, quinoline, isoquinoline,indole, azaindole, benzothiophene, or benzofuran, each optionallyindependently substituted with one to three substituent groups, whereineach substituent group of R³ is independently C₁-C₅ alkyl, acyl, C₁-C₅alkyloxy, halogen, hydroxy, oxo, cyano, trifluoromethyl, aminocarbonyl,amino wherein the nitrogen atom is optionally independently mono- ordisubstituted with a C₁-C₅ alkyl, C₁-C₅ alkenyl, carboxyl, or C₁-C₅alkylthio wherein the sulfur atom is optionally oxidized to a sulfoxideor sulfone, wherein each substituent group of R³ is optionallyindependently substituted with one to three substituents selected fromC₁-C₅ alkyl, C₁-C₅ alkyloxy, halogen, hydroxy, oxo, cyano,trifluoromethyl, aminocarbonyl, amino wherein the nitrogen atom isoptionally independently mono- or disubstituted with a C₁-C₅ alkyl, orC₁-C₅ alkylthio wherein the sulfur atom is optionally oxidized to asulfoxide or sulfone, or a tautomer ester, amide or salt thereof.
 4. Thecompound of Formula (IA) according to claim 3, wherein: R³ is a pyridyl,quinoline, isoquinoline, indole, azaindole, benzothiophene, orbenzofuran, wherein each substituent group of R³ is independently C₁-C₅alkyl, acyl, C₁-C₅ alkyloxy, halogen, hydroxy, oxo, cyano,trifluoromethyl, aminocarbonyl, amino wherein the nitrogen atom isoptionally independently mono- or disubstituted with a C₁-C₅ alkyl, orC₁-C₅ alkylthio wherein the sulfur atom is optionally oxidized to asulfoxide or sulfone, wherein each substituent group of R³ is optionallyindependently substituted with one to three substituents selected fromC₁-C₅ alkyl, halogen, hydroxy, oxo, cyano, trifluoromethyl,aminocarbonyl, amino wherein the nitrogen atom is optionallyindependently mono- or disubstituted with a C₁-C₅ alkyl, or C₁-C₅alkylthio wherein the sulfur atom is optionally oxidized to a sulfoxideor sulfone, or a tautomer ester, amide or salt thereof.
 5. A compoundselected from:4-[2,2,2-Trifluoro-1-hydroxy-1-(1-phenyl-1H-indazol-5-yl)ethyl]quinoline-3-carboxylicacid dimethylamide;4-[2,2,2-Trifluoro-1-hydroxy-1-(1-phenyl-1H-indazol-5-yl)ethyl]quinoline-3-carboxylicacid methylamide;4-[2,2,2-Trifluoro-1-hydroxy-1-(1-phenyl-1H-indazol-5-yl)ethyl]quinoline-3-carboxylicacid amide;4-[2,2,2-Trifluoro-1-hydroxy-1-(1-phenyl-1H-indazol-5-yl)ethyl]quinoline-3-carboxylicacid ethyl ester;2,2,2-Trifluoro-1-(1-phenyl-1H-indazol-5-yl)-1-quinolin-4-ylethanol;2,2,2-Trifluoro-1-(2-methylquinolin-4-yl)-1-(1-phenyl-1H-indazol-5-yl)ethanol;2,2,2-Trifluoro-1-isoquinolin-1-yl-1-(1-phenyl-1H-indazol-5-yl)ethanol;2,2,2-Trifluoro-1-isoquinolin-4-yl-1-(1-phenyl-1H-indazol-5-yl)ethanol;2,2,2-Trifluoro-1-(3-methylpyridin-2-yl)-1-(1-phenyl-1H-indazol-5-yl)ethanol;2,2,2-Trifluoro-1-(4-methylpyridin-2-yl)-1-(1-phenyl-1H-indazol-5-yl)ethanol;2,2,2-Trifluoro-1-(5-methylpyridin-2-yl)-1-(1-phenyl-1H-indazol-5-yl)ethanol;2,2,2-Trifluoro-1-(6-methylpyridin-2-yl)-1-(1-phenyl-1H-indazol-5-yl)ethanol;2,2,2-Trifluoro-1-(1-phenyl-1H-indazol-5-yl)-1-pyridin-2-ylethanol;1-Benzo[b]thiophen-3-yl-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol;2,2,2-Trifluoro-1-(1H-indol-4-yl)-1-(1-phenyl-1H-indazol-5-yl)ethanol;2,2,2-Trifluoro-1-(1H-indol-3-yl)-1-(1-phenyl-1H-indazol-5-yl)ethanol;4-{2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}quinoline-3-carboxylicacid dimethylamide;4-{2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}quinoline-3-carboxylicacid methylamide;4-{2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}quinoline-3-carboxylicacid amide;4-{2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}quinoline-3-carboxylicacid ethyl ester;2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-quinolin-4-ylethanol;2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(2-methylquinolin-4-yl)ethanol;2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-isoquinolin-1-ylethanol;2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-isoquinolin-4-ylethanol;1-Benzofuran-5-yl-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;1-Benzofuran-2-yl-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1H-indol-4-yl)ethanol;2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1-methyl-1H-indol-4-yl)ethanol;1-Benzo[b]thiophen-3-yl-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;2,2,2-Trifluoro-1-(6-fluoropyridin-2-yl)-1-(1-phenyl-1H-indazol-5-yl)ethanol;2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1H-indol-7-yl)ethanol;2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1-methyl-1H-indol-7-yl)ethanol;2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1-methyl-1H-indol-5-yl)ethanol;2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1-methyl-1H-indol-6-yl)ethanol;4-{2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}indole-1-carboxylicacid tert-butyl ester;1-Methyl-4-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-quinolin-2-one;1-(1-Allyl-1H-indol-4-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;3-(4-{2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}indol-1-yl)propane-1,2-diol;3-Hydroxy-4-(4-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}indol-1-yl)butyronitrile;2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-[1-(2-hydroxyethyl)-1H-indol-4-yl]ethanol;2-(4-{2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}indol-1-yl)acetamide;N-Methyl-2-(4-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}indol-1-yl)acetamide;1-[1-(2-Cyclopropyl-2-hydroxyethyl)-1H-indol-4-yl]-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;1-(7-Bromo-1-methyl-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;1-Methyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylicacid methyl ester;1-Methyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylicacid;1-Methyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylicacid amide;1-Methyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylicacid methylamide;1-Methyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylicacid (2-cyanoethyl)amide;1-Methyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylicacid (2-methoxyethyl)amide;1-Methyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylicacid (2-methoxyethyl)methylamide;2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1-methyl-7-nitro-1H-indol-3-yl)ethanol;1-(7-Amino-1-methyl-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;1-Methyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylicacid carbamoylmethylamide;1-Methyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylicacid cyanomethylamide;1-(1-Allyl-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;N-(1-Methyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indol-7-yl)methanesulfonamide;3-(3-{2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}indol-1-yl)propane-1,2-diol;1-Benzyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylicacid methyl ester;2-(3-{2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}indol-1-yl)acetamide;2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-[1-(2-hydroxyethyl)-1H-indol-3-yl]ethanol;N-Methyl-2-(3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}indol-1-yl)acetamide;1-Allyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylicacid methyl ester;1-(1-Allyl-1H-imidazol-4-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;3-(4-{2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}imidazol-1-yl)propane-1,2-diol;1-Allyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylicacid amide;1-(2,3-Dihydroxypropyl)-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylicacid amide;1-(1-Allyl-1H-indol-3-yl)-2,2,2-trifluoro-1-(1-p-tolyl-1H-indazol-5-yl)ethanol;3-{3-[2,2,2-Trifluoro-1-hydroxy-1-(1-p-tolyl-1H-indazol-5-yl)ethyl]indol-1-yl}propane-1,2-diol;2,2,2-Trifluoro-1-(5-fluoro-1H-indol-3-yl)-1-(1-p-tolyl-1H-indazol-5-yl)ethanol;2,2,2-Trifluoro-1-(5-fluoro-1H-indol-3-yl)-1-[1-(2-fluorophenyl)-1H-indazol-5-yl]ethanol;2,2,2-Trifluoro-1-(5-fluoro-1H-indol-3-yl)-1-[1-(4-methoxyphenyl)-1H-indazol-5-yl]ethanol;2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(5-methoxy-4-methyl-1H-indol-3-yl)ethanol;1-(4-Chloro-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(6-methoxy-1H-indol-3-yl)ethanol;1-(2,5-Dimethyl-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(7-methoxy-1H-indol-3-yl)ethanol;2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1H-indol-3-yl)ethanol;1-(6-Bromo-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;1-(7-Bromo-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;1-(5-Bromo-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(5-methyl-1H-indol-3-yl)ethanol;2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(2-methyl-1H-indol-3-yl)ethanol;1-(6-Chloro-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;1-(5-Chloro-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;1-(4-Bromo-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;2,2,2-Trifluoro-1-(5-fluoro-1H-indol-3-yl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;2,2,2-Trifluoro-1-(4-fluoro-1H-indol-3-yl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;2,2,2-Trifluoro-1-(6-fluoro-1H-indol-3-yl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(5-methoxy-1H-indol-3-yl)ethanol;2,2,2-Trifluoro-1-(7-fluoro-1H-indol-3-yl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(6-methyl-1H-indol-3-yl)ethanol;2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(7-methyl-1H-indol-3-yl)ethanol;3-{2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-5-carbonitrile;2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1-methyl-1H-indol-3-yl)ethanol;1-(6-Bromo-1-methyl-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;1-Methyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-6-carbonitrile;1-Methyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-6-carboxylicacid methyl ester;2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-{6-[(2-methoxyethyl)methylamino]-1-methyl-1H-indol-3-yl}ethanol;2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-[6-(2-methoxyethylamino)-1-methyl-1H-indol-3-yl]ethanol;1-{6-[(2-Dimethylaminoethyl)methylamino]-1-methyl-1H-indol-3-yl}-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;1-[6-(2-Dimethylaminoethylamino)-1-methyl-1H-indol-3-yl]-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;1-[5-(2-Dimethylaminoethylamino)-1-methyl-1H-indol-3-yl]-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;N-Methyl-2-{3-[2,2,2-trifluoro-1-hydroxy-1-(1-p-tolyl-1H-indazol-5-yl)ethyl]indol-1-yl}acetamide;2-{3-[2,2,2-Trifluoro-1-hydroxy-1-(1-p-tolyl-1H-indazol-5-yl)ethyl]indol-1-yl}acetamide;2,2,2-Trifluoro-1-[1-(2-hydroxyethyl)-1H-indol-3-yl]-1-(1-p-tolyl-1H-indazol-5-yl)ethanol;and3-{3-[2,2,2-Trifluoro-1-hydroxy-1-(1-p-tolyl-1H-indazol-5-yl)ethyl]indol-1-yl}propane-1,2-diol,or a tautomer ester, amide or salt thereof.
 6. A compound selected from:2,2,2-Trifluoro-1-(1-phenyl-1H-indazol-5-yl)-1-quinolin-4-ylethanol;2,2,2-Trifluoro-1-(1H-indol-4-yl)-1-(1-phenyl-1H-indazol-5-yl)ethanol;1-Benzo[b]thiophen-3-yl-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol;2,2,2-Trifluoro-1-(1-phenyl-1H-indazol-5-yl)-1-quinolin-4-ylethanol;2,2,2-Trifluoro-1-isoquinolin-1-yl-1-(1-phenyl-1H-indazol-5-yl)ethanol;1-Benzo[b]thiophen-3-yl-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1-methyl-1H-indol-4-yl)ethanol;1-Benzo[b]thiophen-3-yl-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;2,2,2-Trifluoro-1-(6-fluoropyridin-2-yl)-1-(1-phenyl-1H-indazol-5-yl)ethanol;2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1H-indol-7-yl)ethanol;2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1-methyl-1H-indol-7-yl)ethanol;2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1-methyl-1H-indol-5-yl)ethanol;2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1-methyl-1H-indol-6-yl)ethanol;4-{2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}indole-1-carboxylicacid tert-butyl ester;1-Methyl-4-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-quinolin-2-one;1-(1-Allyl-1H-indol-4-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;3-(4-{2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}indol-1-yl)propane-1,2-diol;3-Hydroxy-4-(4-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}indol-1-yl)butyronitrile;2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-[1-(2-hydroxyethyl)-1H-indol-4-yl]ethanol;2-(4-{2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}indol-1-yl)acetamide;N-Methyl-2-(4-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}indol-1-yl)acetamide;1-[1-(2-Cyclopropyl-2-hydroxyethyl)-1H-indol-4-yl]-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;1-(7-Bromo-1-methyl-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;1-Methyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylicacid methyl ester;1-Methyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylicacid;1-Methyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylicacid amide;1-Methyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylicacid methylamide;1-Methyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylicacid (2-cyanoethyl)amide;1-Methyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylicacid (2-methoxyethyl)amide;1-Methyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylicacid (2-methoxyethyl)methylamide;2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1-methyl-7-nitro-1H-indol-3-yl)ethanol;1-(7-Amino-1-methyl-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;1-Methyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylicacid carbamoylmethylamide;1-Methyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylicacid cyanomethylamide;1-(1-Allyl-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;N-(1-Methyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indol-7-yl)methanesulfonamide;3-(3-{2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}indol-1-yl)propane-1,2-diol;1-Benzyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylicacid methyl ester;2-(3-{2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}indol-1-yl)acetamide;2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-[1-(2-hydroxyethyl)-1H-indol-3-yl]ethanol;N-Methyl-2-(3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}indol-1-yl)acetamide;1-Allyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylicacid methyl ester;1-Allyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylicacid amide;1-(2,3-Dihydroxypropyl)-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylicacid amide;1-(1-Allyl-1H-indol-3-yl)-2,2,2-trifluoro-1-(1-p-tolyl-1H-indazol-5-yl)ethanol;3-{3-[2,2,2-Trifluoro-1-hydroxy-1-(1-p-tolyl-1H-indazol-5-yl)ethyl]indol-1-yl}propane-1,2-diol;2,2,2-Trifluoro-1-(5-fluoro-1H-indol-3-yl)-1-(1-p-tolyl-1H-indazol-5-yl)ethanol;2,2,2-Trifluoro-1-(5-fluoro-1H-indol-3-yl)-1-[1-(2-fluorophenyl)-1H-indazol-5-yl]ethanol;2,2,2-Trifluoro-1-(5-fluoro-1H-indol-3-yl)-1-[1-(4-methoxyphenyl)-1H-indazol-5-yl]ethanol;2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(5-methoxy-4-methyl-1H-indol-3-yl)ethanol;1-(4-Chloro-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(6-methoxy-1H-indol-3-yl)ethanol;1-(2,5-Dimethyl-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(7-methoxy-1H-indol-3-yl)ethanol;2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1H-indol-3-yl)ethanol;1-(6-Bromo-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;1-(7-Bromo-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;1-(5-Bromo-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(5-methyl-1H-indol-3-yl)ethanol;2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(2-methyl-1H-indol-3-yl)ethanol;1-(6-Chloro-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;1-(5-Chloro-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;1-(4-Bromo-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;2,2,2-Trifluoro-1-(5-fluoro-1H-indol-3-yl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;2,2,2-Trifluoro-1-(4-fluoro-1H-indol-3-yl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;2,2,2-Trifluoro-1-(6-fluoro-1H-indol-3-yl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(5-methoxy-1H-indol-3-yl)ethanol;2,2,2-Trifluoro-1-(7-fluoro-1H-indol-3-yl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(6-methyl-1H-indol-3-yl)ethanol;2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(7-methyl-1H-indol-3-yl)ethanol;3-{2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-5-carbonitrile;2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1-methyl-1H-indol-3-yl)ethanol;1-(6-Bromo-1-methyl-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;1-Methyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-6-carbonitrile;1-Methyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-6-carboxylicacid methyl ester;2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-{6-[(2-methoxyethyl)methylamino]-1-methyl-1H-indol-3-yl}ethanol;2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-[6-(2-methoxyethylamino)-1-methyl-1H-indol-3-yl]ethanol;1-{6-[(2-Dimethylaminoethyl)methylamino]-1-methyl-1H-indol-3-yl}-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;1-[6-(2-Dimethylaminoethylamino)-1-methyl-1H-indol-3-yl]-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;1-[5-(2-Dimethylaminoethylamino)-1-methyl-1H-indol-3-yl]-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;N-Methyl-2-{3-[2,2,2-trifluoro-1-hydroxy-1-(1-p-tolyl-1H-indazol-5-yl)ethyl]indol-1-yl}acetamide;2-{3-[2,2,2-Trifluoro-1-hydroxy-1-(1-p-tolyl-1H-indazol-5-yl)ethyl]indol-1-yl}acetamide;2,2,2-Trifluoro-1-[1-(2-hydroxyethyl)-1H-indol-3-yl]-1-(1-p-tolyl-1H-indazol-5-yl)ethanol;and3-{3-[2,2,2-Trifluoro-1-hydroxy-1-(1-p-tolyl-1H-indazol-5-yl)ethyl]indol-1-yl}propane-1,2-diol,or a tautomer ester, amide or salt thereof.
 7. A compound selected from:2,2,2-Trifluoro-1-(1-phenyl-1H-indazol-5-yl)-1-quinolin-4-ylethanol;2,2,2-Trifluoro-1-(1H-indol-4-yl)-1-(1-phenyl-1H-indazol-5-yl)ethanol;1-Benzo[b]thiophen-3-yl-2,2,2-trifluoro-1-(1-phenyl-1H-indazol-5-yl)ethanol;2,2,2-Trifluoro-1-(1-phenyl-1H-indazol-5-yl)-1-quinolin-4-ylethanol;2,2,2-Trifluoro-1-isoquinolin-1-yl-1-(1-phenyl-1H-indazol-5-yl)ethanol;1-Benzo[b]thiophen-3-yl-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;1-Benzo[b]thiophen-3-yl-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;2,2,2-Trifluoro-1-(6-fluoropyridin-2-yl)-1-(1-phenyl-1H-indazol-5-yl)ethanol;2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1H-indol-7-yl)ethanol;2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1-methyl-1H-indol-7-yl)ethanol;2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1-methyl-1H-indol-5-yl)ethanol;2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1-methyl-1H-indol-6-yl)ethanol;4-{2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}indole-1-carboxylicacid tert-butyl ester;1-Methyl-4-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-quinolin-2-one;1-(1-Allyl-1H-indol-4-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;3-(4-{2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}indol-1-yl)propane-1,2-diol;3-Hydroxy-4-(4-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}indol-1-yl)butyronitrile;2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-[1-(2-hydroxyethyl)-1H-indol-4-yl]ethanol;2-(4-{2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}indol-1-yl)acetamide;N-Methyl-2-(4-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}indol-1-yl)acetamide;1-[1-(2-Cyclopropyl-2-hydroxyethyl)-1H-indol-4-yl]-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;1-(7-Bromo-1-methyl-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;1-Methyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylicacid methyl ester;1-Methyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylicacid;1-Methyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylicacid amide;1-Methyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylicacid methylamide;1-Methyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylicacid (2-cyanoethyl)amide;1-Methyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylicacid (2-methoxyethyl)amide;1-Methyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylicacid (2-methoxyethyl)methylamide;2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1-methyl-7-nitro-1H-indol-3-yl)ethanol;1-(7-Amino-1-methyl-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;1-Methyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylicacid carbamoylmethylamide;1-Methyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylicacid cyanomethylamide;1-(1-Allyl-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;N-(1-Methyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indol-7-yl)methanesulfonamide;3-(3-{2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}indol-1-yl)propane-1,2-diol;1-Benzyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylicacid methyl ester;2-(3-{2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}indol-1-yl)acetamide;2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-[1-(2-hydroxyethyl)-1H-indol-3-yl]ethanol;N-Methyl-2-(3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}indol-1-yl)acetamide;1-Allyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylicacid methyl ester;1-Allyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylicacid amide;1-(2,3-Dihydroxypropyl)-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-7-carboxylicacid amide;1-(1-Allyl-1H-indol-3-yl)-2,2,2-trifluoro-1-(1-p-tolyl-1H-indazol-5-yl)ethanol;3-{3-[2,2,2-Trifluoro-1-hydroxy-1-(1-p-tolyl-1H-indazol-5-yl)ethyl]indol-1-yl}propane-1,2-diol;2,2,2-Trifluoro-1-(5-fluoro-1H-indol-3-yl)-1-(1-p-tolyl-1H-indazol-5-yl)ethanol;2,2,2-Trifluoro-1-(5-fluoro-1H-indol-3-yl)-1-[1-(2-fluorophenyl)-1H-indazol-5-yl]ethanol;2,2,2-Trifluoro-1-(5-fluoro-1H-indol-3-yl)-1-[1-(4-methoxyphenyl)-1H-indazol-5-yl]ethanol;2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(5-methoxy-4-methyl-1H-indol-3-yl)ethanol;1-(4-Chloro-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(6-methoxy-1H-indol-3-yl)ethanol;1-(2,5-Dimethyl-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(7-methoxy-1H-indol-3-yl)ethanol;2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1H-indol-3-yl)ethanol;1-(6-Bromo-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;1-(7-Bromo-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;1-(5-Bromo-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(5-methyl-1H-indol-3-yl)ethanol;2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(2-methyl-1H-indol-3-yl)ethanol;1-(6-Chloro-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;1-(5-Chloro-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;1-(4-Bromo-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;2,2,2-Trifluoro-1-(5-fluoro-1H-indol-3-yl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;2,2,2-Trifluoro-1-(4-fluoro-1H-indol-3-yl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;2,2,2-Trifluoro-1-(6-fluoro-1H-indol-3-yl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(5-methoxy-1H-indol-3-yl)ethanol;2,2,2-Trifluoro-1-(7-fluoro-1H-indol-3-yl)-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(6-methyl-1H-indol-3-yl)ethanol;2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(7-methyl-1H-indol-3-yl)ethanol;3-{2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-5-carbonitrile;2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-(1-methyl-1H-indol-3-yl)ethanol;1-(6-Bromo-1-methyl-1H-indol-3-yl)-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;1-Methyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-6-carbonitrile;1-Methyl-3-{2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-hydroxyethyl}-1H-indole-6-carboxylicacid methyl ester;2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-{6-[(2-methoxyethyl)methylamino]-1-methyl-1H-indol-3-yl}ethanol;2,2,2-Trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]-1-[6-(2-methoxyethylamino)-1-methyl-1H-indol-3-yl]ethanol;1-{6-[(2-Dimethylaminoethyl)methylamino]-1-methyl-1H-indol-3-yl}-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;1-[6-(2-Dimethylaminoethylamino)-1-methyl-1H-indol-3-yl]-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;1-[5-(2-Dimethylaminoethylamino)-1-methyl-1H-indol-3-yl]-2,2,2-trifluoro-1-[1-(4-fluorophenyl)-1H-indazol-5-yl]ethanol;N-Methyl-2-{3-[2,2,2-trifluoro-1-hydroxy-1-(1-p-tolyl-1H-indazol-5-yl)ethyl]indol-1-yl}acetamide;2-{3-[2,2,2-Trifluoro-1-hydroxy-1-(1-p-tolyl-1H-indazol-5-yl)ethyl]indol-1-yl}acetamide;2,2,2-Trifluoro-1-[1-(2-hydroxyethyl)-1H-indol-3-yl]-1-(1-p-tolyl-1H-indazol-5-yl)ethanol;and3-{3-[2,2,2-Trifluoro-1-hydroxy-1-(1-p-tolyl-1H-indazol-5-yl)ethyl]indol-1-yl}propane-1,2-diol,or a tautomer ester, amide or salt thereof.
 8. A pharmaceuticalcomposition comprising a compound according to one of claims 1 to 7, ora tautomer ester, amide or salt thereof, and a pharmaceuticallyacceptable excipient or carrier.